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Abstract
Introduction: Insulin resistance is the hall mark of a number of pathological conditions 
and is thought to play a major role in the cardiovascular risk associated with them. This 
thesis critically evaluates two insulin resistant conditions - polycystic ovary syndrome 
(PCOS) and type 2 diabetes (T2DM) - where there are many unresolved issues. During 
the course of these studies, the effect of weight loss and medications in modifying 
cardiovascular risk in these conditions was evaluated.
Methods: The first studies focused on a randomised open labelled parallel study of 
metformin and rimonabant in obese patients with PCOS. Subsquently, an extension to 
this study was undertaken where patients who were on rimonabant were changed over to 
metformin, whereas those on metformin were continued on metformin for another 3 
months. As part of this study the effect of rimonabant and metformin on incretin 
hormones in patients with PCOS was studied.
The next studies focused on a randomised double blind placebo controlled study on the 
pleotrophic effect of atorvastatin in patients with PCOS. Subsequent metformin therapy 
after atorvastatin treatment was undertaken. This study led to the investigation of the 
effect of simvastatin and atorvastatin on biological variation of lipids in patients with 
T2DM that has got implications in treating to lipid targets. A corollary to this study was 
whether the biological variation of LDL calculated using Friedewald formula differed 
from that of direct LDL.
14
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Results:
In the first series of studies, after 12 weeks of rimonabant there was a significant 
reduction in anthropometric and metabolic parameters as well as biochemical 
hyperandrogenemia in patients with PCOS. There was no change in any of these 
parameters in the metformin treated group. In three months extension arm to this study, 
metformin maintained the weight loss as well as enhanced the metabolic and 
biochemical parameters achieved by treatment with rimonabant, compared to 6 months 
of metformin treatment alone. There was a significant and reversible increase in 
glucose-dependent insulinotropic polypeptide (GIF) levels after 3 months of rimonabant 
treatment. There were no changes in GIF or glucagon-like peptide-1 (GLP-1) levels 
with metformin.
In the second series of studies it has shown that atorvastatin was effective in reducing 
inflammation, biochemical hyperandrogenemia and metabolic parameters in patients 
with polycystic ovary syndrome after a 12 week period compared to placebo. The 
subsequent effect of three months metformin treatment was augmented by atorvastatin 
pre-treatment compared to placebo pre-treatment. In the subsequent study it was shown 
that the coefficient of variation (CV) of TC, LDL, HDL and TG on simvastatin was 
significant but comparable to atorvastatin in patients with T2DM. However, subsequent 
directly measured LDL cholesterol was shown to be an order of magnitude more stable 
when taking equivalent doses of atorvastatin rather than simvastatin.
Conclusion: Both weight loss using rimonabant and atorvastatin were effective in 
reducing biochemical hyperandrogenemia and metabolic profile in patients with PCOS. 
The effect of rimonabant might be partly mediated through modulating GIF levels.
15
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There was a significant biological variation in lipid profile in patients with T2DM who 
are on simvastatin and atorvastatin that may lead to lipid targets in patients with diabetes 
which are significantly lower than the current evidence suggests and thereby more 
difficult to achieve. LDL targets can be consistently met at higher mean LDL 
concentrations (and with less lipid monitoring) using atorvastatin rather than simvastatin 
when direct LDL is used.
16
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Format of the thesis
This thesis evaluated cardiovascular risk reduction in two related insulin resistant states 
- polycystic ovary syndrome and T2DM. The first chapter is the "Introduction" where a 
literature review is done setting the background for the studies done in this thesis. The 
second chapter described the methodology involved in the studies. Chapters from 3-9 
describes the 7 studies which were done for this thesis. Chapter 10 begins by 
summarising my conclusions before discussing my findings in the context of current 
management. 
Aim of this work
1) To see if the reduction of biochemical hyperandrogenaemia and insulin 
resistance by rimonabant through weight loss was superior to insulin 
sensitisation with metformin in obese women with PCOS and if subsequent 
metformin treatment would maintain any of the initial improvement. We aimed 
to establish whether rimonabant might have an effect on the incretin system that 
may augment its weight reduction effect in patients with PCOS.
2) To study the effects of atorvastatin in patients with PCOS and the effect of 
subsequent metformin treatment.
3) To establish the biological variability of directly measured LDL and calculated 
LDL in patients with T2DM who are on statin treatment and to determine how 
this could influence the ability for patients to maintain cholesterol values below 
target thresholds.
17
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Chapter 1
Introduction
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1.1 Conditions associated with Insulin resistance
Although the insight into clinical implications of insulin resistance has dramatically
increased in the past 50 years, much uncertainty remains about the association between
insulin resistance and human disease (1). The exact prevalence of insulin resistance is
unknown since relative hyperinsulinaemia and other features of the insulin resistance
syndrome can be identified in a proportion of apparently healthy individuals. This is
due to the difficulties of defining insulin resistance in clinical terms and of quantifying
insulin action in humans.
Physiological states of insulin resistance
Insulin sensitivity spans a broad range (threefold to fourfold) even among apparently
healthy people with normal glucose tolerance. Many inherited and acquired factors can
affect insulin sensitivity. Some of these, sex for example, are immutable. However,
associated factors such as regional adiposity, skeletal muscle mass and level of physical
conditioning are potentially modifiable. Hormonal changes associated with puberty and
pregnancy (second and third trimesters) often lead to substantial increases in insulin
requirements.
Conditions associated with insulin resistance
Insulin resistance occurs in many aetiologically diverse human disorders (Table 1 and
2). In the extreme insulin resistance syndromes (Table 2) resistance is an important
determinant of the clinical phenotype.
19
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Table 1
Pathological conditions associated with insulin resistance in humans
Acquired conditions
Antagonism of insulin action:
Acute counter regulatory hormone excess (trauma, severe sepsis, acute myocardial 
infarction, diabetic ketoacidosis common) 
Medications (corticosteroids, B blockers common) 
Thyrotoxicosis (common) 
Polycystic ovary syndrome (relatively common) 
Acromegaly (rare) 
Phaeochromocytoma (rare) 
Cushing's syndrome (rare) 
Insulinoma (rare)
Glucagonoma syndrome (very rare) 
Cardiological syndromes: 
Congestive cardiac failure (common) 
Atheromatous disease (common) 
Microvascular angina (uncommon) 
Other major organ failure (relatively common): 
Hepatic cirrhosis 
Chronic renal failure
20
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Inherited (all uncommon or rare) 
Myotonic dystrophy 
Prader-Willi syndrome 
Alstrom's syndrome 
Laurence-Moon-Biedl syndrome 
Werner's syndrome
21
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Table 2-Syndromes associated with extreme insulin resistance
Insulin receptor mutations:
Leprechaunism
Rabson-Mendenhall syndrome
Type A insulin resistance (mutations are relatively uncommon)
Post-binding defects in insulin action:
Lipodystrophic diabetes syndromes (includes inherited and acquired forms)
Type C insulin resistance (post-receptor defect; overlaps with type A)
Insulin receptor antibodies:
Type B insulin resistance (usually associated with evidence of other autoimmune
disease)
All of these syndromes are uncommon or rare. Glucose tolerance may be only
minimally impaired if compensatory hyperinsulinaemia is sufficient to overcome the
defect.
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1.1.1 Relationship between hyperinsulinemia, insulin resistance and 
cardiovascular risk factors
Cross-sectional studies have reported an association of insulin resistance (as determined 
by the hyperinsulinemic euglycemic clamp) with atherosclerosis as measured by carotid 
ultrasound or coronary angiography(6, 7). Hyperinsulinemia has been identified as a 
risk factor for coronary heart disease in several (8-11), but not in all, studies. However 
the negative studies were done on elderly subjects (13) and high risk subjects (12). 
Hypertension
Insulin resistance has been strongly associated with hypertension in lean subjects(15). 
Fasting insulin levels predicted the development of hypertension in lean but not in obese 
subjects(16). 
Dyslipidemia
Hyperinsulinemia and insulin resistance have been consistently related to dyslipidemia 
(2, 17, 18) with a preponderance of small dense low density-lipoprotein has been 
associated with coronary heart disease(19). Studies have confirmed that elevated insulin 
levels are associated, cross-sectionally with increased triglyceride levels, decreased 
HDL levels and hypertension(17, 20). In the San Antonio Heart study increased fasting 
insulin levels significantly predicted the development of T2DM, low HDL levels, high 
triglyceride levels and hypertension over an 8 year follow up. Subjects who developed 
multiple metabolic disorders had higher insulin concenterations than those who 
developed only a single disorder. 
Impairment offibrinolysis
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High levels of plasma plasminogen activator inhibitor (PAI-1) have been associated 
consistently with increased insulin concentrations and insulin resistance(21, 22). It has 
been suggested that an increased PAI-1 could form a link between insulin resistance and 
coronary heart disease(23).
1.2 Polycystic ovary syndrome
"Giovane rustica, maritata.modicamente pingue, etinfeconda, con due ovaie piu grandi 
del normale, come uova di colomba, bernoccolute, lucenti et biancastre... " (Young 
peasant woman, married, moderately lump and infertile, with ovaries larger than normal, 
like doves' eggs, lumpy, shiny and whitish...) This description from 1721 by the Italian 
scientist Antonio Vallisneri is probably the first text of polycystic ovary syndrome 
PCOS) (24). In 1844 Chereau described sclerotic changes in the ovary (25). The 
association between hyperandrogenism and diabetes was first described by Achard and 
Thiers in 1921, in the paper "Le virilism pilaire et son association a I'insuffisance 
glycolytique" (26). and was called "the diabetes of bearded women (diabete des 
femmes a barbe)" (27).
In 1935, the two American gynaecologists, Stein and Leventhal published a classic 
paper on a series of seven patients(28). They described bilaterally enlarged polycystic 
ovaries, "two to four times the normal size, sometimes distinctly globular", "tunica 
thickened, though, andfibrotic ", "follicle cysts near the cortex and almost entirely 
confined to the cortex ". "The colour of the ovary was oyster gray with bluish areas 
where the cysts were superficial and appeared on the surface as sago-like bodies ". 
Other characteristics included oligo-amenorrhea, hirsutism and infertility.
24
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According to Stein and Leventhal the diagnosis was based on the clinical appearance: 
hirsuitism, amenorrhea, infertility and histological specimen of polycystic ovaries with 
prominent theca, fibrotic thickening of the tunica albuginea and multiple cystic 
follicles(28). In the 1960s it became evident that the "Stein-Leventhal syndrome" 
represented a variety of clinical manifestations. In the early 1970s, the scientific 
community focused on the changed function in the hypothalamic- pituitary-ovarian axis, 
increased serum levels of LH, and elevated LH/FSH ratio(29).
In the late 1970s the concept of PCOS developed. Burghen et al. were first to point out a 
link between PCOS and insulin resistance. They demonstrated that hyperandrogenism 
correlate with hyperinsulinemia in obese PCOS women(30). Later, ultrasound became 
central in visualizing polycystic ovaries (PCO) and diagnosing PCOS. Swanson et al. 
were the first to describe the typical ultrasonographic appearance of polycystic ovaries 
in 1981(31), and Adams et al. refined the criteria for the ultrasonographic diagnosis of 
PCO(32).
The first treatment for PCOS was bilateral wedge resection of the ovaries, suggested by 
Stein and Leventhal. They reported regain of regular menstruations in seven patients, 
and pregnancy in two women, after wedge resection. Haifa century later Gj0nnasss, a 
Norwegian gynaecologist, introduced laparoscopic ovarian drilling, as a more 
conservative method with fewer problems with adhesions(33). 
1.2.1 Definition of PCOS
Polycystic ovary syndrome (PCOS), a disorder characterised by hyperandrogenism and 
chronic anovulation(34), is one of the most common endocrinopathies in pre- 
menopausal women and the most common cause of anovulatory infertility.
25
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Until 2003 there was no international consensus on the definition of PCOS. In the 
United States, the National Institute of Health (NIH) Conference on PCOS 1990 
recommended that diagnostic criteria should include evidence of hyperandrogenism 
(clinical or biochemical) and ovulatory dysfunction in the absence of non-classic 
congenital adrenal hyperplasia (CAH). Polycystic ovarian morphology was not 
considered essential. A clear definition of ovulatory dysfunction, hirsutism or 
hyperandrogenism was, however, not given (35). PCOS according to this definition was 
recognized in three principal phenotypes:
1) Women with hirsutism, hyperandrogenemia and oligo-ovulation,
2) Women with hirsutism and oligo-ovulation and
3) Women with hyperandrogenemia and oligo-ovulation.
In Europe, the definition of PCOS was restricted to a condition with polycystic ovaries, 
identified by ultrasonography and one or more of the following; oligo/amenorrhea, 
hyperandrogenism, obesity, elevated serum testosterone and / or elevated LH 
concentrations (35). Ovulatory dysfunction was not mandatory. The need for a 
universal agreement on the definition of PCOS was obvious.
In Rotterdam in 2003, the European Society of Human Reproduction and Embryology 
(ESHRE) and the American Society of Reproductive Medicine (ASRM) achieved a new 
consensus(36). The new definition reflects the awareness that PCOS represents a 
multitude of clinical expressions and emphasizes the importance of realising it. 
According to the Rotterdam 2003 consensus, two of the following three criteria must be 
fulfilled for the diagnosis:
26
27
1. Polycystic ovaries; 12 or more follicles in each ovary, each follicle measuring 2-9 mm 
in diameter and/or ovarian volume >10ml. One polycystic ovary is sufficient for the 
diagnosis.
2. Oligo-/anovulation; clinically diagnosed as oligo-/ amenorrhea, i.e. menstrual cycles 
longer than 35 days or less than 10 menstruations per year.
3. Hyperandrogenism; clinical or biochemical.
The clinical definition of hyperandrogenism includes: hirsutism, acne and androgen
alopecia, but the evaluation of hirsutism is difficult, because of racial differences (37,
38). Cosmetic treatment abolishes the expression and although there exists standardised
scoring, the Ferrimann-Gallwey score is seldom used (39).
The Rotterdam consensus on the definition of PCOS has not defined clinical
hyperandrogenism. The definition of biochemical hyperandrogenism is not without
problems;
1. Modern immunoassay methods in routine clinical practice have recently been shown 
to be inaccurate for measuring testosterone in women(40).
2. Normative ranges are not established, and adjustment for age and BMI should be 
recommended.
3. Other androgens than testosterone should also be considered, especially DHEAS and
androstenedione.
The diagnosis of PCOS should not be based on one single criterion, and it can be argued
that PCOS is a diagnosis of exclusions. Congenital adrenal hyperplasia, non-classic
congenital adrenal hyperplasia, Gushing syndrome, acromegaly and androgen secreting
tumours should be ruled out.
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It is important to realise that the Rotterdam criteria has expanded the definition of PCOS 
compared with the NIH criteria, and created two new phenotypes i.e. 1) women with 
PCO, hirsutism / hyperandrogenemia and regular ovulations and 2) women with PCO, 
oligo-ovulations and normal androgens(41).
1.2.2 Clinical profile of PCOS
In clinical practice, women with PCOS present with infertility (mean incidence, 74%), 
menstrual irregularity (dysfunctional bleeding, 29%; amenorrhoea, 51%), 
hyperandrogenism (69%), and virilization (21%) (42). The endocrine profile of women 
with PCOS is characterised by high plasma concentrations of ovarian and adrenal 
androgens, gonadotropin abnormalities, a relative increase in oestrogen levels derived 
from conversion of androgens, reduced levels of sex hormone binding globulin (SHBG), 
and often high levels of insulin (43).
1.2.3 The association between insulin resistance and PCOS
Approximately 60-70% of PCOS patients are obese(44), with a central body fat 
distribution pattern described as visceral obesity that is well known to be highly 
associated with insulin resistance (IR). However, PCOS patients have evidence of 
insulin resistance independent of obesity (45-47). Insulin sensitivity is decreased by 35- 
40% in women with PCOS, independent of obesity, a decrease similar in magnitude to 
that seen in T2DM mellitus(48); still, any degree of obesity further impairs insulin 
action. About 50-70% of all women with PCOS have some degree of insulin resistance 
(49). It is now evident that PCOS has major metabolic consequences related to insulin 
resistance. Insulin resistance in PCOS may be considered a risk factor for gestational
28
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diabetes (GD) (50); the prevalence of GD in PCOS patients has been reported to be 40- 
46%. A link between insulin resistance and hypertensive disorders in pregnancy has 
been widely reported; pre-eclampsia is reported to be more frequent in PCOS patients 
than in normal women (51) and in one case control study, the incidence of this disorder 
was found to be as high as 28.5%(52). Evidence supporting the possibility of insulin 
resistance playing a role in the development of endometrial cancer has been 
provided(53, 54); increased risk for endometrial cancer was reported in women with 
increased serum levels of insulin(55) and lower serum levels of SHBG(56), both 
prominent features of women with PCOS and of insulin resistance. In addition, an 
increased prevalence of endometrial cancer among women with PCOS, including young 
women with the disorder has been reported(57, 58). Insulin resistance is associated with 
an increased risk for several disorders, including T2DM mellitus (T2DM) or, 
hypertension, dyslipidemia (low high-density lipoprotein cholesterol and high 
triglycerides), elevated plasminogen activator inhibitor type 1 (PAI-1), elevated 
endothelin-1, endothelial dysfunction, and heart disease.
Evidence that PCOS is associated with a high risk for the development of T2DM and 
heart disease is mounting. Regarding diabetes risk, prospective clinical trials have 
demonstrated a 31-35% prevalence of impaired glucose tolerance (IGT) and 7.5-10% 
prevalence of T2DM in women with PCOS(44, 59). Furthermore, studies (59, 60) 
demonstrated that both obese and lean PCOS patients are at increased risk of IGT or 
overt diabetes during their third or fourth decade; up to 20%of PCOS patients have IGT 
or T2DM by the third decade and up to 30-50% of obese women with PCOS will 
develop IGT or T2DM by the age of 30 years(44, 62). Regarding cardiovascular risk,
29
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PCOS is associated with increased prevalence of several cardiovascular risk factors, 
including hypertension and dyslipidemia. In addition, women with PCOS display 
surrogate markers for early atherosclerosis, such as increased PAI-1(59, 69, 70), 
endothelin-l(71), and CRP concentrations(72). Several studies (73-75) suggest that 
PCOS is associated with endothelial dysfunction that is linked to insulin resistance and 
is a risk factor for cardiovascular disease. PCOS women were shown to have higher 
mean carotid intima media thickness (IMT) compared with age-matched normal women, 
a striking illustration of the early atherogenic process in PCOS(76). PCOS women have 
a greater prevalence and extend of coronary artery calcification(77); the extent of which 
closely correlates with the atherosclerotic plaque burden(78) and predicts an increased 
risk of cardiovascular events(79). In addition, several studies reported an increased 
prevalence of cardiovascular heart disease in PCOS (67, 73, 76, 80, 81). Women with 
PCOS may represent the larges unique female population at high risk for premature 
atherosclerotic heart disease. The above considerations indicate that PCOS is not only 
an infertility or cosmetic problem, but perhaps a primary general heath problem at 
whose root lays insulin resistance.
Similarly, androgens do cause mild insulin resistance in women (82) and lowering 
circulating androgen levels pharmacologically or by blocking androgen action with 
receptor antagonists do slightly improve insulin resistance in hyperandrogenemic 
women (83). However, the magnitude of change is not in the range of the insulin 
resistance associated with PCOS (83) and therefore, androgens may amplify but do not 
account for insulin resistance in adult women with PCOS. Most of the evidence on the 
directionality of the relationship between insulin resistance and hyperandrogenism
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would suggest that the direction of causation is from insulin to androgen and not the 
reverse. For example, weight loss and administration of insulin sensitisers that 
specifically reduce insulin concentrations, results in a reduction in circulation androgen 
concentrations(84). However, administration of a gonadotropin-releasing hormone 
analogue that reduces androgen secretion from the ovary by suppressing gonadotropins, 
does not result in a reduction in insulin(85).
The paradox of insulin promoting androgen production in ovarian and adrenal tissues in 
the face of insulin resistance in peripheral tissues has been partly explained by tissue 
differences in insulin sensitivity in PCOS such that the steroidogenic tissues are insulin- 
sensitivity, whereas the major tissues involved in carbohydrate metabolism, namely fat 
and muscle, are insulin resistant(86).
1.2.4 The relationship between hyperinsulinemia and hyperandrogenism in PCOS: 
IGF-I is produced by human ovarian tissue, and IGF-I receptors are present in the 
ovary(87, 88). Insulin in high concentrations can mimic IGF-I actions by occupancy of 
the IGF-I receptor, and this has been a proposed mechanism for insulin-mediated 
hyperandrogenism(91, 92). However, it has recently been shown that insulin has specific 
actions on steroidogenesis acting through its own receptor(93). Moreover, these actions 
appear to be preserved in insulin-resistant states (93, 94), presumably because of 
differences in receptor sensitivity to this insulin action or because of differential 
regulation of the receptor in this tissue.
Studies in which insulin levels have been lowered for prolonged periods have been 
much more informative. This has been accomplished for 7 days to 3 months with agents 
that either decrease insulin secretion, diazoxide(95) or somatostatin (96), or that
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improve insulin sensitivity, metformin(70) or troglitazone(97). Circulating androgen 
levels have decreased significantly in women with PCOS in these studies. Sex hormone 
binding globulin (SHBG) levels have increased(95, 97), compatible with a major role 
for insulin in regulating hepatic production of this protein(98, 99). However, estrogen 
levels also decreased significantly, suggesting that insulin has diffuse effects on 
steroidogenesis(97).
In summary, studies in which insulin levels have been lowered by a variety of 
modalities indicate that hyperinsulinemia augments androgen production in PCOS. 
Moreover, this action appears to be directly mediated by insulin acting through its 
cognate receptor rather than by spill over occupancy of the IGF-I receptor. Intrinsic 
abnormalities in steroidogenesis appear to be necessary for this insulin action to be 
manifested since lowering insulin levels does not affect circulating androgen levels in 
normal women. Further, in many PCOS women, lowering insulin levels ameliorates but 
does not abolish hyperandrogenism.
On the other hand, modest hyperandrogenism characteristic of PCOS may contribute to 
the associated IR. Additional factors are necessary to explain the IR, since suppressing 
androgen levels does not completely restore normal insulin sensitivity(83, 100). Further, 
androgen administration does not produce IR of the same magnitude as that seen in 
PCOS(45, 101, 102). Finally, there are clearly defects in insulin action that persist in 
cultured PCOS skin fibroblasts removed from the hormonal milieu for generations(103). 
1.2.5 The relationship between metabolic syndrome and PCOS
PCOS is associated with an increase of cardiovascular risk factors, including 
dyslipidemia, which in these patients typically consists of elevated total cholesterol and
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LDL(66, 68, 104, 105). In the long term, PCOS is associated with increased thickness 
of the carotid intima and media(76).
The consequences of PCOS extend beyond the reproductive axis; women with the 
disorder are at substantial risk for the development of metabolic and cardiovascular 
abnormalities similar to those that make up MS(106). This finding is not surprising, 
since both PCOS and metabolic syndrome (MS) share IR as a central pathogenetic 
feature(107). The PCOS might thus be viewed as a sex-specific form of MS, and the 
term "syndrome XX" has been suggested as an apt term to underscore this 
association(lOS).
MS is a consistent feature of the majority of obese women with PCOS, although it can 
also be detected in many normal-weight affected women.(82, 109) Studies using ATPIII 
criteria to assess the prevalence of the MS in PCOS women has found prevalence rate 
ranging from 43% to 46%(106, 110). It has also been described that there is higher free 
testosterone and lower sex-hormone-binding globulin (SHBG) levels in those women 
with the MS with respect to those without it, as well as a higher prevalence of acanthosis 
nigricans and a greater tendency to have a family history of PCOS(110). These results 
were in accordance with a cross-sectional population-based study which reported a 
different concentration of some sex hormones between premenopausal women with and 
without the ATPIII-defmed MS (111). Therefore, collectively, 82% of PCOS women 
had at least one feature of MS, a finding consistent with a very large presence of single 
or grouped metabolic abnormalities in this disorder. Compared to those without any
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criteria, the other two groups were progressively more obese and had a higher 
prevalence of the abdominal pattern of fat distribution.
In addition, women presenting with MS were characterized by higher systolic and 
diastolic blood pressure, higher pulse rate, greater frequency of liver enzyme 
abnormalities, worsened IR, higher glycosylated haemoglobin and a more severe 
hyperandrogenemia with respect to those without the MS. Taken together, these findings 
demonstrate that the prevalence of the MS in women with PCOS is higher than that of 
the general population, regardless of ethnicity and geographical area. They also indicate 
a strong association between the MS and the hyperandrogenic state(l 12).
1.2.6 The relationship between obesity and PCOS
The cause of obesity in PCOS remains unknown, but obesity is present in at least 30 
percent of cases; in some series, the percentage is as high as 75(113). Increased 
adiposity, particularly visceral adiposity that is reflected by an elevated waist 
circumference (>88 cm [35 in.]) or waist-to-hip ratio, has been associated with 
hyperandrogenemia, IR, glucose intolerance, and dyslipidemia. Attenuation of IR, 
whether accomplished by weight loss or with medication, ameliorates (but not 
necessarily normalizes) many of the metabolic aberrations in women with PCOS(107) 
i.e obesity causes the expression of PCOS phenotype. 
1.2.7 The role of insulin sensitisers in PCOS.
A reduction in insulin levels pharmacologically ameliorates sequelae of both 
hyperinsulinemia and hyperandrogenemia. The place of insulin-reduction therapies in 
treating PCOS is evolving. These therapies can effectively manage the established
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metabolic derangements in PCOS, but whether they can prevent them is not yet
established.
1.2.8Metformin
Galega officinalis or French lilac is a perennial herb that blooms in July and August in
most of Europe. It can be grown as far north as Trondheim. The extract of Galega
officinalis contains isoamyline guanidine, a hypoglycemic compound, which was used
to treat diabetes mellitus in medieval Europe (114). The biguanide metformin was
discovered in the 1950s to have hypoglycaemic effect. Two guanine molecules that are
dimethylated make up metformin. In 1957 metformin was introduced as an agent for
treatment of diabetes mellitus type-2. The use of metformin was restricted during the
next decades because of reports of deaths associated to lactic acidosis during metformin
treatment. The drug had a renaissance in the 1990s, when metformin was proven to be
particularly useful in the treatment of diabetes mellitus type 2.
1.2.9 Mechanism of action of Metformin
In non-diabetic patients, metformin does not influence blood glucose levels.
In patients with diabetes mellitus type-2, metformin lowers fasting blood glucose and
improves glucose tolerance. The anti hyperglycaemic activity of metformin is achieved
by stimulation of peripheral glucose uptake, reduced hepatic gluco-neogenesis and to a
minor degree delayed intestinal absorption. Metformin has a major effect on hepatic
gluco-neogenesis. In non-diabetic subjects metformin has been demonstrated to lower
cholesterol and LDL/HDL cholesterol ratio (116). A recent study suggests that the
mechanisms of action of metformin might be through its activation of AMP- activated
protein kinase (117).
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Although metformin appears to influence ovarian steroidogenesis directly(l 18, 119) this 
effect does not appear to be primarily responsible for the attenuation of ovarian 
androgen production in women with PCOS. Rather, metformin inhibits the output of 
hepatic glucose, necessitating a lower insulin concentration and thereby probably 
reducing the androgen production of theca cells. Subject characteristics and control 
measures for effects of weight change, dose of metformin, and outcome vary widely 
among published studies of metformin in PCOS.
Metformin also improved fasting insulin levels, blood pressure, and levels of low- 
density lipoprotein cholesterol(120). These effects were judged to be independent of any 
changes in weight that were associated with metformin, but controversy persists as to 
whether the beneficial effects of metformin are entirely independent of the weight 
loss(121) that is typically seen early in the course of therapy. Finally, the rates of 
spontaneous miscarriage and gestational diabetes are reportedly lower among women 
with PCOS who conceive while taking metformin(122-125). But, the long-term effects 
of metformin in pregnancy are unknown.
However, in one recent randomised trial involving 626 infertile women with PCOS with 
metformin, clomiphene or combination, clomiphene was superior to metformin in 
achieving live birth although metformin significantly reduced body weight, IR and 
hyperandrogenemia compared to clomiphene(126) suggesting that reduction of insulin 
resistance alone doesn't improve fertility. 
1.2.10 The effect of Metformin on weight reduction
Out of seven RCTs, which had weight as endpoint, six demonstrated reduction of body 
weight with metformin treatment compared with placebo (127). The studies lasted from
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one to six months and the average reduction in BMI was 4%. However, in a systematic 
review and meta-analysis of RCTs, Lord et al. concluded that there was no evidence that 
metformin caused weight reduction in PCOS women (128). Weight reduction seems to 
be dose-related in obese PCOS women (129).
1.2.11 Effects of Metformin on androgen levels
In RCTs the average reduction of androgen hormone levels (free testosterone, free 
androgen index and total testosterone) were around 20%, with wide variations, in the 
metformin groups (130-135). The data on SHBG are inconclusive (127).
1.2.12 The effect of metformin in obese PCOS
Metformin therapy to ameliorate the hormonal and metabolic consequences of PCOS is 
common in practice(136, 137). Studies have shown that metformin can reduce body 
mass index of around 4% and androgen measures of around 20% compared to 
placebo(138), but may be less effective in overweight patients especially with BMI 
more than 36 kg/m2(129, 139, 140)
1.2.13 Adverse effects of Metformin
Gastrointestinal side effects occur in about 20 % of patients. Adverse effects are usually 
transient and resolve within one month of treatment, but 5 % of the patients cannot 
tolerate the drug. Gastrointestinal side effects, such as bloatedness, nausea, vomiting, 
diarrhoea, constipation and metallic taste are most frequent. Increasing the dose slowly 
and taking with food, could diminish side effects. A severe and feared adverse effect is 
the development of lactic acidosis. This occurs in less than 1 in 10 000 patient years, and 
it has never been observed when contraindications to metformin administration are 
adhered to. The contraindications to metformin are impaired renal and hepatic function,
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alcohol abuse, and serious cardiovascular and pulmonary diseases. These are all 
conditions that predisposes to lactic acidosis per se.
1.3 The effect of weight loss PCOS
Obesity, particularly an abdominal deposition of fat, is common in PCOS patients (141). 
Together with the presence of insulin resistance, obesity contributes to the 43% 
prevalence of the metabolic syndrome in PCOS patients(142). Diet-induced weight loss 
ameliorates the clinical signs and symptoms of PCOS, including hyperandrogenism and 
insulin resistance(143), menstrual dysfunction(144), and oligoovulation(145). Even 
modest weight loss of less than 10% of initial body weight has been shown to increase 
the frequency of ovulation, improve conception, and reduce testosterone, free androgen 
index, hyperlipidemia, hyperglycaemia and insulin resistance in women with 
PCOS.(146, 147)
However, the magnitude of the weight loss usually attained after caloric restriction 
combined with increased physical activity is usually moderate, in the range of 5-10% of 
the initial body weight, and is frequently not maintained for long periods of time (148, 
149). Therefore, PCOS patients usually require treatment with insulin sensitizers or oral 
contraceptives to control their symptoms even after successful nonpharmacological 
treatment. It has been shown that hyperandrogenism, menstrual function, and insulin 
resistance may completely improve after bariatric surgery(150).
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1.3.1 The effect of weight loss on improvement of insulin resistance in PCOS:
Since a high percentage of PCOS patients are obese, the role of weight loss in the 
management of this syndrome may be significant. The literature is encouraging on this 
point, although most studies have not included a control group(151, 152); statistical 
samples have also been small(153-155) and heterogeneous(151) but all studies agree that 
weight loss has a positive effect on hyperinsulinemia in women with PCOS. The effect 
did not seem to require great weight loss, but became evident with losses of 2-5%(146). 
In addition to a reduction in insulin resistance, weight loss also involves a parallel 
improvement in endocrine status of PCOS patients. Significant improvements in 
hirsutism and ovulation, with restoration of regular cycles and an increased incidence of 
spontaneous pregnancies in 30% of patients, have also been reported (151-155).
1.3.2 Does weight reduction lead to other health benefits?
Weight loss of 5% to 10% generally lessens many health risks, including cardiovascular 
risks, although such improvements are most notably demonstrable in studies specifically 
conducted in high-risk populations, and the benefits are presumed to be greater when 
healthier weight is maintained for long periods(156). When weight loss is achieved 
primarily via pharmacological interventions, these benefits have not occurred quite so 
consistently. Weight loss of 5-10% reduces the long-term risk of diseases associated 
with obesity(157). For every 1kg an obese person loses, serum concentration of LDL 
cholesterol falls by 0.02mmol/L, triglyceride falls by 0.015mmol/L and HDL cholesterol 
rises by 0.009mmol/L(158), and in those who are hypertensive, blood pressure falls by 
about l-2mmHg(159).
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1.3.3 Are interventions aimed at lifestyle modifications effective?
Reduced caloric intake and increased physical activity are generally accepted as the 
foundations of any approach directed at weight reduction, but these lifestyle 
interventions do not appear to provide long-lasting success for obese individuals 
wishing to lose weight. About half of the weight lost with the help of lifestyle 
interventions is regained at 1 year; after 3 to 5 years, only about 1 in 5 individuals 
maintains clinically meaningful weight loss, and more than half of obese patients return 
to their baseline weights(160). One systematic review concluded that dietary and 
lifestyle therapy leads to less than 5 kg of weight loss after 2 to 4 years(156).
1.4 What is the current state of antiobesity drug therapy? 
1.4.1 Sibutramine
It is a mixed norepinephrine serotonin uptake inhibitor. A recent meta-analysis 
estimated that 1 year treatment with sibutramine yields an average placebo-subtracted 
weight loss of 4.5kg(161). Some evidence suggests that sibutramine helps patients 
maintain initial weight reductions. In the Sibutramine Trial of Obesity Reduction and 
Maintenance (STORM)(162), Sibutramine is associated with small increases in BP and 
heart rate in obese patients with and without hypertension (161). It is contraindicated 
for patients with uncontrolled or poorly controlled hypertension, CHD, congestive heart 
failure, arrhythmias, and stroke and those taking monoamine oxidase inhibitors. The 
product label advises caution in using sibutramine for patients receiving the selective 
serotonin reuptake inhibitor class of antidepressants.
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1.4.2 Orlistat
Orlistat (Xenical), a lipase inhibitor that reduces fat absorption in the gut. A recent 
meta-analysis estimated that orlistat treatment led to an average placebo-subtracted 
weight loss of 2.7 kg at 1 year (163). Overall, the magnitude of weight loss achievable 
with orlistat appears to be less than that with sibutramine after 1 to 2 years. However, 
orlistat is the only antiobesity drug with a published 4-year RCT. In a Swedish study of 
3305 obese, nondiabetic patients (21% had impaired glucose tolerance), orlistat 
treatment was associated with a 3.6-kg weight loss compared with 1.4 kg for placebo at 
4 years (intention-to-treat [ITT] analysis)(164). The cumulative incidence of diabetes 
mellitus was 6.2% with orlistat therapy and 9.0% with placebo; a difference in diabetes 
incidence was detectable only in the subgroup of patients with impaired glucose 
tolerance at baseline.
No major safety concerns have been identified with orlistat therapy. Approximately 15% 
to 30% of those taking orlistat experience oily stool, faecal urgency, or oily spotting, 
and 7% report faecal incontinence, particularly at the initiation of treatment(163). 
1.4.3 Phentermine
Phentermine remains the most prescribed antiobesity drug in the United States, where 
prescriptions for the drug, which was approved in 1959, outnumber combined 
prescriptions for sibutramine and orlistat(165). Whereas phentermine is approved for 
short-term use (generally taken as 12 to 16 weeks), physicians commonly prescribe it for 
longer periods) 165). Its long-term efficacy (for at least 1 year) has never been tested in 
an RCT.
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1.4.4 Rimonabant
The story of rimonabant begins with the understanding that endocannabinoids, cannabis- 
like substances in the central nervous system, play a significant role in stimulating the 
drive for food ingestion. The endocannabinoid system interacts with several 
neuropeptides that modulate hunger and satiety signals, with the net result being 
stimulation of appetite (166). In 1990, Matsuda et al(167) reported that a specific 
cannabinoid receptor, CB1, was found extensively in the brain. CB1 receptors appear to 
regulate the activity of mesolimbic dopamine neurons, thereby possibly modulating 
hedonistic or reward behaviours mediated by dopamine(168), and to interact with 
neuropeptides such as the melanocortins and gut peptides such as ghrelin in regulating 
food intake(169, 170). This knowledge sparked the development of numerous CB1 
antagonists, of which rimonabant has by far had the most success in human applications. 
In animal studies, considerable evidence indicates that rimonabant suppresses 
eating(171) and reduces the preference for sweet foods(172). 
1.4.4.1 Cannabinoid receptors
The endocannabinoid system consists of endogenous cannabinoids (endocannabinoids), 
cannabinoid receptors and the synthetic and degrading enzymes responsible for 
synthesis and degradation of endocannabinoids. Endocannabinoids are so named 
because they were first identified as activating the same receptors as cannabinoids, the 
primary psychoactive components of cannabis. The first endocannabinoid identified was 
arachidonoyl ethanolamide (anandamide; from the Sanskrit for 'internal bliss'). 
Anandamide is only one of a large family of related bioactive acyl ethanolamides. The 
second endocannabinoid identified was 2-arachidonoyl glycerol (2-AG).
42
43
The synthesis, cellular transport and degradation of endocannabinoids are tightly 
regulated processes (174). A feature that distinguishes endocannabinoids from many 
other neuromodulators is that they are not synthesised in advance and stored in vesicles. 
Rather, their precursors exist in cell membranes and are cleaved by specific enzymes. 
This form of synthesis is often referred to as 'on demand'.. 
The identification of cannabinoid receptors grew out of a desire to understand the 
psychoactive effects of-tetrahydro D9 cannabinol (THC), the principal psychoactive 
component of cannabis. Although several experiments hinted at the existence of specific 
protein receptors for D9-THC, Allyn Hewlett et al.(174) provided definitive proof for a 
cannabinoid receptor. Their work established that cannabinoids activated a G protein- 
coupled receptor (GPCR) that inhibited adenylyl cyclase. Furthermore, they developed a 
binding assay for this receptor and showed that quite high levels of this receptor were 
present in certain brain regions (174).
The development of high affinity cannabinoid receptor agonists permitted the mapping 
of cannabinoid receptor distribution in the brain (181, 182). These initial auto- 
radiographic studies also established that cannabinoid binding sites are highest in the 
brain regions implicated in the actions of cannabis (181, 182). 
The cloning of a cannabinoid receptor by Matsuda et al. (167), provided the final 
evidence for the existence of a cannabinoid receptor and permitted the identification of 
cannabinoid receptor-expressing neurones. This cloning was swiftly followed by the 
cloning of a second cannabinoid receptor, designated CB2, from a promyelocytic cell 
line (183). (Of course, the first cannabinoid receptor was then designated as CB1).
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I.4.4.2 Does rimonabant produce greater weight loss than other currently available 
antiobesity drugs?
Treatment with rimonabant 20 mg and diet is associated with 3.9- to 5.4-kg (8.6- to
II.9-lb) greater weight loss than could be achieved with placebo and diet after 1 year; 
this finding is similar to the efficacy noted with sibutramine treatment in 1-year RCTs. 
The 7.4-kg weight loss observed with continuous 2-year treatment with rimonabant 20 
mg/d in the RIO-North America study is an impressive finding because there was 
further weight loss and not weight regain during the second year. Although the STORM 
trial (162) showed significant weight reduction with sibutramine treatment for 2 years, 
only those patients who had achieved at least 5% weight loss in the first 6 months 
continued further in the study; thus, the net weight loss reported at 2-year follow-up was 
for the initial responders to sibutramine, and the 2-year sibutramine results could not be 
compared with RIO-North America study findings. In 4 separate 2-year RCTs (184-187) 
patients treated with orlistat regained some degree of the weight during the second year 
of continuous treatment. At this time, RIO-North America is the only 2-year RCT with 
rimonabant; studies of longer duration (5 years) will provide more valuable information 
about efficacy, safety, and cost-benefit analysis of rimonabant therapy.
1.4.4.3 What about reduction in cardiovascular and metabolic risk factors with 
rimonabant?
In the 4 RIO trials, rimonabant treatment led to a negligible reduction in systolic BP that 
ranged from 0.2 to 2.3 mm Hg relative to placebo and no reduction in diastolic BP. A 
consistent reduction in TGs has been observed with rimonabant in all RIO trials, with
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placebo-subtracted decreases ranging from 12% to 16%. Furthermore, HDL-C showed 
consistent improvement with rimonabant treatment in all RIO trials, with placebo- 
subtracted increases ranging from 7% to 9%. However, weight loss achieved with 
rimonabant has not led to reductions in total cholesterol or LDL-C. It is notable that 
sibutramine-promoted weight loss also led to improvements in TGs and HDL-C but not 
in total cholesterol or LDL-C in most studies. In contrast, long-term treatment with 
orlistat is often associated with greater improvements in total cholesterol and LDL-C 
relative to placebo and less so to improvements in TG and HDL-C(163, 188). 
In the RIO-Diabetes trial that enrolled overweight or obese patients with T2DM who 
were given metformin or a sulfonylurea, treatment with rimonabant for 1 year reduced 
HbAlC by 0.7% relative to placebo. Changes in glycemic indices were less remarkable 
with rimonabant treatment in the other 3 RIO studies. A recent meta-analysis has 
estimated that sibutramine treatment was associated with an average 0.7% absolute 
reduction in HbAlC among overweight adults with T2DM in studies of 12 to 26 weeks' 
duration (189).
In summary, the most notable changes in lipids with rimonabant treatment in RIO trials 
were a 12% to 16% reduction in TGs and a 7% to 9% increase in HDL-C. Rimonabant 
has demonstrated somewhat meaningful improvements in TG and HDL-C, but other 
highly effective interventions are available for this purpose(190). Nicotinic acid and 
fibric acids reduce TGs by 20% to 50% and raise HDL-C by 10% to 35%. Thus, the 
value of rimonabant for obese patients with dyslipidemia and/or T2DM as monotherapy 
remains open to question. 
The strengths of rimonabant are as follows:
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(1) In 4 well-designed studies with >6600 overweight and obese patients, rimonabant 
has demonstrated consistent efficacy with regard to weight reduction.
(2) Rimonabant offers a novel mechanism of action, which may make it well suited as 
an alternative for people who do not respond well to other agents and for combination 
treatment with other antiobesity agents.
(3) Weight loss achieved with rimonabant also appears to improve some features of
metabolic syndrome.
The limitations of rimonabant are the following:
(1) Rimonabant increases the risk of psychiatric adverse events - ie depressed mood
disorders and anxiety (191). In view of this the European Medicines Age ncy (EMEA),
the European Union (EU) body which is responsible for monitoring the safety of
medicines, has recommended the suspension of the marketing authorisation of
rimonabant. The EMEA has concluded that the benefits of rimonabant no longer
outweigh its risks and the market authorisation was suspended across the EU from July
2008.
(2) Weight-reduction efficacy is not superior to the modest effects observed with 
currently approved antiobesity drugs.
(3) Although some features of metabolic syndrome have been shown to improve 
modestly, no reduction in LDL-C occurs, although this appears to be the case with all 
centrally acting antiobesity drugs.
(4) Whereas rimonabant has been shown to be superior to placebo in helping smokers 
quit in short duration trials, its overall efficacy is not particularly impressive, and it has 
been judged to be not approvable for this indication at this time.
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1.5 Does rimonabant modulate incretin hormones to produce weight loss? 
1.5.1 The Incretin Effect
The role of the gastrointestinal tract in influencing insulin secretion and glucose 
homeostasis has been recognized since the beginning of the 20th century (192). Zunz 
and La Barre first proposed the term "incretin" in reference to an insulin-stimulatory 
hypoglycemic factor found in the extract of duodenum. Incretin hormones have since 
been defined as hormones produced by the gastrointestinal tract in response to nutrient 
entry, which then stimulate insulin secretion. The enteroinsular axis refers to the 
regulation of pancreatic islet hormone secretion by such incretin hormone signals from 
the gastrointestinal tract (193).
The concept of the incretin effect developed from the observation by Elrick and 
colleagues and Mclntyre and colleagues that insulin responses to oral glucose exceeded 
those measured after intravenous administration of equivalent amounts of glucose (194, 
195). They concluded that gut-derived factors, or incretins, influenced postprandial 
insulin release. Nutrient entry into the stomach and proximal gastrointestinal tract causes 
release of incretin hormones, which then stimulate insulin secretion (196). This 
insulinotropism, or ability to stimulate insulin secretion, can be quantified by comparing 
insulin or C-peptide responses to oral vs. intravenous glucose loads. In this way, it has 
been shown that the incretin effect is responsible for about 50% to 70% of the insulin 
response to oral glucose in healthy individuals (197, 198). Although many postprandial 
hormones have incretin-like activity, the 2 predominant incretin hormones are glucose- 
dependent insulinotropic polypeptide, also known as gastric inhibitory polypeptide 
(GIF), and glucagon-like peptide-1 (GLP-1).
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1.5.2 The Incretin Hormones: GIF and GLP-1
GIF and GLP-1 both belong to the glucagon peptide superfamily and thus share amino 
acid sequence homology. GIF and GLP-1 are secreted by specialized cells in the 
gastrointestinal tract and have receptors located on islet cells as well as other tissues. As 
incretins, both are secreted from the intestine in response to ingestion of nutrients, which 
results in enhanced insulin secretion. The insulinotropic effect of GIP and GLP-1 is 
dependent on elevations in ambient glucose. Both are rapidly inactivated by the 
ubiquitous enzyme dipeptidyl peptidase IV (DPP-IV). The characteristics of GIP and 
GLP-1 are summarized in the Table 3.
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Table 3. Characteristics of GIF and GLP-1
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Peptide
Secreted by
Stimulated by
Metabolized by
Effects on insulin secretion
Effects on gastric emptying
Effects on beta-cell proliferation
Effects on glucagon secretion
Effects on food intake
Effects on insulin sensitivity
Secretion in type 2 diabetes
Insulinotropic response to 
exogenous administration in type 2 
diabetes
GIF
42 amino acid
K cells, primarily in 
duodenum and proximal 
jejunum
Oral ingestion of nutrients
DPP-IV
Stimulates
Accelerates?
Stimulates*
None significant
None significant
?
Preserved
Impaired
GLP-1
30/31 amino acid
L cells, primarily in 
ileum and colon
Oral ingestion of 
nutrients
Dpp-rv
Stimulates
Slows
Stimulates*
Suppresses
Reduces
Improves?
Impaired
Preserved
*In cell-line studies
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1.5.3 GIF
Discovered in 1971, GIF is a single 42-amino acid peptide synthesized in and secreted 
by specialized enteroendocrine K-cells. These cells are concentrated primarily in the 
duodenum and proximal jejunum, although they also can be found throughout the 
intestine (199). The main stimulant for GIF secretion is ingestion of carbohydrate- and 
lipid-rich meals (200). Following ingestion, circulating plasma GIF levels increase 10- 
to 20-fold. The half-life of intact GIF is estimated to be approximately 7.3 minutes in 
healthy subjects and 5.2 minutes in diabetic subjects (201).
GIF secretion reaches peak concentrations 15-30 minutes following ingestion of oral 
glucose or lipids, even before absorption of nutrients into the gut (202, 203). This 
suggests a potential role for other influences in GIF secretion. GIF secretion is also 
closely correlated with GLP-1 secretion, suggesting a paracrine relation between the 2 
hormones (204, 205).
Following secretion into the circulation, intact GIF (1-42 amide) is cleaved at the NH2- 
terminus by DPP-IV, resulting in the formation of the inactive truncated GIF (3-42 
amide), which lacks incretin activity and may even act as an antagonist of GIF at its 
receptor (199).
The GIF receptor also has been cloned and is related to the receptors for other members 
of the glucagon peptide super family. The GIF receptor is expressed in the pancreatic 
islets, as well as the gut, adipose tissue, heart, pituitary, adrenal cortex, and the brain 
(206). GIF was initially thought to act predominantly on the stomach as an inhibitor of 
gastrointestinal motor activity and acid secretion, hence the name gastric inhibitory
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polypeptide. This was based on observations in the canine stomach (207). However, 
further studies in humans have been unable to demonstrate any significant role of 
physiologic GIF on gastric acid secretion (208).
The incretin effect of GIF was first appreciated in the 1970s. The physiologic effects of 
GIF have been elucidated using GIF receptor antagonists, GIF peptide antagonists, and 
GIF receptor knockout mice, in addition to GIF infusion protocols. Blocking GIF 
binding to its receptor results in attenuated glucose-dependent insulin secretion 
following oral glucose load in rats and mice (211). Similarly, administration of GIF 
antagonists or GIF antisera markedly reduces the postprandial insulin release in rats 
(212). GIF receptor knockout mice demonstrate normal fasting glucose levels but mild 
glucose intolerance following oral glucose loads (213, 214). Interestingly, they also 
exhibit resistance to diet-induced obesity following months of high-fat feeding. 
Additionally, in the leptin-deficient ob/ob mouse, the GIF receptor knockout genotype 
appears to decrease the extent of obesity that develops (214).
GIF infusion has consistently demonstrated stimulation of insulin secretion in isolated 
rat islets, isolated perfused rat pancreas, dogs, and humans (207, 215-217). During 
stepwise euglycemic, mild hyperglycemic (54 mg/dL above basal), and moderate 
hyperglycemic (143 mg/dL above basal) clamps, Elahi and colleagues (217) have 
demonstrated that GIF infusion results in insulin secretion only in the presence of 
elevated glucose concentrations. Furthermore, they demonstrated that GIF is not 
glucagonotropic in normal humans during either euglycemic or hyperglycemic 
conditions. Thus, the effect of endogenously released GIF appears to be an important
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mechanism of postprandial insulin secretion and does not appear to play a role in the 
fasting state.
GIF has many non-incretin effects. Unlike other insulin secretagogues, GIF stimulates 
beta-cell proliferation and cell survival in INS-1 islet cell-line studies (218, 219). 
Furthermore, animal studies have suggested a role for GIF in lipid metabolism by 
stimulating lipoprotein lipase activity, inducing fatty acid incorporation into adipose 
tissue and stimulating fatty acid synthesis (220-222). However, in humans, there is no 
clear evidence for an effect of GIF on lipid metabolism. GIF also appears to stimulate 
glucagon secretion from the isolated perfused rat pancreas, although human studies have 
not demonstrated any significant influence on glucagon secretion (217). Furthermore, 
unlike GLP-1, GIF appears to act by accelerating emptying of the stomach rather than 
by inhibiting gastrointestinal motility (199). 
1.5.4 GLP-1
GLP-1, a product of the glucagon gene, was first identified in the early 1980s. GLP-1 is 
a 30/31 amino acid peptide synthesized and secreted by enteroendocrine L-cells located 
predominantly in the ileum and colon, although also by L-cells in the duodenum and 
jejunum. Other incretin products of the glucagon gene include glicentin, which is 
biologically inactive, and oxyntomodulin, which has some insulinotropic properties 
(223). Like GIF, the GLP-1 receptor is widely expressed in pancreatic islets, the brain, 
heart, kidney, and the gastrointestinal tract. There are 2 major forms of biologically 
active GLP-1 secreted following meal ingestion: GLP-1 (7-37) and GLP-1 (7-36) amide, 
which differ by a single amino acid. The majority of the circulating active GLP-1 
appears to be GLP-1 (7-36) amide, although both are equipotent and have similar
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biological activities (224). GLP-1 secretion from the distal gut is triggered by neural 
and endocrine signals initiated by nutrient entry into the lumen of the proximal GI tract. 
Circulating levels of GLP-1 increase rapidly within minutes of food ingestion and are 
highly correlated with the release of insulin (225, 226). Like GIP, GLP-1 enhances 
insulin secretion only in the presence of elevated glucose concentrations. DPP-IV 
rapidly cleaves GLP-1 to its truncated inactive metabolite. Infused GLP-1 has a shorter 
half-life than GIP, approximating 2 minutes in both nondiabetic and diabetic human 
subjects (227).
GLP-1 exerts many biological effects, and most of the GLP-1 actions studied in animal 
studies also have been demonstrated in human studies. GLP-1 is responsible for a 
significant part of the insulin response to oral glucose, and both animal and human 
studies with GLP-1 receptor antagonists suggest that GLP-1 may be essential for normal 
glucose tolerance. GLP-1 not only enhances insulin secretion but also suppresses the 
secretion of glucagon in a glucose-dependent fashion (231). There is increasing 
evidence that, like GIP, GLP-1 increases beta-cell proliferation and promotes beta-cell 
survival. GLP-1 has also been shown to slow gastric emptying in animal and human 
studies, resulting in slowed nutrient entry to the intestine and decreased postprandial 
glucose concentrations.
There is also a significant interest in the role of GLP-1 in the regulation of food intake 
and weight loss. In rodents, acute intracerebroventricular injection of GLP-1 or GLP-1 
receptor agonists results in reduction of food intake. Furthermore, central administration 
of the GLP-1 receptor antagonist exendin 9-39 results in increased food intake in rats 
(235).
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1.6 Is there any potential role of statins in the treatment of PCOS?
Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis (236). 
The ovaries of women with PCOS are typically enlarged with prominent hyperplasia of 
ovarian theca-interstitial cells and excessive production of androgens by these cells(237- 
239).
Statins have been shown to inhibit growth of vascular smooth muscle(240-242), 
cardiomyocytes(243), and mesangial cells(244). It is likely that statin induced inhibition 
of growth is related to blockage of HMG-Co (A). Products of HMG-Co (A) include 
mevalonate and several downstream isoprenoids including geranyl pyrophosphate and 
farnesyl pyrophosphate. These isoprenoids play an important role in the post- 
translational modifications (e.g., granulation and farnesylation) of a variety of small 
GTPase proteins, such as Ras and Rho(244, 245).
Both Ras and Rho are involved in the regulation of various cellular processes such as 
proliferation, apoptosis, and differentiation. An inhibition of HMG-Co (A) and a 
consequent decrease of the genanylation or farnesylation of Ras and Rho may inactivate 
important signal transduction pathways regulating mitotic activity. Studies have 
indicated that statin-induced inhibition of proliferation of mesanglial cells was 
associated with a repression of activation of Rho GTPase/p21 signaling; this effect was 
independent of its cholesterol-lowering actions(244). Comparable mechanisms may be 
involved in mevastatin-induced inhibition of theca-interstitial proliferation. The effects 
of mevastatin on steroidogenesis are most likely related to the inhibition of cholesterol
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synthesis and a consequent decrease in the availability of the precursors of progesterone 
and testosterone.
Studies in men produced contradictory findings. Some investigators reported that the 
use of statins was associated with a decrease of testosterone levels(246, 247); however, 
other researchers found no significant change in testosterone level after even prolonged 
use of several statins(248-250). In postmenopausal women, use of statins led to a 
borderline decrease of progesterone(251). The same study also evaluated the effects of 
statin in a small population of premenopausal women and detected no significant 
changes in progesterone or estrogen levels; testosterone levels were not documented. In 
another small study of seven postmenopausal women, a low dose of simvastatin had no 
effect on plasma levels of progesterone or testosterone(252)
1.6.1 What are the pleotrophic effects of statins?
Pleiotropic effects of a drug are actions other than those for which the agent was 
specifically developed. These effects maybe related or unrelated to the primary 
mechanism of action of the drug, and they are usually unanticipated. Pleiotropic effects 
may be undesirable (such as side effects or toxicity), neutral, or, as is especially the case 
with HMG-CoA reductase inhibitors (statins), beneficial. Pleiotropic effects of statins 
include improvement of endothelial dysfunction, increased nitric oxide bioavailability, 
antioxidant properties, inhibition of inflammatory responses, and stabilization of 
atherosclerotic plaques. These and several other emergent properties could act in concert 
with the potent low-density lipoprotein cholesterol-lowering effects of statins to exert 
early as well as lasting cardiovascular protective effects. Understanding the pleiotropic
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effects of statins is important to optimize their use in treatment and prevention of 
cardiovascular disease.
What potential mechanisms might explain the early effects of statin therapy? Statins 
inhibit HMG-CoA reductase, which is responsible for the reduction in circulating LDL 
cholesterol beginning one to two weeks after therapy initiation. Statins also inhibit 
HMG-CoA reductase within endothelial cells, vascular smooth muscle cells, and 
inflammatory cells (the monocyte/macrophage system), which affects important 
signaling pathways. In cell culture, animal, and clinical studies, these effects appear 
within hours after statin administration and may be dose dependent (253, 254).
As HMG-CoA reductase inhibitors (statins) became more widely used in greater 
numbers of patients, their effects beyond lipid lowering began to emerge. Such 
pleiotropic effects include improvement of endothelial dysfunction, increased nitric 
oxide bioavailability, antioxidant effects, anti-inflammatory properties, and stabilization 
of atherosclerotic plaques. Additional effects of growing interest include the ability to 
recruit endothelial progenitor cells (EPCs), a putative immunosuppressive activity, and 
inhibition of cardiac hypertrophy. Research indicates that some of the pleiotropic effects 
of statins may be unrelated to the cholesterol-lowering properties of the drugs. Others 
may even be fully dissociated from inhibition of HMG-CoA reductase, and many take 
place at very low drug concentrations.
The pleotrophic effect of statin includes improvement of endothelial dysfunction, 
normalized vasomotion, increased bioavailability of nitric oxide, antioxidant effects, 
anti-inflammatory effects, reduction of serum CRP, reduction of adhesion molecules,
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plaque stabilization, stimulation of endothelial progenitor cell recruitment, 
immunomodulation and inhibition of myocardial hypertrophy.
Although the possibility that statins might have pleiotropic effects was met at first with a 
healthy skepticism, the vast amount of knowledge accrued over the past few years has 
moved these effects into the spotlight. Many of the statin pleiotropic effects operate 
independently of LDL-cholesterol reduction, correlate poorly or not at all with LDL- 
cholesterol changes, take place rapidly, and are rapidly reversible on discontinuation of 
the drug. Direct effects in the absence of LDL or total cholesterol modification have 
been shown both in vitro and in vivo.
1.7 What is the clinical relevance of biological variation?
Most bio-analytes measured in clinical chemistry laboratories change with time. The 
knowledge of the temporal changes following acute illnesses, for example, in serum 
troponin concentration after myocardial infarction is necessary for the selection of the 
most appropriate time to draw samples to aid in the diagnostic process and the correct 
interpretation of the results.
Changes that occur in health are also important. Many analytes can vary over an 
individual's lifetime, simply because of natural biological factors involved in the aging 
process with particularly important periods being neonatal period, childhood, puberty 
and menopause. In addition, certain analytes have predictable biological rhythms which 
may be daily (circadian), monthly or seasonal. The knowledge of these rhythms is 
clearly crucial as the samples must be collected at the appropriate times and the results 
interpreted with this information.
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Most analytes, however, do not have cyclical rhythms that are clearly defined but have 
variation that can be described as random fluctuation around a homeostatic setting point. 
For example if a series of samples from one individual for a particular laboratory test is 
taken the results are often not exactly the same number. This biological variation may 
have contributors, e.g., pre-analytical influences (variation in sample collection, such as 
patient posture, exercise and the application of a tourniquet), analytical variation (such 
as assay imprecision and calibration errors) and inherent biological variation around the 
homeostatic setting point which is also called the within-subject (or intraindividual) 
biological variation.
Even amongst healthy individuals if the same test were performed repeatedly on various 
individuals the mean of each person's results would not exactly match as individuals 
homeostatic setting points usually vary. This difference between individuals is called 
between-subject (or inter-individual) variation.
Data on biological variation of physiological response variables are useful for many 
purposes in clinical chemistry such as to set quality specifications derive reference 
change values and assess the utility of conventional reference values. An important 
example of quality specification is the American Diabetes Association documented 
quality specification for glycated haemoglobin analysis which ensures uniformity of 
measurement across many countries.
Clinical practice often leads to a situation where serial measurements are made in an 
individual to monitor health or chronic disease states such as diabetes. The significance
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of change in serial measures of an analyte is fundamental to correctly interpreting these 
serial results. The reference change value or critical difference between two consecutive 
samples in an individual subject (i.e, the smallest percentage change unlikely to be due 
to biological variability) for each analyte is needed for this analysis and is dependent on 
the biological variation data (both in health and in disease) of the analyte being tested 
(270).
Data on biological variation is also important in testing the utility of conventional 
reference ranges and n the objective assessment of a tests suitability to be used for the 
purposes of screening. To be suitable for use as a screening test the relative intra- to 
inter individual variation of the analyte in the population being tested should be similar 
(i.e. the within subject variation for the test should be similar to the variation of the 
population as a whole) and this is mathematically represented by the index of 
individuality (Iol).(271) The lol is derived from the ratio of intra- and inter individual 
variation. When the lol for a particular test is <0.6, conventional population based 
reference intervals are of limited value in the detection of unusual results for a particular 
individual. When the lol is >1.4, the variation of an individual will fit populations' 
reference limits more closely so being suitable as a screening test. Serum creatinine, for 
example, has an lol of only 0.27 which contrasts with a newer marker of renal function, 
cystatin C, which has got an lol of 1.64(272). This means the latter test is likely to be 
the more useful to screen subjects for reduced glomerular filtration rate (GFR) using a 
population-based (rather than a subjects own) reference interval.
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1.7.1 Is there any biological variation of lipids?
In order to assess an individual patient, one should sample the lipids from at least 2 
different collections and average the results. Another situation involves the evaluation 
of change in the patient's lipid values following intervention, whether the intervention is 
diet, lifestyle changes, or drug therapy. A difference between the baseline and new 
values should fall greater than 2.77 times the standard deviation of the biological 
variation, expressed in units of the test measurement, to be significant at a 95% 
confidence interval. For example, if the baseline value for LDL-C was 167 mg/dL and 
one assumed a biological variation of 6%, and then the biological variation would be 
10.0 mg/dL. This biological variation multiplied times 2.77 yields 27.7 mg/dL. A new 
value of 150 mg/dL provides a difference of 17 mg/dL, which is less than 27.7 mg/dL, 
and thus, the difference between the values is not significant. The new value would have 
to decline to a value of 139 mg/dL or less in order to represent a significant decrease. In 
this example, one has assumed that the biological variation was 6% for LDL-C. Ideally, 
one would use a value derived from the patient, because biological variation varies 
somewhat from person to person.
One can compare the difference between two sequential values with the biological 
variation. Biological variation is a measure of the random disturbances of an analyte's 
value, measured at different times. When the difference > Z square root 2 SD (BV) then 
the difference is due to an underlying disease process or physiologic change. A Z value 
of 1.96 yields a 95% confidence limit. When using multiple sequential values or time 
periods exceeding that for the empirically derived biological variance, a random walk 
model allows one to estimate the spread of the variance. For a difference, (delta) to be
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significant, delta > Z square root 2n SD(BV), where n is the ratio of time reflecting the 
longer time period divided by the shorter time period. Not all variances grow to this 
degree over time, because restoring forces diminish the extent of random disturbances. 
The relationship between a biological variance measured over a longer time period to 
the one measured over a shorter period can be expressed in terms of this restoring force 
as SD2 BV,n = SD2 BV,1 sigma(n) j=l e(-2)(j-l)phi, where n is the ratio of time 
periods. One can calculate phi using this formula and a spreadsheet. From phi one can 
calculate the biological variance for any time period, within experimental limits, and 
compare the difference in sequential values with it. Test intervals can be calculated 
based on these biological variances.
Recently reported estimates of within individual biological variation (CVbiological) for 
key lipids and lipoproteins are listed in table 4 together with the NCEP recommended 
goals for precision for these analytes. From these figures the contribution of analytical 
imprecision to the total result variability has been calculated from the formula given by 
Fraser and Harris(270) and is shown to range from < 3% for triglyceride, through < 12% 
for total cholesterol and LDL-c, to < 15% for HDL, This is in line with the 
recommendation of Harris that it is desirable that CVanalytical should be less than 50% 
of CVbiological on the empirical basis that total result variability due to the analytical 
component is less than 11.8% in such circumstances(270). The clinical utility of an 
investigation is then largely determined by the individual biological variation of the 
parameter.
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On the basis of these figures for biological variation and acceptable imprecision, the 
Smallest Significant Difference (SSD%) between consecutive measurements has been 
calculated, together with the number of serial results which must be averaged to estimate 
the Homeostatic Set Point (HSP) of an individual to a given degree of 
accuracy(270).(table 4). These statistics are an important consideration in use of lipid 
and lipoprotein measurements to assess risk, response to therapy or attainment of a 
therapeutic goal: The SSD between consecutive measurements (p<0.05) is 
approximately 15% for total cholesterol, 20% for HDL-c and LDL-c and 50% for 
triglycerides.
A single measurement will be within 15% of the HSP for total cholesterol, within 20% 
for HDL-c and LDL-c. To achieve a more accurate estimate within 10%, however, 
requires the mean of two, three and four measurements respectively for these analytes. 
For triglyceride, which has a much greater biological variation, the mean of two results 
will estimate the HSP to within 30% and it requires five results to be within 20%.
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Table 4. NCEP Analytical Goals for Lipid and Lipoprotein Measurements
Cholesterol
Triglyceride
HDL-c
LDL-c
Total error (%)
9
15
13
12
Consistent with
Bias (%)
3
5
5
4
CVa (%)
3
5
4*
4
Total error = % Bias + 1.96 (CVanalytical)
* When HDL-c >/= 1.04 mmol/L, 40 mg/dL
Key: LDL-c = low density lipoprotein-cholesterol; HDL-c = high density lipoprotein- 
cholesterol
63
64
Table 5. Influence of Analytical and Biological Variation on the Clinical Utility of 
Lipid Measurements
CVanalytical (%)
CVbiological (%)
Contribution (%) of
analytical imprecision to
total variability
of serial results
SSD (%) between 
consecutive
test results
Total-c
3.0
6.0
11.8
15.7
HDL-c
4.0
7.1
14.8
21.5
LDL-c
4.0
8.3
11.0
19.0
Triglyceride
5.0
21.0
2.8
50.4
Number of results to estimate
HSP within ±10%
HSP within ±15%
HSP within ±20%
HSP within ±30%
2
1
3
2
1
4
2
1
18
8
5
2
Key: SSD = smallest significant difference (p<0.05), unidirectional; HSP = homeostatic 
set point (p<0.05); Total-c = total cholesterol; HDL-c = high density lipoprotein- 
cholesterol; LDL-c = low density lipoprotein-cholesterol
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Table 6
Important Considerations for the Measurement of Blood Lipids
• The accuracy of lipid measurements must be traceable to the CDC reference 
methodology accuracy base
• Inclusion of high density lipoprotein-cholesterol (HDL-c) improves specificity 
and sensitivity in risk calculations
• Direct use of computer programs allows greater accuracy than point score tables 
and charts derived from the same statistical functions
• To accurately assess total-cholesterol, high density lipoprotein-cholesterol 
(HDL-c) and LDL-c the mean of three measurements is required
• Several measurements are required for triglyceride
• Non-fasting total and HDL-c measurements are adequate for initial risk 
assessment
• A follow-up fasting profile including triglyceride is necessary if an elevated total 
or low HDL-c is identified
• When dyslipidaemia is identified consideration should be given to genetic and 
secondary causes with family screening and referral to specialists when 
appropriate
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1.7.2 How can we minimise the sources of pre-analytical variation?
Careful attention to patient preparation and blood collection technique can do much to 
facilitate accurate assessment of patients by controlling factors which induce variability 
in lipid and lipoprotein concentrations. These include:
• Prandial status:
A 12-hour fast essential for triglyceride measurement and calculated LDL, but 
not essential for total- or HDL-c measurements
• Lifestyle:
The patient should be metabolically stable and advised to maintain their normal 
diet, alcohol intake, smoking and exercise habits prior to testing
• Pregnancy or illness:
Investigation should be deferred for two weeks after a minor illness, 2-3 months 
after pregnancy, major illness or myocardial infarction. A sample taken within 
24 hours of the onset of myocardial infarction, however may match the pre- 
infarction state
• Phlebotomy:
Increases in lipid concentrations of up to 15%, resulting from diffusion of water 
from blood vessels into tissues, can occur within 15 minutes of changing from a 
supine to a standing position or if a tourniquet is applied for more than five 
minutes. Blood samples should therefore be drawn after the patient has been
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seated for at least five, preferably 15 minutes. If necessary, a tourniquet should
not be applied for more than one minute
Multiple Measurements:
As discussed earlier, medical decisions should be based on the required number
of measurements performed within two months and at least one week apart. To
avoid inter-laboratory differences in bias, these measurements should be
performed by the same laboratory.
1.7.3 Is measured LDL more reliable than calculated LDL in patients with type 2 
diabetes?
Hypercholesterolemia is one of the most common risk factors for cardiovascular disease. 
The guidelines stress the importance of utilizing both diet and drug therapy, if 
necessary, to achieve LDL-C target concentrations. Therefore, accurate and precise 
estimations of patients' LDL-C concentrations are necessary to appropriately identify 
individuals with hypercholesterolemia and to monitor response to diet and drug 
treatment.
For clinical purposes, LDL-C is generally determined from the Friedewald equation 
(277), which assumes that the amount of cholesterol in very-low density lipoproteins 
(VLDL) can be estimated by dividing the blood triglyceride concentration by a factor of 
five. The Friedewald equation correlates well with LDL-C concentrations determined by 
ultracentrifugation if blood triglyceride concentrations are <4.52 mmol/L. However, the
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reliability of the LDL-C calculation depends upon the accuracy and precision of total 
cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglyceride 
measurements. Poor analytic precision in any or all of these measurements will 
contribute to the variability observed in LDL-C concentrations. The biologic variability 
inherent in each of the three lipid measurements will also contribute to the total 
variability of the LDL-C concentration when the Friedewald equation is used. In 
particular, the biologic CV of blood triglyceride concentrations may be ^0% and may 
interfere with the reliability of the LDL-C calculation. Biologic variation is also a major 
component of the variability in HDL-C measurements, and is frequently in the range of 
7-8%. Although analytic variability can often be reduced with methodological advances 
in the laboratory, sources of error introduced by excessive biologic variability are not 
easily overcome.
The total variability for LDL-C measurements calculated by the Friedewald equation 
has been reported to be as high as 9.6% (278, 279), which implies that individual LDL- 
C readings could vary by up to 40% ( ± 2 SD) from one measurement to the next by 
chance alone. The usual approach to reduce this variability is to calculate the mean of 
several serial specimens (273, 280). For example, to decrease the LDL-C CV to 5%, a 
level adequate to detect most LDL-C responses to diet and drug therapy, at least two, 
and as many as five, serial blood specimens may have to be analyzed and averaged 
(281).
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To address these limitations of the Friedewald equation, a direct LDL-C assay has been 
developed. By using solid-phase immunocapture, HDL-C and VLDL-C are removed by 
centrifugation. The LDL-C remaining in the filtrate is quantified by an enzymatic 
cholesterol assay. The accuracy of this method compared with both standard 
ultracentrifugal techniques and the Friedewald calculation has been favourable, with an 
analytic imprecision of <5% (282). Because this assay measures LDL-C independently 
of other lipid fractions, it may potentially reduce the variability introduced into the 
Friedewald equation from the cumulative analytic and biologic variability of 
triglyceride, HDL-C, and total cholesterol measurements. For this reason, a direct assay 
of LDL-C may be a more useful test even when triglyceride concentrations are not 
markedly increased. For example, decreasing the variability of LDL-C measurements 
may reduce the number of serial specimens necessary to accurately reflect LDL-C 
concentrations in a patient.
Because the calculated LDL-C is derived from total cholesterol, triglycerides, and HDL- 
C measurements, one may expect that the considerable variability of these three 
measurements would contribute directly to the observed variability in the calculated 
LDL-C value. By determining LDL-C directly, the dependence upon three separate and 
relatively variable lipid measurements, total cholesterol, HDL-C, and triglycerides, is 
eliminated. The analytic precision of the direct LDL-C assay was excellent, meeting the 
precision criteria set for total cholesterol of <3% and performing better than reported 
for other direct LDL-C assays involving chemical precipitation methods. The analytic 
variability for total cholesterol, HDL-C, triglycerides, and the calculated LDL-C 
measurements were also <3%, comparing favourably with most previously published
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reports(279). On the other hand, the high biologic variability present in LDL-C 
measurements increased the total variability of both the calculated and direct LDL-C 
estimations. The total variability (CV) for either measurement measurements was 
greater than the total variability present for the direct LDL-C assay. However, despite 
the larger total variability present in HDL-C and triglyceride measurements, only the 
variability derived from total cholesterol determination was significantly associated with 
the variability of the calculated LDL-C. This suggests that an accurate and reliable total 
cholesterol measurement is of primary importance to ensure the accuracy and precision 
of LDL-C estimations with the Friedewald formula. Recommendations to improve both 
accuracy and precision of the total cholesterol concentration to CVs of <3% have been 
formulated, and will help to ensure the reliability of the calculated LDL-C 
determination.
An examination of the Friedewald equation suggests why neither triglyceride nor HDL- 
C variability is an important determinant of LDL-C variability. By dividing blood 
triglyceride concentrations by 5 to estimate \TLDLC, the equation limits the impact of 
triglyceride variability on the LDL-C measurement. Further, both HDL-C and VLDL-C 
concentrations are usually less than half of LDL-C concentrations, also diminishing their 
impact on calculated LDL-C variability. Therefore, increasing triglyceride 
concentrations are likely to add progressively more variability to the calculated LDL-C 
measurement.
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When should the direct LDL-C measurement be ordered? In patients with triglycerides 
>4.52 mmol/L, VLDL-C cannot be estimated accurately, and the calculated LDL-C 
becomes less accurate and precise(283). The calculated LDL-C may also be less reliable 
in patients with T2DM(284) and liver disease (285), possibly because of the propensity 
towards increased blood triglycerides in these illnesses. On the other hand, the direct 
LDL-C assay accurately measures LDL-C with triglyceride concentrations to 9.03 
mmol/L or higher. Patients requiring lipid determinations while not fasting may have 
increased triglyceride concentrations and may also benefit from a direct LDL-C 
measurement.
Although the direct LDL-C assay is less expensive than the calculated LDL-C value, it 
does not provide the additional information of triglyceride and HDL-C measurements. 
When this additional information is important, and the triglyceride concentrations are 
<4.52 mmol/L, a routine lipid panel and calculated LDL-C are probably sufficient. 
However, if the triglycerides may potentially increase above this concentration, or if 
only the LDL-C concentration is required, then the direct LDL-C assay should be the 
test of choice.
According to current recommendations for lipid monitoring in the hypercholesterolemic 
patient, triglyceride and HDL-C determinations, in addition to LDL-C, should be 
obtained yearly, whereas total cholesterol can be used to assess therapeutic effectiveness 
at interim visits. The direct LDL-C assay is less expensive than the standard lipid panel, 
yet provides a more accurate assessment of LDL-C than does the total cholesterol alone.
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Therefore, the direct LDL assay may have a role in routine monitoring of 
hypercholesterolemia therapy when triglyceride and HDL-C values are not required.
The direct LDL-C assay does not reduce the variation in LDL-C compared with the 
conventional LDL-C calculation. Therefore, serial specimens are still necessary to 
accurately assess LDL-C values and gauge response to therapy. However, because the 
direct assay is accurate even when triglycerides are increased, and because it allows a 
less expensive assessment of LDL-C (as an isolated test) than does the standard lipid 
panel, it appears to have a potentially useful role in lipid disorder management.
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Chapter 2
Methods
73
74
2.1 Laboratory Methods and Reagents
2.1.1 Intervention Studies
Study bloods and measurement were done after an overnight fast. Compliance was 
monitored by counting returned medication. Fasting venous blood was collected into 
serum gel and fluoride oxalate tubes. Samples were separated by centrifugation at 2000 
g for 15 min at 4oC, and the aliquots stored at -20oC. Serum testosterone was measured 
on an Architect analyzer (Abbott Laboratories, Maidenhead, UK), and SHBG was 
measured by immunometric assay with fluorescence detection on the DPC Immulite 
2000 analyzer using the manufacturer's recommended protocol. The free androgen 
index was obtained as the total testosterone xlOO/SHBG. Total cholesterol, 
triglycerides, and high-density lipoprotein cholesterol (HDL-C) levels were measured 
enzymatically using a Synchron LX20 analyzer (Beckman-Coulter, High Wycombe, 
UK). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald 
equation. Serum insulin was assayed using a competitive chemiluminescent 
immunoassay performed on the manufacturer's DPC Immulite 2000 analyzer 
(Euro/DPC, Llanberis, UK). The analytical sensitivity of the insulin assay was 2uU/ml, 
the coefficient of variation was 6%, and there was no stated cross-reactivity with 
proinsulin. Plasma glucose was measured using a Synchron LX 20 analyzer (Beckman- 
Coulter, High Wycombe, UK), using the manufacturer's recommended protocol. The 
coefficient of variation for the assay was 1.2% at a mean glucose value of 94.6 mg/dl 
(5.3mmol/liter) during the study period. The insulin resistance was calculated using the 
homeostasis model assessment (HOMA) method (HOMA-IR= (insulin x glucose)/22.5).
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2.1.2Biological Variability Studies
The biological variation of TC, HDL-C, LDL-C and triglycerides was assessed by 
measuring 12 hour fasting blood samples at four-day intervals on 10 consecutive 
occasions. Fasting venous blood was collected into serum gel tubes (Becton Dickinson, 
Oxford, U.K.) at the same time each day (0800-0900) after the patient had been seated 
for at least 5 minutes and tourniquet was not applied for more than a minute. Samples 
were separated by centrifugation at 2000g for 15 min at 4°C, and two aliquots of the 
serum were stored at -20°C within 1 h of collection. The serum samples were split 
before assay. Before analysis, all of the serum samples were thawed and thoroughly 
mixed. The duplicate samples (i.e., two per visit) were randomised and then analysed 
for cholesterol, triglycerides and HDL cholesterol in a continuous batch on a Synchron 
LX 20 analyser (Beckman-Coulter, High Wycombe, U.K.) using a single batch of 
reagents. LDL cholesterol was calculated using the Friedewald formula. The analytical 
sensitivity of the insulin assay was 2uU/ml and there was no stated cross-reactivity with 
proinsulin. Plasma glucose was measured using a Synchron LX 20 analyser 
(Beckman_Coulter, High Wycombe, UK), using the manufacturer's recommended 
protocol. The coefficient of variation for this assay was 1.2% at a mean glucose value 
of 5.3 mmol/L. 
2.2 Statistical Analysis
Statistical analysis was performed using SPSS for Windows, version 15.0 (SPSS, 
Chicago, IL) and Microsoft Excel. Results were considered significant if the two-tailed 
p value was less than 0.05. Details of sample size calculations for the biological
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variability studies are given below. The sample size calculation for the intervention 
studies are described in the relevant chapters.
2.2.1 Interventional studies
Comparisons between the two treatment groups, with respect to percentage changes 
from baseline were carried out using the paired t test for biochemical data and clinical 
observations. The Wilcoxon signed rank test was applied to biochemical data that 
violated the assumptions of normality when tested using the Kolmogorov-Smirnov test.
2.2.2 Biological variability studies
Biological variability data was analyzed by calculating the analytical and within-subject 
variability according to the methods of Fraser and Harris(270). By this technique, 
analytical variance (SDA2) was calculated from the difference between duplicate results 
for each specimen (SDA2 = 7M2/2N, where d is the difference between duplicates, and 
N is the number of paired results). The variance of the first set of duplicate results for 
each subject on the 10 assessment days was used to calculate the average biological 
intraindividual variance (SDK) by subtraction of the mean SDA2 from the observed 
dispersion (equal to SDI2 + SDA2). The standard deviation of intraindividual variations 
(SDI) was estimated as square roots of the respective variance component estimates. An 
individual's coefficient of variation (CV) for each lipid parameter was calculated as the 
SDI/mean value x 100% and then expressed as a mean value for each treatment. 
2.3 Ethics
All subjects gave their informed written consent prior to entering the studies that had 
been approved by the Hull and East Riding Local Research Ethics Committee and South 
Humber Local Research Ethics Committee.
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Chapter 3
A Comparison between Rimonabant and Metformin in
Reducing Biochemical Hyperandrogenaemia and Insulin
Resistance in Patients with Poly cystic Ovary Syndrome: A
Randomised Open Labelled Parallel Study.
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3.1 Introduction: Polycystic ovary syndrome (PCOS) is a common disorder of women 
of reproductive age group affecting more than 10% of Caucasian women and is 
characterised by insulin resistance, chronic anovulation and androgen excess.(107) 
Obesity is present in varying degrees in women with PCOS and is associated with 
hyperandrogenaemia and insulin resistance(286). Even modest weight loss of less than 
10% of initial body weight has been shown to increase the frequency of ovulation, 
improve conception, and reduce testosterone, free androgen index, hyperlipidaemia, 
hyperglycaemia and insulin resistance in women with PCOS.(146, 147) 
Metformin is commonly used in patients with PCOS and is reported to improve body 
weight, insulin resistance, sex hormone binding globulin (SHBG) and 
hyperandrogenaemia.(133, 287) Although metformin's actions appear to be mediated by 
activation of AMP-activated protein kinase, its precise molecular mechanism of action 
remains unclear (288). However, it has been shown to be of limited use in very obese 
women with polycystic ovary syndrome in some studies.(140) Rimonabant, a 
cannabinoid receptor 1 blocker, (289, 290) has shown an improvement in metabolic 
syndrome, waist circumference, lipid parameters and particularly insulin resistance in 
obese subjects.(291-293) The aim of this study was to see if the reduction of 
biochemical hyperandrogenaemia and insulin resistance by rimonabant through weight 
loss was superior to insulin sensitisation with metformin in obese women with PCOS.
3.2 Research Design and Methods
This was a randomised open labelled parallel study with metformin and rimonabant in 
20 patients with PCOS with a body mass index (BMI) ^Okg/m2 . The diagnosis of 
PCOS was based on all three diagnostic criteria of the Rotterdam consensus, namely
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clinical and biochemical evidence ofhyperandrogenaemia (Ferriman-Gallwey score >8; 
free androgen index >8 respectively), oligomenorrhoea or amenorrhea and polycystic 
ovaries on transvaginal ultrasound.(36) Subjects had no concurrent illness, were not on 
any medication for the preceding 6 months and were not planning to conceive. None of 
the patients had successful pregnancy or miscarriage at least 5 year prior to the study 
entry. Subjects were advised not to change their lifestyle including physical activity or 
dietary habits during the study period. Non-classical 21-hydroxylase deficiency, 
hyperprolactinaemia, Gushing's disease and androgen-secreting tumours were excluded 
by appropriate tests. All patients gave informed consent. Randomisation was performed 
using a random number generator. The study was approved by the Hull and East Riding 
Local Research Ethics committee
The twenty patients were randomised to either metformin 500mg t.d.s or to rimonabant 
20mg daily. Clinical and biochemical assessments were performed at randomisation and 
at the end of the 3-month period. The primary end point of the study was a change in 
free androgen index and insulin resistance. The secondary end points were change in 
weight and waist circumference.
Study bloods and measurement were done after an overnight fast. Compliance was 
monitored by counting returned medication. Fasting venous blood was collected into 
serum gel and fluoride oxalate tubes. Samples were separated by centrifugation at 2000 
g for 15 min at 4°C, and the aliquots stored at -20°C. Serum testosterone was measured 
on an Architect analyzer (Abbott Laboratories, Maidenhead, UK), and SHBG was 
measured by immunometric assay with fluorescence detection on the DPC Immulite
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2000 analyzer using the manufacturer's recommended protocol. The free androgen 
index was obtained as the total testosterone xlOO/SHBG. Total cholesterol, 
triglycerides, and high-density lipoprotein cholesterol (HDL-C) levels were measured 
enzymatically using a Synchron LX20 analyzer (Beckman-Coulter, High Wycombe, 
UK). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald 
equation. Serum insulin was assayed using a competitive chemiluminescent 
immunoassay performed on the manufacturer's DPC Immulite 2000 analyzer 
(Euro/DPC, Llanberis, UK). The analytical sensitivity of the insulin assay was 2uU/ml, 
the coefficient of variation was 6%, and there was no stated cross-reactivity with 
proinsulin. Plasma glucose was measured using a Synchron LX 20 analyzer (Beckman- 
Coulter, High Wycombe, UK), using the manufacturer's recommended protocol. The 
coefficient of variation for the assay was 1.2% at a mean glucose value of 94.6 mg/dl 
(5.3mmoI/liter) during the study period. The insulin resistance was calculated using the 
homeostasis model assessment (HOMA) method (HOMA-IR= (insulin x glucose)/22.5). 
Data are reported as mean ± SEM.
3.3 Statistical analysis and sample size calculation
The power of the study to demonstrate a significant reduction in total testosterone was 
based on a previous study showing a significant reduction in total testosterone 
concentration after treatment with metformin(294). Using two-sided 5% significance 
level, a sample of 10 patients per group was found to be needed (assuming a 20% 
dropout rate) to detect changes in total testosterone with 90% power. Statistical analysis 
is detailed in section 2.2.1
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3.4 Results
All 20 subjects recruited completed the 3-month study period. The compliance was 
98% in both groups. Two subjects given metformin reported having mild nausea and 
heartburn that resolved within 4 weeks; no subject required any dose reduction. All 
patients continued to have an irregular cycle and there was no difference in progesterone 
measurements before and after the study suggesting that phase of the menstrual cycle 
was not a confounder for the androgen or insulin results. 
The mean age group of patients was 28.6 ± 1.2 years (metformin 29.8 ± 1.8 vs. 
rimonabant 27.4 ±1.5 years). The mean body mass index of the patients did not differ 
between treatment groups (36.86 ±1.0 and 35.7 ±1.4 kg/m ) for rimonabant and 
metformin groups, respectively. Subject characteristics are shown in Table 7. 
Anthropometric parameters
Weight reduced significantly after 12 weeks of rimonabant treatment (104.6 ± 4.6 vs. 
98.4 ± 4.7 kg, p<0.01) with a corresponding reduction in waist circumference (116.0 ± 
3.3 vs. 109.2 ± 3.7 cm, p<0.01), hip circumference (128.5 ± 4.0 vs. 124.1 ± 4.2 cm, p< 
0.03) and waist hip ratio (0.90 ± 0.02 vs. 0.88 ± 0.01, p <0.01). In the metformin group 
these parameters were unchanged after treatment. 
Biochemical hyperandrogenaemia
After 12 weeks of rimonabant there was a significant reduction from baseline in free 
androgen index (26.6 ± 6.1 vs. 16.6 ± 4.1 pO.Ol) and testosterone (4.6 ± 0.4 vs. 3.1 ± 
0.3 nmol/L (132.7 ± 11.5 vs. 89.4 ± 8.65ng/dL) p <0.01) (Figure 1) but there was no 
significant reduction in the metformin treated group (FAI p = 0.38; testosterone p =
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0.57). The percentage reduction in testosterone was significantly higher in patients 
treated with rimonabant for 12 weeks compared to the metformin group (-33.2 ±5.0 vs. 
-7.5 ± 1.0 % p < 0.05). There were no significant changes in SHBG in either group. 
Metabolic parameters
Both treatments reduced glucose levels that reflected in a significant reduction of insulin 
resistance from baseline for rimonabant, but not with metformin, albeit that, the absolute 
change in HOMA-IR did not differ between the 2 groups. There was no significant 
improvement in any of the lipid parameters or for hsCRP within or between study 
groups.
There was a strong positive correlation between weight loss and reduction of 
testosterone levels (r=0.821 p value 0.004) (Figure 1). However there was no 
significant correlation of weight loss with improvement in HOMA-IR (r=0.420 p value 
0.23) or between reductions in testosterone levels with decrease in HOMA-IR (r=0.285 
p value 0.42).
3.5 Discussion:
This randomised open labelled parallel study showed that weight reduction through 
rimonabant 20mg per day improved both hyperandrogenaemia and insulin resistance 
and was a more effective insulin sensitisor than metformin in this obese PCOS group 
over the 3 month period.
Rimonabant led to an average 22% reduction in insulin resistance and patients had a 6% 
mean weight loss in just 12 weeks. These data are in accord with several studies 
showing a reduction in the weight and waist circumference in patients with metabolic
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syndrome treated with rimonabant(291-293), and are also in agreement with the 
metabolic improvements that weight loss in PCOS would predict.(146, 147) However, 
this is the first study that has directly demonstrated these improvements with rimonabant 
in patients with PCOS.
As expected, the subjects treated with rimonabant had a significantly greater degree of 
weight loss than those treated with metformin. There was a 6.2 kg reduction in weight 
(6%) after 12 weeks in patients treated with rimonabant which compares with previous 
studies of rimonabant in obese patients with metabolic syndrome which showed a 4.64 
kg weight loss after one year compared to placebo(295) The weight reduction found 
here with rimonabant translated into a reduction of 6.8 cm or 5.9% in waist 
circumference. Abdominal obesity is associated with an increase in cardiovascular 
risk(296, 297), which is mainly reflected in waist circumference. The reduction in 
insulin resistance by rimonabant may be due to the weight loss alone. However, 
additional less well defined mechanisms have been suggested to contribute to its 
metabolic effects. (298, 299)
In the rimonabant group study there was a 37.6% decrease in the free androgen index 
levels compared to baseline, primarily due to a reduction in the serum testosterone level 
that fell by 33.2% that was significantly greater than that seen with metformin that 
showed fall of 7.5%. The reduction in serum testosterone levels in rimonabant group 
strongly correlated with weight loss but not with decrease in insulin resistance measured 
by HOMA-IR. This data is in accord with reports of weight reduction reducing 
biochemical hyperandrogenism in PCOS(146, 300, 301). This is also in accord with the 
data suggesting that more obese patients are less responsive to metformin 7 ' 19 There were
83
84
no changes in the SHBG levels with either metformin or the rimonabant treatment
groups.
In this study metformin had a more modest effect on weight, with the 1.6% reduction
being comparable with some previous data. (287) However, other studies have shown
that while metformin can reduce body mass index of around 4% and androgen measures
of around 20% compared to placebo(138), it may be less effective in more overweight
patients.(129, 139, 140) This latter point may help account for the lack of response here.
The lack of efficacy through insulin sensitisation with metformin is likely to be due to 
the obesity of this patient group as noted before. Neither treatment affected cholesterol 
or hsCRP over the 3 month period in accord with other studies (294), although 
rimonabant treatment has been reported to reduced triglycerides and increase HDL-C 
concentration over a year period.(295)
This short duration of the study meant that no assessment of clinical 
hyperandrogenaemia could be undertaken, nor of menstrual change and ovulation. The 
irregular menses and lack of change in the progesterone measurements before and after 
the study suggests that the 6kg weight loss with rimonabant had not affected menstrual 
periods over the 12 week period. It must be emphasised that rimonabant is not 
recommended while contemplating pregnancy.
No patient on the study reported side effects to rimonabant and mild side effects in a few 
patients were reported for metformin. In other studies involving rimonabant 
approximately 15% of treated patients (twice as many as with placebo) withdrew from 
trials because of unwanted effects, mainly because of psychiatric disorders especially
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depression.(292, 293, 302, 303) This is of relevance in view of the finding that the 
number of new cases of depressive disorders was 21% in women with PCOS and the 
adjusted odd ratio for depressive disorders in women with PCOS, independent of family 
history, obesity, infertility and other factors, was 4.23 compared to patients without 
PCOS(304). In this study we specifically excluded patients with any history of 
depression or other psychiatric disorders.
In conclusion, this study has demonstrated that rimonabant may have a therapeutic role 
in patients with PCOS by improving anthropometric parameters, insulin resistance and 
biochemical hyperandrogenaemia over a short term 12 weeks period, and was superior 
to insulin sensitisation by metformin in this obese patient group.
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Figure 1 Correlation between reduction in testosterone levels with weight loss
There was a strong positive correlation between weight loss and reduction of 
testosterone levels (R 0.821 p value 0.004) (Figure 1). However there was no 
significant correlation of weight loss with improvement in HOMA-IR (R 0.420 p value 
0.23) or between reductions in testosterone levels with decrease in HOMA-IR (R 0.285 
p value 0.42).
Correlation between reduction in testosterone levels with weight loss
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Pearson Correlation R= 0.821 p value 0.004 (2 tailed significance)
Change in weight expressed in kilograms
Change in testosterone expressed in nmol/L
To convert values for testosterone to nanograms per deciliter, divide by 0.03467
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Chapter 4
Metformin maintains the weight loss and metabolic benefits 
following rimonabant treatment in patients with polycystic
ovary syndrome.
89
4.1 Introduction: Subsequent to the previous study showing rimonabant is superior to 
metformin in improving insulin resistance and hyperandrogenemia in obese patients 
with polycystic ovary syndrome. As discussed in section 1.4.4.3, significant weight 
regain, over 2kg occurs, in the 12 weeks following cessation of rimonabant (303). This 
study was undertaken to see if subsequent metformin treatment after rimonabant would 
maintain any of the initial improvement for weight, insulin resistance and 
hyperandrogenemia in patients with PCOS.
4.2: Research Design and Methods: This was an extension arm with the addition of 
metformin to the randomised open labelled parallel study of metformin and rimonabant 
in 20 patients with PCOS with a body mass index (BMI) ^Okg/m2 . All the patients 
who were on rimonabant were changed over to metformin SOOmg three times daily for 3 
months (rimonabant/metformin group), whereas all the patients who were on metformin 
were continued on metformin for another 3 months (metformin only group) (Figure 2).
The diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam 
consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman- 
Gallwey score >8; free androgen index >8 respectively), oligomenorrhoea or 
amenorrhea and polycystic ovaries on transvaginal ultrasound.(36) Subjects had no 
concurrent illness, were not on any medication for the preceding 6 months and were not 
planning to conceive. None of the patients had successful pregnancy or miscarriage at 
least 5 year prior to the study entry. Subjects were advised not to change their lifestyle 
including physical activity or dietary habits during the study period. Non-classical 21- 
hydroxylase deficiency, hyperprolactinaemia, Cushing's disease and androgen-secreting
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tumours were excluded by appropriate tests. All patients gave informed consent. The 
study was approved by the Hull and East Riding Local Research Ethics committee.
Clinical and biochemical assessments were performed at the end of the 3-month period 
of the extension arm. The primary end point of the study was a change weight and the 
secondary end points were a change in free androgen index and insulin resistance.
Study bloods and measurement were done after an overnight fast. Compliance was 
monitored by counting returned medication. Blood samples were processed and 
analysed as per our previous study (305). Data are reported as mean ± SEM.
4.3 Statistical analysis
Statistical analysis is described in section 2.2.1.
4.4 Results: All the 20 subjects completed the 3-month extension period. The 
compliance was 98% in both groups. All patients tolerated metformin without any side 
effects. All patients continued to have an irregular cycle.
Anthropometric parameters (Table 1)
There was no significant change in weight (98.4 ± 4.7 vs. 98.6 ± 4.8 kg p<0.96) or the 
waist circumference and the waist-hip ratio for the rimonabant/metformin group after 3 
months of metformin (Figure 2), Conversely, there was a significant weight loss 
between 3 and 6 months after metformin treatment (102.2 ± 4.1 vs. 100 ± 4.2 kg 
p<0.01), together with a reduction in waist circumference (110.0 ± 2.4 vs. 109.4 ± 2.3 
cm p=0.05) and waist-hip ratio (0.92 ± 0.02 vs. 0.91 ± 0.02 p=0.05. However, there was
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a significant reduction in weight, waist circumference and waist-hip ratio in both groups 
at 6 months compared to baseline. The percentage reduction in weight, waist 
circumference and waist hip ratio was significantly higher in rimonabant/metformin 
group compared to metformin only group at 6 months compared to baseline [weight (- 
6.0 ± 0.1 vs. -2.8 ± 0.1% p=0.04); waist circumference (-5.0 ± 0.1 vs. -0.6± 0.1% 
p=0.02); waist-hip ratio (-1.7 ± 0.4 vs. -0.3 ± 0.1% p=0.02%)]. 
Metabolic parameters (Table 2)
There was a significant reduction for glucose, insulin and HOMA-IR in the 
rimonabant/metformin group between baseline, 3 and 6 months. However, there was no 
change in any of these parameters after 6 months of metformin alone. The percentage 
change of glucose was significantly more in rimonabant/metformin group compared to 
the metformin group (-7.0 ±0.12 vs. -0.8 ± 0.1 % p <0.01).
There was a significant reduction in total cholesterol and LDL after 6 months in both the 
groups (Table 2). There was also a reduction in triglycerides and improvements in HDL 
in the rimonabant/metformin group that was not seen after 6 months of metformin alone.
Biochemical hyperandrogenemia (Table 3)
There was a significant reduction in the testosterone and FAI between 3 and 6 months in 
both rimonabant/metformin group and metformin group. There was no change in sex 
hormone binding globulin (SHBG) either group. The percentage change from baseline 
to 6 months were greater in the rimonabant/metformin group compared to metformin
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only group [testosterone (-45.0 ± 5.0 vs. -16 ± 2.0% p=0.02); FAI (-53.0 ±5.0 vs. -17.0 
± 12.2% p=0.02)].
There was no significant correlation between weight loss with testosterone (r=0.438 
p=0.21), HOMA-IR (r=0.19 p=0.83) and total cholesterol (r=0.349 p=0.32) in the 
rimonabant pre-treatment group or in the metformin alone group after 6 months 
(testosterone r=0.252 p=0.49; HOMA-IR r=0.12 p=0.75; total cholesterol r=0.124 
p=0.93).
4.5 Discussion
This study demonstrates that in obese patients with PCOS the weight reduction and 
decrease in waist circumference following rimonabant therapy can be maintained if 
patients are subsequently changed onto metformin, while the initial improvements in 
testosterone and insulin resistance can be augmented. The reduction in weight and waist 
circumference was also superior in the rimonabant/metformin group compared to 6 
months of metformin therapy alone.
In the Rio-North America trial, which studied treatment with rimonabant in obese 
patients, those who were re-randomised to placebo following 12 months of treatment 
regained around 2kg of their previous weight loss in 12 weeks which was accompanied 
by a deterioration in their metabolic parameters (303). This highlighted that the cardio 
metabolic risk factors were only improved with sustained weight loss and that long-term 
treatment with rimonabant appeared to be necessary(303). In this study the 
improvement in anthropometric and metabolic parameters achieved with 3 months of
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rimonabant therapy was maintained for a further 3 months by treating patients with 
metformin therapy after the discontinuation of rimonabant.
There was an improvement in weight and waist circumference after 6 months of 
metformin therapy which was not there after the initial 3 months of therapy. The results 
from randomised studies are conflicting on an effect of metformin on weight loss, 
especially obese patients with PCOS (129, 133, 139, 140) where metformin may be less 
effective in patients with a BMI greater than 37. Variations in study groups in pre- 
treatment BMI, metformin dose, duration of metformin therapy, concomitant life style 
changes and patient adherence to treatment may account for many of these differences 
(129, 137).
There was a significant reduction in glucose, insulin and HOMA-IR with metformin 
after rimonabant, over and above the initial changes through rimonabant treatment. 
Rimonabant has been shown to reduce fasting insulin(292) and glucose(302) over a 
period of 1-2 years, but this is the first study to show that the subsequent substitution 
with metformin may maintain and improve the insulin resistance. This suggests that the 
insulin sensitisation action of metformin was complementary to the weight loss caused 
by rimonabant. In comparison, there was no change in any of these parameters after 6 
months of sole metformin treatment, despite the small though significant weight loss, a 
finding that has been found before in obese group patients with PCOS (139).
There was a significant correlation between reduction of weight and testosterone at 3 
months of rimonabant therapy that was lost following subsequent metformin treatment. 
This suggests that the initial weight loss was responsible for the reduction in
93
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testosterone with rimonabant, but that there may be a weight independent action of 
metformin for further testosterone reduction (306, 307). Rimonabant has also been 
found to have weight independent effects which might be mediated through less well 
defined direct pharmacological effects, but these were not obvious during the first phase 
of treatment here (308-313).
There was a significant reduction of total cholesterol and LDL cholesterol after 6 
months of metformin that may have been due more to the reduction in weight than a 
direct effect of metformin as not changes in FAI or insulin resistance were seen. The 
reduction in LDL is consistent with another meta analysis which showed significant 
reduction of LDL with metformin, but no changes in total cholesterol(137). Rimonabant 
has been reported to reduce triglycerides and increase HDL in other studies after 1 -2 
year (292, 302, 303, 312). There was certainly a significant reduction of triglycerides 
and improvement in HDL on metformin in rimonabant pre-treated PCOS patients in this 
study. The apparent lack of improvement in the first 3 months on rimonabant is more 
difficult to explain but might be due to shorter duration of therapy. However, this shows 
that metformin therapy after rimonabant pre-treatment might sustain, or even enhance, 
the beneficial effects of rimonabant in these parameters. Surprisingly there was a 
significant reduction of total cholesterol and LDL cholesterol after metformin therapy in 
rimonabant pre-treated patients which has not been found by others (292, 302, 303, 
312).
Rimonabant is not recommended during pregnancy whereas infertility is an issue in a 
significant proportion of patients with PCOS (314, 315). Since we know weight loss
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has a significant effect on ovulation and the chance of pregnancy (316), rimonabant 
pre-treatment followed by metformin therapy could be an option in this group of 
patients. Moreover, as there is growing evidence that endocannabinoids are involved in 
implantation, pregnancy and miscarriage in animal models and human tissues (317-320), 
it is possible to tentatively speculate that rimonabant priming may actually prove 
beneficial in pathological situations like miscarriage(320) and infertility. 
We made no assessment of clinical hyperandrogenemia, nor of menstrual change and 
ovulation. As such, the blood tests were done without respect to the bleeding pattern so 
there may have been temporary hormonal fluctuations interfering with the results. 
Nevertheless, the irregular menses and lack of change in the progesterone measurements 
before and after the study suggests that rimonabant and metformin had not affected 
menstrual periods over the 24 week period in this obese group. 
In summary, this study has demonstrated the potential for using a single 'course' of 
rimonabant preceding the longer term prescription of metformin. While it could be 
argued that with a longer period of follow-up the separation between 
rimonabant/metformin versus metformin alone may ultimately diminish, there seems 
little doubt that the improvements seen by replacing rimonabant with metformin are 
likely lead to many months of clinically significant anthropometric reduction and risk 
factor benefit. Such short courses of rimonabant may also go some way to addressing 
the concerns surrounding longer term use of cannabinoid receptor blockers. (292, 293, 
302, 303). Indeed, at worst, it may prove that further courses of rimonabant- either 
instead of or in addition to metformin- are all that is required.
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In summary, metformin for 3 months in obese patients with PCOS maintained the 
improvement of weight loss and enhanced the metabolic and biochemical parameters 
achieved by treatment with rimonabant compared to 6 months of metformin treatment.
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Chapter 5
Effect of Rimonabant and Metformin on GIF and GLP-1 in 
Obese Women with Polycystic Ovary Syndrome.
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5.1 Introduction
In chapter 3 rimonabant has been shown to reduce weight, free androgen index (FAI) 
and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) 
compared to metformin during a 12 week period. When subsequently treated for 
another 3 months as described in chapter 4, metformin maintained the weight loss and 
enhanced the metabolic and biochemical parameters achieved by treatment with 
rimonabant, compared to 6 months of metformin treatment alone. 
Metformin's actions appear to be mediated by activation of AMP-activated protein 
kinase(288) where as rimonabant is a cannabinoid receptor 1 blocker. (289, 290) 
Exenitide, an incretinmimetic that shares similar glucoregulatory properties of the 
hormone glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic 
polypeptide (GIP) has been shown to improve FAI and insulin sensitivity measures 
predominantly through weight loss in patients with PCOS(321). We aimed to establish 
whether rimonabant might have an effect on the incretin system that may augment its 
weight reduction effect in patients with PCOS.
5.2 Research Design and Methods
A randomized open labelled parallel study of metformin and rimonabant for 12 weeks in 
20 patients with PCOS with a body mass index (BMI) ^Okg/m2 was undertaken 
(described in chapter 3). This was followed by an extension arm with the addition of 
metformin for another 12 weeks (chapter 4). All the patients who were on rimonabant 
were changed over to metformin SOOmg three times daily for 3 months, whereas all the 
patients who were on metformin were continued on metformin for another 3 months.
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The diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam 
consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman- 
Gallwey score >8; free androgen index >8 respectively), oligomenorrhoea or 
amenorrhea and polycystic ovaries on transvaginal ultrasound.(36) Subjects had no 
concurrent illness, were not on any medication for the preceding 6 months and were not 
planning to conceive. None of the patients had successful pregnancy or miscarriage at 
least 5 year prior to the study entry. Subjects were advised not to change their lifestyle 
including physical activity or dietary habits during the study period. Non-classical 21- 
hydroxylase deficiency, hyperprolactinaemia, Gushing's disease and androgen-secreting 
tumours were excluded by appropriate tests. All patients gave informed consent. The 
study was approved by the Hull and East Riding Local Research Ethics committee.
Clinical and biochemical assessments were performed at baseline, 12 weeks and 24 
weeks. Study bloods and measurement were done after an overnight fast. Compliance 
was monitored by counting returned medication. Blood samples were processed and 
analysed. GIF and GLP-1 were measured using ELISA methods (Linco Research, 
Missouri, USA) with an intra-assay CV of 7.3% at 4.2 pmol/L and 7% at 28 pmol/L 
respectively. Data are reported as mean ± SEM.
Statistical analyses were carried out using the paired t test. The biochemical data was 
normally distributed when tested using the Kolmogorov-Smirnov test. For all analysis, a 
two-tailed P ^).05 was considered to indicate statistical significance. Statistical analysis 
was performed using SPSS for Windows NT, version 14.0 (SPSS Inc., Chicago, IL).
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5.3 Results
All the 20 subjects completed the study. The compliance was 98% in both groups. All 
patients tolerated metformin and rimonabant without any side effects. The mean age 
group of patients was 28.6 ± 1.2 years (metformin 29.8 ± 1.8 vs. rimonabant 27.4 ± 1.5 
years).
There was a significant increase in GIF levels after rimonabant treatment for 3 months 
(7.78 ± 0.38 vs. 21.62 ± 1.96 pmol/L p value - 0.04) that decreased when changed over 
to metformin (21.62 ± 1.96 vs. 8.94 ± 0.4 pmol/L p value - 0.08). There were no 
significant changes in GIF levels either at 3 months (6.88 ± 0.28 vs. 6.08 ± 0.2 pmol/L p 
value - 0.23) or at 6 months (6.08 ± 0.2 vs. 6.22 ± 0.34 pmol/L p value - 0.89) with 
metformin (Figure 3).
There were no significant changes in GLP-1 levels after rimonabant treatment for 3 
months (18.6 ± 0.9 vs. 21.4 ± 1.2 pmol/L p value - 0.42) and 6 months (21.4 ± 1.2 vs. 
21.6 ± 0.9 pmol/L p value - 0.92) or after metformin treatment at 3 months (22.2 ±1.5 
vs. 21.0 ± 1.4 pmol/L p value - 0.72) and 6 months (21.0 ± 1.4 vs. 19.6 ± 1.8 pmol/L p 
value - 0.54). There was no significant correlation between the increase in GIF and 
weight loss with rimonabant (r=0.12 p=0.89)
5.4 Discussion
This study showed a significant (and reversible) increase in GIF levels after 3 months of 
rimonabant treatment. There were no changes in either GLP-1 or GIF levels with 
metformin.
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The increase in GIF levels could be due to rimonabant stimulating incretin hormones 
rather than secondary to weight loss since there was no correlation between weight loss 
and increase in GIF levels. However, this latter finding may simply be a consequence of 
the number of study participants.
Curiously, this study demonstrates that rimonabant affects GIF levels but not GLP - 1 in 
this group of obese patients with PCOS. GLP-1 is produced by L cells located mainly in 
the ileum and colon, and to a lesser extent by L cells in the duodenum and jejunum, 
whereas GIF is produced by K cells in the proximal gut(322). CBl receptors are also 
present in the duodenum and jejunum and activation of CBl receptors depresses gastro­ 
intestinal motility by inhibiting contractile transmitter release. Moreover, CB1 receptor 
activation/agonists inhibit gastric emptying and intestinal transit, delays gastric 
emptying in humans and rodents and also inhibit gastric acid secretion(323), functions 
that precisely mirror those of GIF. In conclusion therefore, it is likely that the increase 
in GIF by rimonabant in patients with PCOS may contribute to the metabolic changes 
found with the drug, but that the rise may simply be a compensatory response to 
maintain gastro-intestinal homeostasis.
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Figure 3
Glucose-dependent insulinotropic polypeptide (GIF) levels after 3 months of 
Rimonabant followed by 3 months of Metformin and after 3, 6 months of Metformin
20
15
10
• 3 months 
Rimonabant 
followed by 3 
months Metformin
6 months of 
Metformin
X axis - visit 1, visit 2, visit 3
Y-axis - Glucose-dependent insulinotropic polypeptide in pmol/L
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Chapter 6
The Effect of Atorvastatin in Patients with Polycystic Ovary 
Syndrome: A Randomized Double Blind Placebo Controlled
Study.
107
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6.1 Introduction: Polycystic ovary syndrome (PCOS) is one of the most common 
endocrine disorders in women of reproductive age with a reported prevalence of 5-7% 
(107, 324, 325). PCOS is associated with a broad range of adverse sequelae, including 
dyslipidemia, hypertension, insulin resistance, hyperandrogenaemia, gestational and 
T2DM, which ultimately increase the risk of cardiovascular morbidity (76, 77, 80, 326- 
331). HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors 
(statins) have been shown to reduce cardiovascular morbidity and mortality in several 
studies (332-334). They also have other, non-lipid lowering effects, demonstrated by 
their benefits amongst hypertensive patients with normal lipids (335) as well as their 
anti-inflammatory effect in patients with rheumatoid arthritis(336). Other pleiotropic 
effects of statins include improvement in endothelial dysfunction, increased nitric oxide 
bioavailability, antioxidant properties, inhibition of inflammatory responses, and 
stabilization of atherosclerotic plaques(337).
In patients with PCOS, simvastatin, with concomitant oral contraceptive (OCP) therapy, 
has recently been shown to reduce testosterone, LH and markers of systemic 
inflammation incrementally more than OCP treatment alone. Both regimes (with and 
without statin treatment) had an adverse effect on glucose metabolism (338). However, 
the OCP accounted for the the majority of the biochemical benefit, which was consistent 
with other OCP studies showing a reduction in testosterone and improvement in SHBG 
in PCOS patients (339-342).
Hypothetically the reduction of inflammation through statin therapy should have a 
beneficial effect in PCOS where the inflammatory marker hsCRP has been shown to be 
elevated. However, the effects of statins alone in patients with PCOS who are treatment
108
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nai've is unknown, and therefore we have performed a double blind randomized placebo 
control study with atorvastatin to investigate this.. 
6.2 Methods
A randomized double blind placebo controlled study was undertaken using atorvastatin 
20mg daily. The diagnosis of PCOS was based on all three diagnostic criteria of the 
Rotterdam consensus being present for each patient, namely clinical and biochemical 
evidence ofhyperandrogenemia (Ferriman-Gallwey score >8; free androgen index >8 
respectively), oligomenorrhoea or amenorrhea and polycystic ovaries on transvaginal 
ultrasound(36). Subjects had no concurrent illness, were not on any medication for the 
preceding 6 months, were not planning to conceive and were using barrier 
contraception. Patients did not use any oral or implantable contraceptives or any other 
treatments likely to affect ovarian function, insulin sensitivity or lipids for at least 3 
months before entering the study. Subjects were advised not to change their lifestyle, 
including physical activity or dietary habits, during the study period. Non-classical 21- 
hydroxylase deficiency, hyperprolactinaemia, Cushing's disease and androgen-secreting 
tumours were excluded by appropriate tests. Compliance with treatment was calculated 
by counting the returned medications. All patients gave informed consent. The study 
was approved by the Hull and East Riding Local Research Ethics committee. This study 
was registered ISRCTN registry - ISRCTN24474824.
Clinical and fasting biochemical assessments were performed at baseline and at the end 
of the 3-month period. The primary end point of the study was a change in high 
sensitivity (hs) CRP and the secondary end points were a change in HOMA-IR and total
109
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testosterone. Blood sample collection and analysis is described in section 2.1.1. Data 
are reported as mean ± SEM.
6.3 Statistical analysis
The sample size was based on the study on the effect of atorvastatin on hsCRP in 
patients with impaired fasting glucose (343). Powered specifically for CRP the 
minimum difference worth detecting/observed difference was 32.7%, estimated within 
group SD was 11.1; therefore, for 90% power and a significance level of 5%, a sample 
size of 16 per group was calculated. Adjusting for a possible 20% drop out rate meant a 
total of 40 patients needed to be recruited. 
Statistical tests are described in section 2.2.1
6.4 Results:
Thirty seven patients completed the study. Two patients from the placebo group and
one patient from atorvastatin group dropped out of the study due to non-compliance.
Following their exclusion, compliance was 99% in both groups. None of the subjects
developed significant side-effects in the course of the study. None of them developed
symptoms of muscle toxicity, and liver function tests and creatine kinase remained
normal throughout the study.
The mean age group of patients was 27.7 ± 1.4 years (atorvastatin 26.6 ± 1.2 vs. placebo
28.8 ± 1.8). The BMI were comparable in both atorvastatin and placebo group (33.20 ±
1.4 vs. 33.92 ± 1.4kg/m2).
There was a significant absolute reduction in total cholesterol, LDL cholesterol,
triglycerides, FAI, SHBG and total testosterone in patients randomized to atorvastatin,
while there were no changes in any of these parameters in the placebo group. (Table
110
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10). The percentage change in total cholesterol, triglycerides, LDL, FAI, SHBG and 
total testosterone were greater in the atorvastatin group compared to placebo group. 
There was a significant reduction in serum insulin levels and HOMA-IR in patients 
taking atorvastatin whilst there was significant increase in both these parameters in 
patients randomised to placebo.
There was no linear correlation between reduction in total cholesterol with improvement 
of FAI (r2=0.015; p=0.95), testosterone (r2=0.1; p=0.69) or SHBG (r2=0.29; p=0.22). 
However there was a significant correlation between reduction in triglycerides and 
reduction of HOMA-IR in atorvastatin group (r2 0.68; p<0.01) 
6.5 Discussion
In patients with PCOS 12 weeks treatment with atorvastatin 20mg resulted in a 
significant reduction in inflammatory markers, insulin resistance and 
hyperandrogenemia, in addition to the expected improvement in lipids. The reduction of 
the hyperandrogenemia was also independent of the improvement of the lipid profile 
with atorvastatin.
The 26% reduction in total cholesterol, 36% reduction in LDL and 21% reduction in 
triglycerides with atorvastatin is comparable with other trials (344, 345), although in this 
study there were no detectable changes in HDL. PCOS is associated with an increase of 
cardiovascular risk factors, including dyslipidemia that typically is reflected in an 
elevated total cholesterol and LDL(66, 68, 104, 105). This is in accord with an report 
using simvastatin 20 mg daily and an OCP containing 20/ig ethinyl estradiol and 150/^g 
desogestrel over 12 weeks that reduced total cholesterol and LDL by 7.5% and 20%, 
respectively(346). In contrast the OCP alone induced a modest increase of TC by 5%
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without any marked effect on LDL cholesterol. In that study triglycerides remained 
virtually unchanged after statin and OCP treatment, but increased significantly by 20% 
after OCP alone in accord with other studies(347, 348).
Of note is the finding that the improvement in biochemical hyperandrogenemia with 
atorvastatin in this study is comparable to anti-androgen agents (349, 350). The 
reduction in testosterone is comparable to the reduction in testosterone by the combined 
OCP (Ethinyl oestradiol/Levonorgestrel combination) that may reduce testosterone by 
27%. However OCPs are more effective in improving SHBG by up to 100% when 
given for 3 months(339, 340, 347). Simvastatin 20mg daily concomitant with an 
OCPgive a 38% decrease in total testosterone (346) compared to a 25% reduction with 
atorvastatin 20mg daily alone. These suggest that there might be a dose dependent 
effect or it might be due to difference in potency and class. Ethinyl 
oestradiol/cyproterone acetate pill has shown to reduce testosterone by around 42% after 
6 month period(351). However, anti-androgens reduce hirsuitism not only by reducing 
hyperandrogenemia, but also by other mechanisms including androgen receptor 
blockage, effect on LH secretion and Sareductase activity(352). This study was too 
short to investigate the improvement of clinical hyperandrogenemia. 
Weight loss of <10% of initial body weight has been shown to reduce testosterone in 
women with PCOS (353). There was no weight change with atorvastatin in this study; 
however, the reduction in testosterone was more than that seen with orlistat (17% 
reduction) and increased SHBG by 4% after 3 months of treatment. However there was 
a 33.2% reduction in testosterone with the endocannabinoid blocker, rimonabant, after 3 
months that correlated with weight loss.
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The reduction of testosterone is more comparable to improvement with insulin 
sensitizers like metformin that gave a 14% decrease in total testosterone in 3 months 
(294) and thiazolindinediones that gave a 6 - 15% reduction in serum testosterone (354- 
357). No improvement in hirsuitism with metformin may be seen(137).
There was a 25% reduction in hs-CRP with atorvastatin in this group of patients with 
PCOS. PCOS is associated with increased levels of indices of low-grade chronic 
inflammation such as hs-CRP (72, 358) that appears to be a predictor of cardiovascular 
events in women. (359, 360). Atorvastatin has been shown to significantly reduce 
hsCRP with a trend to reducing insulin resistance in patients with impaired fasting 
glucose (361).
A reduction in insulin resistance may be central to the improvements seen for 
hyperandrogenaemia and hsCRP. There was a 21% reduction in serum insulin levels and 
a 20% improvement in HOMA-IR with atorvastatin. This improvement in HOMA-IR 
was correlated positively with the degree of reduction in triglyceride levels and is in 
accord with other studies which have demonstrated a similar link in patients with the 
metabolic syndrome and T2DMtreated with atorvastatin (362, 363). Hypothetically, the 
reduction in triglyceride availability leads to an increased use of glucose as the main 
intracellular substrate(363) thereby improving insulin sensitivity. Whatever the reason, 
this mechanism may explain other findings such as reduced development of diabetes 
amongst patients treated with pravastatin in the WOSCOPS trial (364, 365).
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Improvement in biochemical hyperandrogenemia appears to be independent of the 
reduction in total cholesterol, LDL or triglycerides. There was no correlation between 
reduction of lipid levels and improvement in biochemical hyperandrogenemia that 
supports the concept of a pleotrophic effect of statins. Statins inhibit ovarian theca- 
interstitial cell proliferation and steroidogenesis in vitro (236). The ovaries of women 
with PCOS are typically enlarged with prominent hyperplasia of ovarian theca- 
interstitial cells and excessive production of androgens by these ce!ls(237-239). The 
effects of statins on steroidogenesis are most likely related to the inhibition of 
cholesterol synthesis by the mevalonate pathway and a consequent decrease in the 
availability of the precursors of progesterone and testosterone(236). 
Although a short study, patients continued to have irregular periods suggesting 
atorvastatin has not overtly affected menstrual function over the 3 months period. We 
made no assessment of ovulatory function in this study. It must be emphasised that 
atorvastatin is not recommended while contemplating pregnancy. 
In conclusion, atorvastatin 20mg daily improved biochemical hyperandrogenemia, 
insulin resistance and markers of inflammation in patients with polycystic ovary 
syndrome when given over a 12 week period. Statin treatment may therefore prove to be 
a useful adjunct for women with PCOS.
114
Ta
bl
e 
11
: C
om
pa
ri
so
n 
o
f a
n
th
ro
po
m
et
ri
c 
an
d 
ho
rm
on
al
 p
ar
am
et
er
s b
ef
or
e 
an
d 
a
fte
r 
tr
ea
tm
en
t w
ith
 a
to
rv
as
ta
tin
 a
n
d 
pl
ac
eb
o
Pa
ra
m
et
er
W
ei
gh
t (
kg
)
B
M
I 
(k
g/
m
2)
W
ai
st
 (c
m
)
G
lu
co
se
(m
m
ol
/L
)
In
su
lin
 (
^I
U
/m
L)
H
O
M
A
-I
R
TC
 (
m
m
ol
/L
)
LD
L-
C
 (
m
m
ol
/L
)
H
D
L-
C
 (
m
m
ol
/L
)
TG
 (m
m
ol
/L
)
H
s-
C
R
P 
(m
g/
L)
FA
I
Te
st
os
te
ro
ne
 
(n
m
ol
/L
)
SH
B
G
(n
m
ol
/L
)
A
to
rv
as
ta
tin
 g
ro
up
 (n
=1
9)
B
as
el
in
e
91
. 2
9 
±3
.4
33
.2
0 
±1
.4
98
.1
 ±
3.
2
4.
8 
±0
.1
15
.6
± 
1.
8
3.3
 ±
0.
4
4.
6 
±0
.2
2.
9 
±0
.2
1.
07
 ±
0.
1
1.
34
 ±
0.
08
4.
9 
±1
.4
13
.4
 ±
0.
6
4.
1 
±0
.2
31
.1
 ±
1.
0
12
 w
ee
ks
91
.2
0 
±3
.4
33
.1
6±
1.
4
98
.9
 ±
2.
2
4.
9 
±0
.1
12
.4
 ±
 1
.7
2.
7 
±
0.
4
3.
4 
±0
.2
1.
8 
±0
.2
1.
08
 ±
0.
1
1.
08
 ±
0.
13
3.
4 
±1
.1
8.
7 
± 
0.
4
2.
9 
±0
.1
35
.3
 ±
1.
2
p-
va
lu
e
0.
42
0.
42
0.
59
0.
52
<0
.0
1 
a
<0
.0
1 
a
<0
.0
1 
a
<0
.0
1 
a
0.
17
<0
.0
1 
a
0.
04
 a
<0
.0
1 
a
<0
.0
1 
a
<0
.0
1 
a
Pl
ac
eb
o 
gr
ou
p 
(n
=1
8)
Ba
se
lin
e
93
.1
2±
4.
8
33
.9
4 
±1
.5
99
.3
 ±
2.
4
4.
7 
±0
.5
14
.4
 ±
2.
0
3.
0 
±
0.
4
4.
5 
±0
.2
2.
7 
±0
.2
1.1
 ±
0.
08
1.
39
 ±
0.
24
5.
8 
±1
.4
13
.9
±0
.6
4.
4 
±0
.2
31
.9
±0
.9
12
 w
ee
ks
93
.0
5 
±4
.7
33
.9
2 
±1
.4
98
.7
 ±
2.
1
4.
8 
±0
.1
17
.6
±2
.4
3.
8 
±0
.5
4.
6 
±0
.2
2.
7 
±0
.1
1.1
 ±
0.
09
1.
69
 ±
0.
27
5.
7±
1.
6
13
.3
 ±
0.
5
4.
3 
±0
.2
32
.9
 ±
0.
9
P 
va
lu
e
0.
67
0.
67
0.
54
0.
32
0.
04
 a
0.
04
 a
0.
13
0.
77
0.
47
0.
19
0.
90
0.
07
0.
73 0.
14
%
 c
ha
ng
e
A
to
rv
as
ta
tin
0.1
 ±
0.
1
O
.li
O
.l
0.
07
 ±
 0
.0
2
1.
0±
2.
0
-2
1.
 4 
±
4.
0
-1
9.
8 
±5
.2
- 2
6.
4 
± 
3.
0
-3
6.
6 
±5
.0
-4
.0
 ±
3.
9
-2
0.
9 
±3
.8
-2
5.
8 
±7
.0
-3
2.
7 
±2
.6
-2
4.
6 
± 
2.
6
13
.7 
±2
.4
Pl
ac
eb
o
0.
03
 ±
 0
.0
2
0.
03
 ±
 0
.0
2
0.
02
 ±
0.
01
2.
0 
± 
1.
0
34
.2
 ±
19
.7
37
.2
 ±
20
.4
3.1
 ±
1.
1
3.1
 ±
0.
9
3.
0 
±3
.2
36
.8
 ±
21
.0
-8
.8
 ±
8.
2
-3
.1
 ±
2.
0
-0
.1 
± 
1.5
3.
6 
±2
.0
/>
-v
alu
e
0.
82
0.
82
0.
78
0.
90
<0
.0
1 
b
<0
.0
1 
b
0.
01
 b
<0
.0
1 
b
0.
17
<0
.0
1 
b
0.
05
<0
.0
1 
b
<0
.0
1 
b
<0
.0
1 
b
D
at
a 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
. A
ll 
se
ru
m
 re
su
lts
 a
re
 o
bt
ai
ne
d 
fr
om
 f
as
tin
g 
va
ria
bl
es
.
A
ll 
va
ria
bl
es
 w
er
e 
no
rm
al
ly
 d
ist
rib
ut
ed
.
a:
 S
ig
ni
fic
an
t d
iff
er
en
ce
 f
ro
m
 b
as
el
in
e.
b:
 S
ig
ni
fic
an
t d
iff
er
en
ce
s 
fo
r t
he
 c
om
pa
ris
on
 b
et
w
ee
n 
tre
at
m
en
ts.
C
ha
ng
e,
 p
er
ce
nt
 d
iff
er
en
ce
 c
om
pa
re
d 
w
ith
 b
as
el
in
e.
To
 c
on
ve
rt
 v
al
ue
s f
or
 g
lu
co
se
 to
 m
ill
ig
ra
m
s p
er
 d
ec
ili
te
r, 
di
vi
de
 b
y 
0.
05
6.
To
 c
on
ve
rt
 v
al
ue
s f
or
 in
su
lin
 to
 p
ic
om
ol
es
 p
er
 li
te
r, 
m
ul
tip
ly
 b
y 
6.
11
5
116
Chapter 7
Atorvastatin Pre-treatment Augments the Effect of Metformin 
in Patients with Polycystic Ovary Syndrome.
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7.1 Introduction:
The pleotrophic effects of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) 
reductase inhibitors (statins) are increasingly recognized (335-337) including the 
improvement of biochemical hyperandrogenemia in patients with polycystic ovary 
syndrome (PCOS) (346). In Chapter 3 it was shown that atorvastatin improves 
biochemical hyperandrogenemia, insulin resistance and inflammatory markers in 
patients with PCOS (366) .
Metformin has been shown to have a beneficial effect in women with PCOS by reducing 
serum insulin concentrations, lowering androgen levels and improving reproductive 
outcome (133, 137, 287). In chapter 4 metformin has been shown to maintain the 
metabolic benefits following treatment with other medications including 
endocannabinoid blockers in PCOS (367). This study was undertaken to determine if 
metformin would maintain the improvement in insulin resistance and 
hyperandrogenemia in patients with PCOS following atorvastatin, and whether there 
would be an improvement in these parameters in the placebo pre-treatment group.
7.2 Research Design and Methods
This was an extension arm of a randomized double blind placebo controlled study with 
atorvastatin 20mg daily in patients with PCOS. Immediately after stopping the trial 
medication 37 patients (19 patients from the atorvastatin group and 18 patients from the 
placebo group) who completed the study were given metformin 500mg three times daily 
for 3 months.
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The diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam 
consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman- 
Gallwey score >8; free androgen index >8 respectively), oligomenorrhoea or 
amenorrhea and polycystic ovaries on transvaginal ultrasound (36). Subjects had no 
concurrent illness, were not on any medication for the preceding 9 months except study 
medications and were not planning to conceive. None of the patients had successful 
pregnancy or miscarriage at least 5 year prior to the study entry. Subjects were advised 
not to change their lifestyle including physical activity or dietary habits during the study 
period. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing's 
disease and androgen-secreting tumours were excluded by appropriate tests. All patients 
gave informed consent. The study was approved by the South Humber Research Ethics 
committee.
Clinical and biochemical assessments were performed at the end of the 3-month period 
of the extension arm. The primary end points of the study were the change in HOMA-IR 
and total testosterone.
Study bloods and measurement were done after an overnight fast. Compliance was 
monitored by counting returned medication. Blood samples were processed and 
analysed as per our previous study (366). Data are reported as mean ± SEM. 
Statististical analysis are done as per Section 2.2.
7.3 Results:
All the 37 patients completed the study. The mean age group of patients was 27.7 ± 
1.4 years and the mean BMI was 33.42 ± 1.6 kg/m2 . There was no change in cycle
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length in the atorvastatin pre-treatment group (50 ± 6 vs. 48 ± 10 days) or placebo pre- 
treated group (52 ± 10 vs. 50 ± lOdays).
There were significant improvements in insulin and the HOMA-IR index, total 
testosterone, FAI, SHBG and hsCRP with metformin in the atorvastatin pre-treated 
group (Table 1). There were no significant changes in any of these parameters with 
metformin in the placebo pre-treatment group. The percentage change in HOMA-IR, 
FAI and hsCRP, were greater in atorvastatin pre-treated group compared to patients who 
were randomized to placebo pre-treatment.
There was a significant increase in LDL and a non significant increase in total 
cholesterol following the cessation of atorvastatin and starting metformin. However, 
there was a further improvement in triglyceride levels with metformin in atorvastatin 
pre-treated patients. There were no changes in any of the lipid parameters with 
metformin in placebo pre-treated patients. There was no significant improvement of 
weight with metformin in either group. 
7.4 Discussion
In this study atorvastatin pre-treatment both augmented and facilitated the effect of 
metformin in the improvement of the metabolic parameters, biochemical 
hyperandrogenemia and inflammatory markers in patients with PCOS. The 
improvements of these parameters were independent of the deterioration in LDL and 
total cholesterol following cessation of atorvastatin. There was a significant reduction 
in total testosterone with metformin after atorvastatin, over and above the initial changes 
through atorvastatin treatment. Three months of metformin following 3 months of 
atorvastatin reduced total testosterone by 31%, FAI by 41% and increased SHBG by
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18%, whilst there were no significant improvements in any of these parameters with 12 
weeks of metformin following placebo pre-treatment. Statins have been reported to 
inhibit ovarian theca-interstitial cell proliferation and steroidogenesis in vitro most likely 
due to reduced availability of testosterone precursors. (236, 238, 239) In addition, 
statins have also been shown to rapidly activate AMP-activated protein kinase (AMPK), 
a protein kinase that modulates metabolic homeostasis and energy balance in individual 
cells and multiple organs (288), both in-vivo and in-vitro (368). Interestingly, this is the 
same mechanism reported for metformin action and this may explain the augmented 
effects of metformin following atorvastatin treatment.
This study is also the first to demonstrate the enhanced improvement of insulin 
resistance and hsCRP with metformin after atorvastatin pre-treatment. There was a 
reduction of insulin by 16% and HOMA index by 21% that was not seen in patients who 
had been placebo pre-treated. In total, 12 weeks of atorvastatin followed by 12 weeks of 
metformin reduced the insulin levels by 33% and HOMA-IR by 35%. There was also a 
33% reduction of hsCRP with metformin treatment following atorvastatin. There was a 
25% reduction in hs-CRP with atorvastatin in this group of patients with PCOS. This 
may be important for patients with PCOS who have increased levels hs-CRP (72, 358) 
that is a predictor of cardiovascular events in women (359, 360).
As expected there was a rise in total cholesterol by 18% and LDL cholesterol by 37%, 
after stopping the atorvastatin and having 3 months of metformin. However, 
triglycerides improved further (4%) on metformin after stopping atorvastatin. In total, 
there was a 24% reduction in triglycerides after 12 weeks of metformin following 12 
weeks of atorvastatin that paralleled the improvement in insulin resistance.
120
121
There were no significant changes in insulin resistance, biochemical hyperandrogenemia 
and hsCRP in patients who went on to 12 weeks of metformin treatment following 
placebo. This is consistent with other studies which shows that metformin may not be 
effective in all patients with PCOS especially those who are overweight (129, 139, 140).
We made no assessment of clinical hyperandrogenemia or ovulation. As such, the blood 
tests were done without respect to the bleeding pattern so there may have been 
temporary hormonal fluctuations interfering with the results. All the patients continued 
to have irregular periods suggesting that neither atorvastatin pre-treatment nor 
metformin has overtly affected menstrual function over the 6 months period. Due to 
study design we have also not looked whether the combination of atorvastatin and 
metformin would be synergistic.
Statin therapy is contraindicated in any stage of gestation and is recommended to 
discontinue in anticipation of pregnancy (369). On the other hand, infertility is often an 
issue in PCOS, contributed by insulin resistance (314, 315). Atorvastatin pre-treatment 
followed by metformin would be an option in this group of patients in view of 
augmentation of beneficial effects of metformin following atorvastatin. 
In conclusion, the effect of three months metformin treatment was augmented by 
atorvastatin pre-treatment compared to placebo pre-treatment.
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Chapter 8
Variability of lipids in patients with type 2 diabetes taking 
statin treatment: implications for target setting.
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8.1 Introduction
While there is very strong evidence that low density lipoprotein (LDL) cholesterol 
lowering using statin treatment can reduce the incidence of coronary and other major 
vascular events(332-334, 370), in the United Kingdom there is current controversy and 
confusion about what lipid targets should be aimed for once a statin drug is initiated. 
Current guidance from the National Service Framework for Coronary Heart Disease and 
the National Institute for Health and Clinical Excellence (NICE) recommends targets for 
serum total cholesterol (TC) of <5mmol/L and LDL of <3mmol/L, and this has formed 
the basis of the Quality and Outcomes Framework (QOF) of the new General Medical 
Services (nGMS)(371, 372). However, more recent guidance from the Joint British 
Societies, published in December 2005(373), recommends patients should aim for a 
lower target of TC <4mmol/L and an LDL<2mmol/L. This disparity has led the UK's 
National Director for Heart Disease & Stroke to issue a statement in November 2006 
declaring that the previous targets of 5 and 3mmol/L should be kept, at least until 
revised NICE guidance is published(374).
Whether a patient consistently achieves any target depends on both the lipid lowering 
ability of the statin and the variability of lipid parameters while on the drug. Thus, a 
statin drug may be effective at lowering the mean cholesterol in a patient, but if the 
measurement is extremely variable, then they may not always be below their target 
when tested. It has been shown that lipid measurements in healthy volunteers and in 
patients with T2DM who are not on lipid lowering treatment can indeed vary on a day- 
to-day basis(375-377). However, no study to date has looked at lipid variability in 
patients already on statin treatment. Indeed, arguments can be made for statin treatment 
leading to either possible increases or reductions in cholesterol variation within an 
individual. Added to this is the fact that short half-life statins, such as simvastatin, may 
have an effect on lipid variability which is quite different to that of a long half-life
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statin, such as atorvastatin. This study has therefore aimed to establish how the 
biological variability of lipids in patients with T2DM who are on statin treatment could 
influence the ability for patients to maintain cholesterol values below target. In order to 
assess any difference between long and short half-life statins, we have conducted the 
investigation as a cross-over study with equivalent doses of simvastatin and atorvastatin.
8.2 Research Design and Methods
Thirty Caucasian patients with T2DM for at least 3 years and HbAlc between 6 and 9% 
were recruited into the study with informed consent. Nineteen patients were taking 
lOmg atorvastatin before bed and 11 patients on simvastatin 40mg before bed. All the 
patients were on stable doses of medications for at least 3 months. None of the patients 
were on additional lipid lowering therapy or over the counter medications. The insulin 
doses of patients who took insulin were not changed by >10% throughout the study. 
The patients were advised to maintain their normal diet, alcohol intake, smoking and 
exercise habits during the study period. Patients with untreated hypothyroidism or 
nephrotic syndrome were excluded. The biological variation of TC, HDL, LDL and 
triglycerides was assessed by measuring 12 hour fasting blood samples at four-day 
intervals on 10 consecutive occasions. Thereafter the patients on simvastatin were 
changed to the equivalent dose of atorvastatin and vice versa(378). After 3 months, the 
biological variation of lipid parameters were again assessed by measuring fasting blood 
samples at four day intervals on 10 consecutive occasions in these patients. Fasting 
venous blood was collected into serum gel tubes (Becton Dickinson, Oxford, U.K.) at 
the same time each day (0800-0900) after the patient had been seated for at least 5 
minutes and tourniquet was not applied for more than a minute. Samples were separated 
by centrifugation at 2000g for 15 min at 4°C, and two aliquots of the serum were stored 
at
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-20°C within 1 h of collection. All samples were analysed within 12 months of 
collection, and studies have found no stability issues when stored for this long at this 
temperature(379). The serum samples were split before assay. Before analysis, all of the 
serum samples were thawed and thoroughly mixed. The duplicate samples (i.e., two per 
visit) were randomised and then analysed for cholesterol, triglycerides and HDL 
cholesterol in a continuous batch on a Synchron LX 20 analyser (Beckman-Coulter, 
High Wycombe, U.K.) using a single batch of reagents according to our previous 
studies(380). Lipid assays used calibrators assigned from CDC standards and LDL 
cholesterol was calculated using the Friedewald formula(277). All subjects gave their 
informed written consent before entering the study, which had been approved by the 
Hull and East Riding Local Research Ethics Committee. 
Statistical analysis
The CV was used to calculate which mean lipid values would be required to maintain a 
total cholesterol of <5mmol/L (4.9mmol/L or lower) or <4mmol/L and an LDL of 
<3mmol/L or <2mmol/L on 95% or more of testing occasions using a one-sided analysis 
(mean ±1.645xCV)(270). A similar method was used to calculate the value that a single 
lipid measurement would have to be in order to be 95% confident that (a) the mean for a 
patient was below target or (b) subsequent measurements would consistently be below 
target.
8.3: Results
The baseline demographics of patients are given in Table 12. The baseline lipid profile 
where comparable in both groups. One patient from each group dropped out after 
completing one arm because of difficulty to adhere to study protocols. One patient who 
was on atorvastatin initially withdrew from the study due to development of myalgia 
without any rise in creatine kinase (CK) when changed over to simvastatin. Another
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patient on atorvastatin initially withdrew from the study due to development of lethargy 
while on simvastatin which got better after changing back to atorvastatin. None of the 
patients developed elevated liver transminases or CK during the study. There was no 
significant change in glycaemic control during the course of the study in any patients 
(median ± IQR) (7.72 ± 0.98 vs. 7.69 ± 0.88%, p=0.60).
Table 13 shows the mean lipid values and the biological variability in lipids expressed 
as standard deviation (SD) and coefficient of variation (CV) in each treatment group. It 
shows no statistical difference in lipid variability (SD) when the same patients take 
either simvastatin or atorvastatin. Whether patients started on simvastatin or atorvastatin 
made no difference to the results.
Table 14 shows the mean values of total cholesterol required to maintain values of <5 or 
<4mmol/L and to maintain an LDL cholesterol of<3mmol/L or <2mmol/L on up to 95% 
of occasions. Table 15 shows the concentrations of total cholesterol and LDL required 
from a single lipid measurement on statin treatment so that two different criteria are met. 
The first criterion is to be 95% confident that the mean lipid value for a patient is truly 
below target e.g. that their mean total cholesterol is 4.9mmol/L or lower when the target 
is 5mmol/L. The second is to be 95% confident that 95% of subsequent lipid 
measurements are below the specified target. In this regard, Table 14 gives values which 
show 50% confidence that 95% of subsequent measurements are below target.
8.5 Discussion
This study is the first to show that there is clinically significant biological variability in 
the lipid profiles of patients with T2DMwho are on statin treatment, and that this does 
not significantly differ between the short and long half-life statins of simvastatin and 
atorvastatin. Taken together, the coefficient of variation of total cholesterol suggests that 
values can vary by approximately ±15% (2 standard deviations from the mean value) in
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the same individual on treatment, while that of LDL cholesterol can vary by ±24% 
before any laboratory analytical variability is also taken into consideration. 
Studies which examine the normal biological variation in lipids and lipoproteins have 
generally been conducted on healthy subjects (375-377), but the biological component 
should be studied for each disease or treatment state as this may influence the extent of 
intra-individual variation. A meta-analysis of previously published studies has found 
that the mean biological variability (CV) found in healthy individuals is ^>. 1%, ^.5%, 
^.4%, and <22.6% for TC, LDL, HDL and TG respectively(279), whereas these figures 
in patients with T2DM who are not on statins were 5.1%, 8.3%, 4.4% and 17% 
respectively. In this study the CV of TC on atorvastatin and simvastatin was 
comparable at 6.9% and 8.2% respectively, while that for LDL is somewhat higher at 
10.3 and 13.1% respectively.
The variability in lipids on statin treatment found here have several clinical implications, 
the first of which relates to the ongoing debate regarding setting lipid targets in patients 
with or without T2DM. The National Service Framework (NSF) for Coronary Heart 
Disease (CHD) in 2000 laid down standards of care for the prevention and treatment of 
CHD (381). It set a target for TC lowering of <5mmol/L and LDL <3mmol/L, or by 
20-25% (LDL by 30%), whichever results in the lowest absolute level (381). In 
contrast, in December 2005 the Joint British Societies' Guidelines (JBS2) guidelines set 
similar audit targets, but recommended an optimal total cholesterol target level of 
<4.0mmol/L and an LDL<2.0mmol/L(373). Since the publication of JBS2, a statement 
from Professor Roger Boyle, National Director for Heart Disease and Stroke(374), 
points out that current UK national policy for lipid management and current targets for 
cholesterol levels remain those recommended in the NSF for CHD, and not those 
recommended by the JBS2. This has been followed by a response from the Association 
of British Clinical Diabetologists (ABCD) which criticised this statement arguing that in 
the CARDS study(382) the 30% of patients who had TC and LDL-C levels were below
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5 and 3 mmol/L respectively still benefited from statins(383). Diabetes UK has also 
criticised this decision as current NICE guidance does not account of new evidence in 
patients with T2DM(384).
The evidence for the new JBS2 targets themselves arose from the findings of the Heart 
Protection Study, the ASCOT-LLA, PROVE-IT, TNT, PvEVERSAL and GREACE 
studies(385-390). In these studies the mean LDL cholesterol in the active or intensively 
treated groups was 2.3mmol/L, 2.3mmol/L, 1.6mmol/L, 2.0mmol/L, 2.1mmol/L and 
2.5mmol/L respectively. However, the target for LDL cholesterol did not become a 
mean of 2mmol/L, but less than 2mmol/L. From our study, as shown in Table 3, we can 
determine that in order to consistently maintain an LDL of 1.9mmol/L or lower, the 
mean LDL for someone taking atorvastatin or simvastatin has to be around 1.5- 
1.6mmol/L or lower. This means the average LDL needs to be lower than that found in 
the clinical studies from which the target itself is based. This, in turn, is likely to have a 
knock-on effect regarding the potency, dosage and cost of statins (as well as possibly 
other agents) required. In addition, if the aim is to achieve a total cholesterol <5mmol/L 
(as suggested by the Quality and Outcomes Framework (QOF) for UK general 
practitioners) or an LDL<3mmol/L on a consistent basis then the mean values for a 
patient needs to be 4.3-4.4 and 2.4-5mmol/L respectively. This means that existing 
NICE lipid targets may not be as far removed from current evidence than the values of 5 
and 3mmol/L suggest, especially given the fact that adding laboratory analytical 
variation to the biological variation determined here will only reduce these mean values 
further.
This study has thus highlighted the difference between aiming to consistently have a 
patient below a cholesterol target at each visit (as demanded by financial incentives 
schemes such as the QOF) compared to aiming for just their mean value be below the
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same target. By definition, the latter means that a patient whose mean is the same as the 
target value will have half their individual measurements above it, whereas with the 
former any result above target is unacceptable. One effect of this is difference is shown 
in Table 4 where a single total cholesterol reading on treatment must be under 3.7- 
3.9mmol/L before it can be assumed that subsequent measurements will remain below 
5mmol/L, whereas this value can be around 0.5mmol/L higher if just a mean below 
5mmol/L is desired. Repeated measurements help in this regard but, for example, the 
mean of 3 measurements still has to be below 4.0-4.1mmol/L to be sure 95% of ensuing 
results are under 5mmol/L.
There are potential limitations to this study. LDL was calculated using the Friedewald 
formula rather than using direct measurement or analysis after ultracentrifugation. This 
means the variability in cholesterol, triglycerides and HDL could each be contributing to 
the overall variation in LDL found here. There is also a possibility that the Friedewald 
formula may have limitations when applied to a population with diabetes (391). 
Nevertheless, this is the means by which most laboratories currently report LDL and 
none of the patients in the study had triglycerides above the 4.5mmol/L which would 
prohibit use of the calculation. There is also some evidence that calculating LDL in this 
way may not in fact lead to any spurious increase in variability, at least compared to 
direct measurement (392).
Given these difficulties in using estimated LDL in T2DMpatients it is perhaps an 
opportunity to reassess the utility of non-HDL and apolipoprotein B (apoB) 
measurement which seem to be equally useful in detecting high-risk phenotypes in 
hypertriglyceridaemic type 2 diabetic patients, with apoB possibly being superior in 
normotriglyceridaemic subjects(393). The fact that ApoB can be accurately measured in 
non-fasting individuals would only strengthen its appeal.
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It is reassuring that none of the patients in the study developed serious adverse effects 
on statins. The 2 patients withdrawals due to non-severe adverse effects is probably in 
keeping with the 5-10% of patients who develop problems on statin treatment outside 
trial situations (394).
Our data is also reassuring for patients where a switch from lOmg of atorvastatin to the 
less costly generic simvastatin 40mg is being considered. Not only were the mean values 
of TC and LDL achieved by individuals on simvastatin not inferior to that of 
atorvastatin (which is in accordance with other studies (378)), but there were no 
significantly differences in lipid variability. This means that the relatively short half-life 
of simvastatin (2-3 hours) compared to atorvastatin (up to 24 hours)(395) does not seem 
to influence its ability to keep a patient below their lipid target, at least when taken at 
night time (396).
In summary, this study has found that in patients with T2DM taking either simvastatin 
or atorvastatin the mean TC and LDL concentrations needed to keep below target levels 
are much lower than the target value itself. When evidence for lipid targets are derived 
from the mean values obtained in patients participating in the different treatment groups 
of clinical studies, the mean value often becomes the upper target limit for patients.(332- 
334, 378, 397, 398) In doing so, we have shown that this may lead to lipid targets in 
patients with diabetes which are significantly lower than the current evidence suggests 
and thereby more difficult to achieve.
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TablelS. Baseline characteristics of patients in atorvastatin and simvastatin in 
patients with T2DM study
Total Number of patients 
completed the study
Duration of Diabetes 
Median (25-75 Inter Quartile 
Range) months
HbAlc % 
(Mean ± SD)
Sex (Male:Female)
Age (years) 
Median (Range)
Body Mass Index 
(Mean ± SD) Kg/m2
Waist circumference 
(Mean ± SD) cm
Baseline TC 
(Mean ± SD) mmol/L
Baseline LDL-C 
(Mean ± SD) mmol/L
Baseline HDL-C 
(Mean ± SD) mmol/L
Baseline TG 
(Median ± IQL) mmol/L
Simvastatin crossed over to 
Atorvastatin group
10
84(108)
7.75 ±0.98
7:3
58 (48-76)
34.67 ±6.64
1 19.80 ± 16.01
4.08 ±0.71
2.2 ±0.4
1.08 ±0.23
1.9 ±0.6
Atorvastatin crossed over to 
Simvastatin group
16
108(108)
7.69 ±0.91
10:6
64 (46-73)
34.45 ± 7.23
1 14.78 ± 17.29
3.98 ±0.49
2. 18 ±0.44
1.08 ±0.24
1.7 ±0.7
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Chapter 9
LDL cholesterol variability in patients with type 2 diabetes
taking atorvastatin compared to simvastatin:
justification for direct measurement?
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9.1 Introduction
Hypercholesterolemia is one of the most common risk factors for cardiovascular disease 
and elevated low density lipoprotein cholesterol (LDL) is the primary target of 
cholesterol-lowering therapy (399). There is very strong evidence that low density 
lipoprotein (LDL) cholesterol lowering using statin treatment can reduce the incidence 
of coronary and other major vascular events (332-334) including patients with type 2 
diabetes (382, 400). As a consequence of these studies, lipid targets for patients with 
diabetes have been established which, in the US, are mainly centered on LDL. 
Whether a patient consistently achieves any target depends on both the lipid lowering 
ability of the statin and the variability of lipid parameters while on the drug. Thus, a 
statin drug may be effective at lowering the mean cholesterol in a patient, but if the 
measurement is extremely variable, then they may not always be below their target 
when tested. It is also not known whether a patient with more variable lipids is at any 
different a risk of a cardiovascular event than someone with the same mean but much 
more stable lipid values.
Theoretically, in a situation analogous to antihypertensive medication (401), it could be 
argued that the stability of lipids while taking a relatively short half-life statin such as 
simvastatin (2-3 hours) might be different to that of a longer half-life statin like 
atorvastatin (up to 24 hours)(402). However, in the last chapter we found no statistically 
significant difference in LDL variability between simvastatin and atorvastatin when 
calculating LDL using the Friedewald formula (403)
Nevertheless, this equation has many potential sources of error which could lead to a 
spuriously increased estimation of variability in calculated LDL. This is because the
139
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formula derives LDL from the total cholesterol, the HDL cholesterol and estimates the 
very-low density lipoproteins (VLDL) cholesterol from the serum triglyceride 
concentration. Biological variability of all 3 components will therefore be included in 
the apparent LDL variation. The calculated LDL has also been shown to be less reliable 
in patients with type 2 diabetes (284).
Homogeneous (direct) assays for LDL have been available for more than a decade, but 
although they offer potential advantages, uptake of these methods has been slow, partly 
because it has been difficult to demonstrate any clear clinical benefit over the derived 
value, despite the latter's inherent limitations (404). One area of promise for the direct 
assay was the potential to reduce within-individual variability and so lessen the need for 
averaging serial specimens, but variability was found to be no less than with calculated 
LDL among untreated individuals (392). No data on the biological variability of directly 
measured LDL in patients who are taking statin treatment exists, so this study has 
sought to establish this in patients with type 2 diabetes. In order to assess any difference 
between long and short half-life statins, we have conducted the investigation as a cross­ 
over study with equivalent doses of simvastatin and atorvastatin. 
9.2 Research Design and Methods
Thirty Caucasian patients with type 2 diabetes for at least 3 years and HbAlc between 6 
and 9% were recruited into the study with informed consent. Nineteen patients were 
taking lOmg atorvastatin before bed and 11 patients on simvastatin 40mg before bed. 
All the patients were on stable doses of medications for at least 3 months. None of the 
patients were on additional lipid lowering therapy or over the counter medications. The 
insulin doses of patients who took insulin were not changed by >10% throughout the
140
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study. The patients were advised to maintain their normal diet, alcohol intake, smoking 
and exercise habits during the study period. Patients with untreated hypothyroidism or 
nephrotic syndrome were excluded. The biological variation of LDL was assessed by 
measuring 12 hour fasting blood samples at four-day intervals on 10 consecutive 
occasions. Thereafter the patients on simvastatin were changed to the equivalent dose of 
atorvastatin and vice versa. After 3 months, the biological variation of lipid parameters 
were again assessed by measuring fasting blood samples at four day intervals on 10 
consecutive occasions in these patients. Fasting venous blood was collected into serum 
gel tubes (Becton Dickinson, Oxford, U.K.) at the same time each day (0800-0900) after 
the patient had been seated for at least 5 minutes and tourniquet was not applied for 
more than a minute. Samples were separated by centrifugation at 2000g for 15 min at 
4°C, and two aliquots of the serum were stored at -20°C within 1 h of collection. The 
serum samples were split before assay. Before analysis, all of the serum samples were 
thawed and thoroughly mixed. According to our previous studies(405, 406), duplicate 
samples (i.e., two per visit) were randomised and then analysed using a single batch of 
reagents for direct LDL using a Synchron DxC analyser (Beckman-Coulter, High 
Wycombe, U.K.) using LDL reagents and calibrators. It is a homogeneous assay which 
uses a detergent to solubilize the non-LDL lipoprotein particles. After removal, a second 
detergent then solubilizes the remaining LDL which is then measured. The sensitivity 
for the direct LDL assay is <8 mg/dL (<0.21 mmol/L). The imprecision of the assay was 
as determined using duplicate sample as described below. All subjects gave their 
informed written consent before entering the study, which had been approved by the
141
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Hull and East Riding Local Research Ethics Committee. Statistical analysis was done as 
per Section 2.
9.3 Results
The baseline demographics of patients are given in Table 12. One patient from each 
group dropped out after completing one arm because of difficulty to adhere to study 
protocols. One patient who was on atorvastatin initially withdrew from the study due to 
development of myalgia without any rise in creatine kinase (CK) when changed over to 
simvastatin. Another patient on atorvastatin initially withdrew from the study due to 
development of lethargy while on simvastatin which got better after changing back to 
atorvastatin. None of the patients developed elevated liver transminases or CK during 
the study.
The (mean ± SEM) LDL concentration on atorvastatin lOmg was no different than when 
taking simvastatin lOmg (1.67±0.60mmol/L vs. 1.69±0.60 respectively, p=0.19 using an 
unpaired t-test). In contrast, the variability in LDL, expressed as SD, was much lower on 
atorvastatin (average SD ± SEM) (0.17±0.02mmol/L) than on simvastatin 
(0.01±0.003mmol/L, pO.OOOl) (figure 1). This equated to a coefficient of variance 
(CV) of 0.85% for atorvastatin and 10.7% for simvastatin.
Table 2 shows the mean values of LDL required to maintain values of <70, <77 and 
<100 mg/dL on 95% of occasions.
9.4 Discussion
This study has shown that the biological variability of LDL cholesterol, when measured 
using a direct assay method, is substantially lower when patients with type 2 diabetes 
take atorvastatin lOmg compared to simvastatin 40mg daily. This is despite the mean 
LDL values on both treatments being the same.
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These findings contrast with the biological variability we found when LDL was 
calculated using the Friedewald equation on the same samples (277). On simvastatin, the 
CV for calculated LDL was 13.1% compared to 10.7% found here using the direct LDL 
method. For atorvastatin the difference was much larger, with a CV for calculated LDL 
being 10.3%, but <1% for direct LDL. Indeed, in every patient the variability was less 
when taking atorvastatin than with simvastatin. The reason for the reduction in 
variability with the direct assay is probably because the measurement is, as discussed 
above, not influenced by the cumulative variabilities of total cholesterol, HDL 
cholesterol and serum triglycerides.
This difference seen between the 2 statins has clinical implications for achieving LDL 
targets. The American Diabetes Association position statement on dyslipidemia 
management in adults with diabetes recommended lowering LDL cholesterol to < 100 
mg/dL (2.6 mmol/L) as the primary goal of therapy for patients with type 2 diabetes 
(407). There is an argument that this should be lower still (332), with the recent LDL 
target from the UK National Institute for Health and Clinical Excellence (NICE) 
reflecting this by being <2mmol/L (<77g/dL)(408). Based on this study, since direct 
LDL within the same individual varies by approximately ± 20% when taking 
simvastatin compared to only ± 2% for atorvastatin then a much lower mean LDL needs 
to be aimed for with simvastatin than atorvastatin to ensure the patient consistently 
achieves their target goal over time (table 2). Looked at in another way, it means that 
while a single measurement on atorvastatin (in a perfectly performing LDL assay) could 
predict the true mean LDL for that patient within ±2%, the same individual would 
require their LDL to be measured more than 100 times before the same could be said of
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a patient taking simvastatin. In turn, this means that a patient taking atorvastatin may 
require less in the way of statin dose titration and monitoring, especially if a direct LDL 
assay is being used, that will also reflect in an economic benefit. Also, the extremely 
low biological variability of direct LDL rather than total cholesterol (CV<1% vs. 6.9%), 
may indicate this is the preferred way of assessing lipid response to statin treatment. 
It has recently been suggested that lipid monitoring amongst patients taking statin 
treatment may be of limited value because of the biological and analytical variability of 
lipids present while taking pravastatin in the LIPID (Long-Term Intervention with 
Pravastatin in Ischaemic Disease) study (409). This current study may go someway 
towards explaining the LIPID findings, firstly because a short half-life drug was studied 
and secondly because a direct LDL assay was not used.
There is consistent evidence that intermittent or non-adherence to statin treatment- no 
doubt associated with abrupt variations in lipids- is associated with poorer outcomes for 
patients (410, 411). However, it remains a matter of speculation as to whether the 
greater variability of LDL with simvastatin found here may have an influence on plaque 
stability and, ultimately, vascular events. Certainly, cardiovascular risk does rise 
exponentially, rather than linearly, as LDL rises (412-414). Thus, although a patient on a 
treatment causing more variable LDL will be spending the same time above and below 
their mean value as another with comparatively stable LDL, their average risk may be 
higher because their periods of LDL far above their mean will be placing them at 
especially high risk. This will more than cancel out any reduction in risk caused by them 
also having equal periods far below their mean. It has also been shown that 
cardiovascular events rate was favourable with atorvastatin compared to simvastatin in
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both randomized controlled studies(415) and observational studies (416-418). However, 
with the five 'treat to lower targets' studies the 2 least impressive reductions in CV risk 
per mmol/L reduction in LDL were SEARCH(419) and A to Z(420) which used 
simvastatin. The studies which used atorvastatin, PROVE-IT(421), TNT(422) and 
IDEAL(333) produced greater reductions in cardiovascular risk per mmol/L reduction in 
LDL. This could be probably attributed to lesser variability of LDL with atorvastatin 
compared to simvastatin. Until now there has been no proven advantage of direct vs. 
calculated LDL (404) but that we have shown direct LDL is potentially most useful in 
patients on statin treatment.
In summary, this study has found marked differences in the biological variability of 
directly measured LDL when taking simvastatin compared to atorvastatin, which is in 
clear contrast the lack of difference found when calculating LDL. While it is unknown 
whether the increased variability of LDL on simvastatin can influence cardiovascular 
risk, it certainly means that maintaining an LDL concentration below target will be more 
difficult to achieve than when using longer half-life treatments such as atorvastatin. Our 
findings have also shown that direct LDL measurement seems to have a potential 
clinical advantage over calculated LDL when used in patients taking statin treatment.
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Table 17. Mean values of direct LDL-Cholesterol to consistently achieve different 
targets
Target of LDL cholesterol to be 
achieved to produce an LDL 
consistently < 100 mg/dL (2.6 
mmoI/L)
Target of LDL cholesterol to be 
achieved to produce an LDL 
consistently < 77 mg/dL (2.0 
mmoI/L)
Target of LDL cholesterol to be 
achieved to produce an LDL 
consistently < 70 mg/dl (1.8 
mmol/L)
On Simvastatin 40mg 
mg/dL(mmol/L)
85(2.21)
65(1.69)
60(1.56)
On Atorvastatin lOmg 
mg/dL (mmol/L)
99 (2.56)
76(1.98)
69(1.79)
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Chapter 10 
Summary Discussion
150
This thesis has examined three distinct but related aspects of endocrinology where 
currently many unresolved issues exist. First is the effect of weight loss with the 
endocannabinoid receptor blocker, rimonabant, when compared to metformin which is 
the standard therapy of choice in patients with PCOS. Second is the potential 
pleotrophic effect of medication, atorvastatin in therapeutic reduction of insulin 
resistance and hyperandrogenemia in patients with PCOS. Third is the biological 
variability of various lipid parameters including direct LDL with simvastatin and 
atorvastatin in patients with T2DM which will have implications for achieving specific 
lipid targets and may influence cardiovascular risk.
Obesity is present in varying degrees in women with PCOS and is associated with 
hyperandrogenaemia and insulin resistance (286). Even modest weight loss of less than 
10% of initial body weight has been shown to increase the metabolic parameters and 
biochemical hyperandrogenemia in women with PCOS (146, 147). Metformin is 
commonly used in patients with PCOS and is reported to improve body weight, insulin 
resistance, sex hormone binding globulin (SHBG) and hyperandrogenaemia (133, 287). 
However, it has been shown to be of limited use in very obese women with polycystic 
ovary syndrome in some studies (140). However rimonabant, has shown an 
improvement in metabolic syndrome, waist circumference, lipid parameters and 
particularly insulin resistance in obese subjects (291-293). It was shown that weight 
reduction through rimonabant 20mg per day improved both hyperandrogenaemia and 
insulin resistance and was a more effective insulin sensitisor than metformin in this 
obese PCOS group over the 3 month period. Subsequent treatment with metformin for 3 
months in obese patients with PCOS maintained the improvement of weight loss and
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enhanced the metabolic and biochemical parameters achieved by treatment with 
rimonabant compared to 6 months of metformin treatment. There was a significant and 
reversible increase in GIF levels after 3 months of rimonabant treatment but no changes 
in either GLP-1 or GIF levels with metformin. This suggests that the metabolic effects 
of rimonabant in patients with PCOS might be partly due to its influence on GIF 
metabolism in addition to its known endocannabinoid blocking effect. 
Rimonabant has been recently withdrawn from market in view of its psychiatric side 
effects since rimonabant increases the risk of psychiatric adverse events - ie depressed 
mood disorders and anxiety (191). In view of this the European Medicines Age ncy 
(EMEA), the European Union (EU) body which is responsible for monitoring the safety 
of medicines, has concluded that the benefits of rimonabant no longer outweigh its risks 
and the market authorisation was suspended across the EU from July 2008. However, 
there are new endocannabinoid receptor blockers in development. It is unknown 
whether the newer agents will have the same beneficial effects in patients with PCOS 
with comparitevely less side effects. It is also not studied whether the weight loss effect 
of endocannabinoid blockers in PCOS is mediated via modulating oroxogenic hormones 
like ghrelin and peptide YY (PYY). It is also not clear regarding the cellular effect of 
rimonabant in altering adipokines, cytokines and interleukins. 
Statins have been shown to reduce cardiovascular morbidity and mortality in several 
studies (332-334). They also have other, non-lipid lowering effects, demonstrated by 
their benefits amongst hypertensive patients with normal lipids (335) as well as their 
anti-inflammatory effect in patients with rheumatoid arthritis(336). Other pleiotropic 
effects of statins include improvement in endothelial dysfunction, increased nitric oxide
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bioavailability, antioxidant properties, inhibition of inflammatory responses, and 
stabilization of atherosclerotic plaques(337). We looked into the potential pleotrophic 
effect of atorvastatin in patients with polycystic ovary syndrome. It was shown that 
atorvastatin is effective in reducing inflammation, biochemical hyperandrogenemia and 
metabolic parameters in patients with polycystic ovary syndrome after a 12 week period 
compared to placebo. The effect of three months metformin treatment was augmented 
by atorvastatin pre-treatment compared to placebo pre-treatment. 
A reduction in insulin resistance with atorvastatin may explain other findings such as 
reduced development of diabetes amongst patients treated with pravastatin in the 
WOSCOPS trial (364, 365). There is a potential avenue to explore the precise 
mechanism involved in improvement of insulin resistance with statins in patients with 
insulin resistant states using techniques such as insulin clamp studies. 
Statin therapy is contraindicated in any stage of gestation and is recommended to 
discontinue in anticipation of pregnancy (369). On the other hand, infertility is often an 
issue in PCOS, contributed by insulin resistance (314, 315). Atorvastatin pre-treatment 
followed by metformin could be an option in this group of patients in view of 
augmentation of beneficial effects of metformin following atorvastatin. 
This study has also raised a number of unanswered questions which could be explored 
by further studies. The effect of combination of atorvastatin and metformin has not 
been looked at. Whether any other statin like short half life statin, simvastatin or more 
potent statin like rosuvastatin could be better than atorvastatin is not known. Similar to 
study with rimonabant, this study is or relatively shorter duration and longer duration 
studies are needed to look into the effect of statins on ovulation and clinical hirsutism.
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It would also be interesting to look into the effect of statins on adipocytokines and 
interleukins in patients with PCOS. Of course, longer time studies are needed to see 
whether this beneficial effect of statins translates into improved cardiovascular outcome.
T2DM is another area with relative high insulin resistant state where statins have been 
shown to reduce cardiovascular morbidity and mortality. There is very strong evidence 
that low density lipoprotein (LDL) cholesterol lowering using statin treatment can 
reduce the incidence of coronary and other major vascular events (332-334, 370). 
Hence, accurate and precise estimations of LDL concentrations are necessary to 
appropriately identify individuals with hypercholesterolemia and to monitor response to 
treatment. There were no statistically significant difference in LDL variability between 
simvastatin and atorvastatin when calculating LDL using the Friedewald formula. 
However, in patients with T2DM taking either simvastatin or atorvastatin the mean TC 
and LDL concentrations needed to consistently remain below a target are much lower 
than the target value itself which means that guideline target limits extrapolated from the 
mean values of patients participating in clinical studies may overestimate the lipid 
reductions required. Interestingly, directly measured LDL cholesterol is an order of 
magnitude more stable when taking equivalent doses of atorvastatin rather than 
simvastatin. This means LDL targets can be consistently met at higher mean LDL 
concentrations (and with less lipid monitoring) using atorvastatin rather than 
simvastatin. Whether this relative instability of LDL on simvastatin may influence its 
ability to reduce cardiovascular events should be explored further.
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Given these difficulties in using estimated LDL in T2DM patients, the variability of 
non-HDL and apolipoprotein B (apoB) measurement which could be accurately 
measured in non-fasting individuals should be explored further which seem to be 
equally useful in detecting high-risk phenotypes in hypertriglyceridaemic type 2 diabetic 
patients, with apoB possibly being superior in normotriglyceridaemic subjects (393).
In conclusion both weight loss using rimonabant and atorvastatin is effective in reducing 
biochemical hyperandrogenemia and metabolic profile in patients with PCOS. The 
effect of rimonabant might be partly mediated through modulating Glucose-dependent 
insulinotropic polypeptide (GIF) levels. There is a significant biological variation in 
lipid profile in patients with T2DM who are on simvastatin and atorvastatin which may 
lead to lipid targets in patients with diabetes which are significantly lower than the 
current evidence suggests and thereby more difficult to achieve. However LDL targets 
can be consistently met at higher mean LDL concentrations (and with less lipid 
monitoring) using atorvastatin rather than simvastatin.
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Metformin maintains the weight loss and metabolic benefits 
following rimonabant treatment in obese women with 
polycystic ovary syndrome (PCOS)
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Summary
Objective Rimonabant has been shown to reduce weight, free 
androgen index (FAI) and insulin resistance in obese patients with 
polycystic ovary syndrome (PCOS) compared to metformin. Studies 
have shown that significant weight regain occurs following the 
cessation of rimonabant therapy. This study was undertaken to 
determine if subsequent metformin treatment after rimonabant 
would maintain the improvement in weight, insulin resistance and 
hyperandrogenaemia in PCOS.
Design An extension study for 3 months with the addition of 
metformin to the randomised open labelled parallel study of 
metformin and rimonabant in 20 patients with PCOS with a body 
mass index > 30 kg/m2. Patients who were on 3 months of rimonabant 
were changed over to metformin for 3 months, whereas those on 
3 months of metformin were continued on metformin for another 
3 months.
Measurements The primary end-point was a change in weight; 
secondary end-points were a change in FAI and insulin resistance. 
Results The mean weight loss of 6-2 kg associated with 3 months 
of rimonabant treatment was maintained by 3 months of metformin 
treatment (mean change +0-2 kg, P = 0-96). Therefore, the percentage 
reduction in weight remained significantly higher in the rimonabant/ 
metformin group compared to metformin only subjects at 6 months 
compared to baseline (-6-0 ± 0-1% vs. -2-8 ± 0-1%, P = 0-04). The 
percentage change in testosterone and FAI from baseline to 6 months 
was also greater in the rimonabant/metformin group. [Testosterone 
(-45-0 ± 5-0% vs. -16 ± 2-0%, P = 0-02); FAI (-53-0 ± 5-0% vs. 
-17-0 ± 12-2%, P = 0-02)]. HOMA-IR continued to fall significantly 
in the rimonabant/metformin group between 0, 3 and 6 months 
(4-4 ± 0-5 vs. 3-4 ± 0-4 vs. 2-7 ± 0-3, respectively, P < 0-01) but not at 
all in the metformin only group (3-4 ± 0-7 vs. 3-4 ± 0-8 vs. 3-7 ± 0-8, 
respectively, P = 0-80). Total cholesterol and LDL reduced significantly
Correspondence: Thozhukat Sathyapalan, Michael White Diabetes Centre, 
220-236 Analby Road, Hull Royal Infirmary, Hull, HU3 2JZ, UK. Tel.: +44 
1482675387; Fax: +44 1482675385; E-mail: tsathyapal@rediffmail.com
in both groups, but improvements in triglycerides and HDL were 
limited to the rimonabant/metformin group. 
Conclusions In these obese patients with PCOS, metformin 
maintained the weight loss and enhanced the metabolic and 
biochemical parameters achieved by treatment with rimonabant, 
compared to 6 months of metformin treatment alone.
(Received 28 May 2008; returned for revision 27 June 2008; finally 
revised 29 June 2008; accepted 30 June 2008)
Introduction
Rimonabant and metformin have been shown to improve insulin 
resistance and hyperandrogenaemia in patients with polycystic ovary 
syndrome (PCOS) though metformin may not be effective in obese 
patients with PCOS. Recently, we have shown that rimonabant will 
reduce weight and was superior to insulin sensitization by metformin 
in reducing free androgen index (FAI) and insulin resistance in obese 
PCOS patients treated over a 12-weeks period. However, previous 
studies have shown that significant weight regain, over 2 kg occurs, 
in the 12 weeks following cessation of rimonabant.5 This study was 
undertaken to see if subsequent metformin treatment after rimonabant 
would maintain any of the initial improvement for weight, insulin 
resistance and hyperandrogenaemia in patients with PCOS.
Methods
Research design and methods
This was an extension arm with the addition of metformin to 
the randomised open labelled parallel study of metformin and 
rimonabant in 20 patients with PCOS with a body mass index 
(BMI) £ 30 kg/m2 . All the patients who were on rimonabant were 
changed over to metformin 500 mg three times daily for 3 months 
(rimonabant/metformin group), whereas all the patients who were 
on metformin were continued on metformin for another 3 months 
(metformin only group).
124
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The diagnosis of PCOS was based on all three diagnostic criteria 
of the Rotterdam consensus, namely clinical and biochemical 
evidence of hyperandrogenaemia (Ferriman-Gallwey score > 8; 
FAI>8, respectively), oligomenorrhoea or amenorrhea and 
polycystic ovaries on transvaginal ultrasound. 6 Subjects had no 
concurrent illness, were not on any medication for the preceding 
6 months and were not planning to conceive. None of the patients 
had successful pregnancy or miscarriage at least 5 years prior to the 
study entry. Subjects were advised not to change their lifestyle 
including physical activity or dietary habits during the study period. 
Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, 
Cushing's disease and androgen-secreting tumours were excluded by 
appropriate tests. All patients gave informed consent. The study 
was approved by the Hull and East Riding Local Research Ethics 
committee.
Clinical and biochemical assessments were performed at the end 
of the 3-month period of the extension arm. The primary end-point 
of the study was a change weight and the secondary end-points were 
a change in FAI and insulin resistance.
Study bloods and measurement were done after an overnight fast. 
Compliance was monitored by counting returned medication. Blood 
samples were processed and analysed as per our previous study.4 
Data are reported as mean ± SEM.
Statistical analysis
Comparisons between the metformin only group and the rimonabant/ 
metformin group from baseline were carried out using the paired 
t-test for biochemical data and clinical observations. The Wilcoxon 
signed rank test was applied to biochemical data that violated the 
assumptions of normality when tested using the Kolmogorov- 
Smirnovtest. The effect of treatment was evaluated by first computing 
the percentage change from baseline in all variables studied and then 
the percentage change seen for each variable in both groups was 
compared, thus negating the differences in the baseline values of the 
two groups. Between-group comparison of percent changes was 
performed using independent samples f-test. For all analysis, a 
two-tailed P = 0-05 was considered to indicate statistical significance. 
Statistical analysis was performed using SPSS for Windows NT, 
version 14-0 (SPSS Inc., Chicago, IL).
waist circumference and waist: hip ratio. However, there was a 
significant reduction in weight, waist circumference and waist: hip 
ratio in both groups at 6 months compared to baseline. The percentage 
reduction in weight, waist circumference and waist: hip ratio was 
significantly higher in rimonabant/metformin group compared to 
metformin only group at 6 months compared to baseline [weight 
(-6-0 ± 0-1 vs. -2-8 ± 0-1%P = 0-04); waist circumference (-5-0 ± 0-1 
vs. -0-6 ± 0-1% P = 0-02); waist: hip ratio (-1-7 ± 0-4 vs. -0-3 ± 0-1% 
P = 0-02)].
Metabolic parameters (Table 2)
There was a significant reduction for glucose, insulin and HOMA-IR 
in the rimonabant/metformin group between baseline, 3 and 
6 months. However, there was no change in any of these parameters 
after 6 months of metformin alone. The percentage change of 
glucose was significantly more in rimonabant/metformin group 
compared to the metformin group (-7-0 ± 0-12% vs. -0-8 ± 0-1%, 
P<0-01).
There was a significant reduction in total cholesterol and LDL 
after 6 months in both the groups (Table 2). There was also a 
reduction in triglycerides and improvements in HDL in the 
rimonabant/metformin group that was not seen after 6 months of 
metformin alone.
Biochemical hyperandrogenaemia (Table 2)
There was a significant reduction in the testosterone and FAI 
between 3 and 6 months in both rimonabant/metformin group and 
metformin group. There was no change in SHBG either group. The 
percentage change from baseline to 6 months were greater in the 
rimonabant/metformin group compared to metformin only group 
[testosterone (-45-0 ± 5-0% vs. -16 ± 2-0%, P = 0-02); FAI (-53-0 ± 
5-0% vs. -17-0 ± 12-2%, P = 0-02)].
There was no significant correlation between weight loss with 
testosterone (r = 0-438, P = O21), HOMA-IR (r = 0-19, P = 0-83) 
and total cholesterol (r = 0-349, P = 0-32) in the rimonabant pre- 
treatment group or in the metformin alone group after 6 months 
(testosterone r = 0-252, P = 0-49; HOMA-IR r = 0-12, P = 0-75; total 
cholesterol r = 0-124, P = 0-93).
Results
All the 20 subjects completed the 3-month extension period. 
The compliance was 98% in both groups. All patients tolerated 
metformin without any side-effects. All patients continued to have 
an irregular cycle.
Anthropometric parameters (Table 1)
The mean age group of patients was 28-6 ±1-2 years (metformin 
29-8 ± 1-8 vs. rimonabant 27-4 ± 1-5 years). There was no significant 
change in weight or the waist circumference and the waist: hip ratio 
for the rimonabant/metformin group after 3 months of metformin. 
Conversely, there was a significant weight loss between 3 and 
6 months after metformin treatment, together with a reduction in
Discussion
This is the first study to demonstrate that in obese patients with 
PCOS the weight reduction and decrease in waist circumference 
following rimonabant therapy can be maintained with subsequent 
metformin initiation, whilst improving further both testosterone 
levels and insulin resistance. The reduction in weight and waist 
circumference was also superior in the rimonabant/metformin 
group compared to 6 months of metformin therapy alone.
In the Rio-North America trial with rimonabant treatment in 
obesity, there was 2 kg weight gain within 12 weeks of stopping 
rimonabant, with an associated deterioration in their metabolic 
parameters.5 Thus, cardio metabolic risk factor improvement was 
only sustained with weight loss maintenance, leading to the suggestion 
that long-term treatment rimonabant therapy was necessary. 5 In this
©2009 The Authors
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Rimonabant pretreatment followed by metformin in obese patients with PCOS 127
study the addition of metformin after rimonabant treatment 
appeared to provide weight maintenance preventing weight rebound.
The improvement in weight and waist circumference was seen at 
6 months but not after 3 months of metformin therapy. Study results 
of metformin on weight loss, especially obese patients with PCOS 1"3 '7 
are conflicting, particularly a BMI > 37 may make metformin 
ineffective. Variations in study groups in pretreatment BMI, 
metformin dose, duration of metformin therapy, concomitant life 
style changes and patient adherence to treatment may account for 
many of these differences and makes comparison difficult. 2 '8
The significant reduction in glucose, insulin and HOMA-IR with 
metformin after rimonabant was unexpected and may have reflected 
that weight loss may have facilitated its effect, and that the insulin 
sensitization action of metformin was complementary to the weight 
loss caused by rimonabant. However, rimonabant has been shown 
to reduce fasting insulin and glucose over a period of 1-2 years. 
There was no change in any of these parameters after 6 months of 
sole metformin treatment, despite the small though significant 
weight loss, a finding that has been found before in obese group 
patients with PCOS. 1
There was a significant correlation between weight reduction and 
testosterone at 3 months of rimonabant therapy that was lost 
following subsequent metformin treatment. This suggests that the 
initial weight loss was responsible for the reduction in testosterone 
with rimonabant, but that there may be a weight independent action of 
metformin for further testosterone reduction. ' Rimonabant has also 
been found to have weight independent effects which might be medi­ 
ated through less well defined direct pharmacological effects. 13 ' 1 '1
The significant reduction of total cholesterol and LDL cholesterol 
after 6 months of metformin was more likely to be due to weight 
reduction than a direct effect of metformin as FAI and insulin resistance 
were unchanged, meta analysis which showed significant reduction 
of LDL with metformin, but no changes in total cholesterol. 
Rimonabant has been reported to reduce triglycerides and increase 
HDL in other studies after 1-2 years. 5'9 ' 10 ' 17 There was certainly a 
significant reduction of triglycerides and improvement in HDL on 
metformin in rimonabant pretreated PCOS patients in this study. 
The apparent lack of improvement in the first 3 months on rimonabant 
is more difficult to explain but might be due to shorter duration of 
therapy. However, this shows that metformin therapy after rimonabant 
pretreatment might sustain, or even enhance, the beneficial effects 
of rimonabant in these parameters. Surprisingly there was a significant 
reduction of total cholesterol and LDL cholesterol after metformin 
therapy in rimonabant pretreated patients which has not been found 
byothers. 5 '9 ' 10 ' 17
Rimonabant is contraindicated in pregnancy; however, infertility 
is often a significant issue in PCOS. 19'20 Weight loss has a significant 
effect on ovulation and the chance of pregnancy; therefore, 
rimonabant pretreatment followed by metformin therapy could 
hypothetically be an option in this group of patients. Moreover, as 
there is growing evidence that endocannabinoids are involved in 
implantation, pregnancy and miscarriage in animal models and 
human tissues,22"25 though whether they are involved in miscarriage 
and infertility is unknown.
We made no assessment of clinical hyperandrogenaemia, or of 
menstrual change and ovulation. As such, the blood tests were done
without respect to the bleeding pattern so there may have been 
temporary hormonal fluctuations interfering with the results. 
Nevertheless, the irregular menses and lack of change in the progester­ 
one measurements before and after the study suggests that 
rimonabant and metformin had not affected menstrual periods over 
the 24-week period in this obese group.
In summary, weight maintenance by metformin was achieved 
after 3 months of rimonabant therapy and there was an enhancement 
of metabolic parameters, over and above that seen by metformin 
also. This may be a novel strategy in this patient group where obesity 
is a major issue.
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Editorial
Polycystic Ovary Syndrome, Inflammation, 
and Statins: Do We Have the Right Target?
Kathleen M. Hoeger
Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, New York
(J Clin Endocrinol Metab 94: 35-37, 2009)
Polycystic ovary syndrome (PCOS) is a common and complex endocrinopathy in reproductive-aged women presenting 
multiple clinical challenges. Women with PCOS experience men­ 
strual cycle irregularity, androgen excess in the form of acne and 
hirsutism, as well as infertility (1), and are at significantly in­ 
creased risk of diabetes (2). There is also evidence of increased 
cardiovascular risk demonstrated by abnormal lipid profiles (3) 
and early evidence of preclinical cardiovascular disease such as 
increased carotid artery intima media thickness (4) and coronary 
artery calcification (5). Several studies have demonstrated an 
increased inflammatory state, noted by increased high-sensitivity 
C-reactive protein (hs-CRP) levels (6,7).hs-CRPhas been shown 
to be predictive of an elevated risk for cardiovascular disease in 
women (8), but there is controversy as to whether this marker is 
on the causal pathway to cardiovascular disease and whether it 
remains an appropriate target for therapy (9).
Although there is ongoing debate as to whether CRP is an ap­ 
propriate target for medical therapy, a recent randomized trial of 
rosuvastatin or placebo in an older population at increased risk for 
cardiovascular disease but with normal low-density lipoprotein 
(LDL) cholesterol (<130 mg/dl) and elevated hs-CRP (>2 mg/liter) 
(JUPITER trial) was recently halted at 2 yr into a 4-yr trial when 
interim analysis suggested that treatment with rosuvastatin was 
associated with an unequivocal reduction in cardiovascular mor­ 
bidity and mortality (10). Although the details of the study 
results are still pending, it is suggestive that lipid parameters 
alone are insufficient as a measure of cardiovascular risk.
PCOS is well recognized to be associated with increased car­ 
diovascular disease risk, although not all studies support an in­ 
creased rate of cardiovascular events (11,12). Nonetheless, given 
the increase in measures of cardiovascular risk, effort toward 
cardiovascular disease prevention and reduction in diabetes risk 
are recommended in PCOS. Despite the increased prevalence of 
dyslipidemia in women with PCOS, there are few studies exam-
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ining the impact of statin therapy and none in the a bsence of oral 
contraceptive cotreatment (13). In the current issue of the Jour­ 
nal of Endocrinology and Metabolism, Sathyapalan et al. (14) 
report on a placebo-controlled trial of 40 young women with 
PCOS treated with 20 mg of atorvastatin or placebo for 12 wk. 
The authors chose hs-CRP as their primary outcome measure 
based on the concern regarding increased markers of inflamma­ 
tion that have been reported in women with PCOS in prior stud­ 
ies (6). Inflammation has been associated with increased risk of 
atherosclerosis and with development of type 2 diabetes (15). 
Women included in the current trial had a mean age of 28 yr and 
a body mass index of 33.7 kg/m2 . PCOS was diagnosed by pres­ 
ence of irregular cycles, androgen excess, and ultrasound find­ 
ings of polycystic ovarian morphology.
At the end of the 12-wk trial, subjects receiving atorvastatin 
had a 25% reduction in hs-CRP compared with a nonsignificant 
reduction in the placebo group. Despite the reduction, however, 
hs-CRP remained significantly elevated in the treatment group at 
study conclusion (3.4 mg/liter). Additionally, subjects receiving 
atorvastatin demonstrated a 24.6% reduction in total testoster­ 
one and a 32.7% reduction in free androgen index, significantly 
more than in the placebo group. Notably, total cholesterol, LDL 
cholesterol, and triglycerides all improved in the atorvastatin 
group compared with placebo, as would be anticipated with 
statin use, as did fasting insulin and homeostasis model assess­ 
ment of insulin resistance measures, both of which rose in the 
placebo group. Testosterone improvement was significantly cor­ 
related with changes in insulin measures but did not correlate 
with lipid changes.
Current recommendations for statin therapy are based on 
lipid measures, primarily LDL cholesterol. In this population of 
young women with PCOS, the mean lipid parameters were 
within the normal range, and therefore these women would not 
have been targeted by traditional recommendations to start sta-
Abbreviations: CRP, C-reactive protein, hs-CRP, high-sensitivity CRP; LDL, low-density li- 
poprotein; PCOS, polycystic ovary syndrome
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tin therapy. Specific cardiovascular risk factors otherwise in this 
young population are not detailed, but it is likely they would be 
relatively low risk on Framingham scoring (<10% risk of myo- 
cardial infarction in the next 10 yr). This study did not look at 
other intermediate cardiovascular endpoints such as measures of 
carotid artery plaques or coronary artery calcium scores, both of 
which have been shown to be abnormal in young women with 
PCOS (4,5). This was a short trial that was not designed to look 
for reduction in cardiovascular disease, and implications of this 
finding with respect to cardiovascular disease prevention for this 
population are not clear. Although reduction in CRP may ulti­ 
mately prove to be beneficial to young women with PCOS with 
respect to cardiovascular protection, the level was not normal­ 
ized by this trial, and at study conclusion CRP remained elevated. 
The benefit to cardiovascular protection of a lower but not nor­ 
mal CRP is not clear.
What of the impact of statins on other common features of 
PCOS? This may be relatively more important given the overall 
concerns of young women with PCOS, who experience irregular 
cycles and hirsutism as key features of the disease. In this trial, 
there was no significant improvement in menstrual cycle length, 
which remained at over 50 d in the statin treatment group and no 
difference from placebo. Additionally, whereas the authors did 
find a significant reduction in serum testosterone and free an- 
drogen index, there was no clinical measure of hirsutism re­ 
ported. Indeed in a trial of 12-wk duration, it is unlikely that a 
long-term measure such as hirsutism would be impacted. It 
would be useful for future studies of longer duration, however, 
to examine this endpoint.
Obesity is a common finding in women with PCOS. In this 
trial, subjects were significantly obese at the trial onset and were 
instructed not to change their baseline activity, lifestyle, or diet 
during the 12-wk trial. Therefore, despite the metabolic and en­ 
docrine improvements, there were no improvements in body 
mass index during the trial. Several studies have demonstrated 
reduction in CRP with weight reduction (16). Weight reduction 
in PCOS is also associated with improvements in androgens, 
menstrual cycle, and fertility (17). Overall recommendations for 
first-line treatment of PCOS in the presence of obesity include 
lifestyle change. In other populations, a comparison of lifestyle 
change and statin therapy proved equally effective in reduction 
of cholesterol (18), although maintenance of lifestyle changes 
over the long term is notoriously challenging.
Fertility is impaired in PCOS, and treatments for PCOS such 
as lifestyle therapy, and possibly insulin sensitizers, are associ­ 
ated with improvement in ovulatory function. Spontaneous 
pregnancies occur in PCOS and often without prediction because 
women are often oligo-ovulatory. There is a possible teratogenic 
risk for statin therapy in early pregnancy, and therefore there is 
concern raised when these agents are given to young women in 
the absence of contraception. This study did not measure ovu­ 
latory function, but statin use was not associated with improve­ 
ment in menstrual cycle length, suggesting no impact on ovula- 
tion. Nonetheless, statins should be used in reproductive-aged 
with the appropriate cautions.
What can we therefore conclude with respect to the role of 
statin therapy in PCOS ? Current recommendations for statin use
are based on lipid parameters and family history of cardiovas­ 
cular disease. These recommendations may change as larger and 
more inclusive trials examine the impact of statins for other in­ 
dications. Inflammation may indeed prove to be the right target 
to improve insulin sensitivity and ultimately reduce cardiovas­ 
cular disease risk. The American Academy of Pediatricians now 
recommends giving consideration to statin use for children as 
young as 8 yr in the presence of severe hyperlipidemia (19). This 
recommendation has met with considerable controversy because 
there are no long-term studies to suggest that early treatment in 
childhood prevents cardiovascular events better than attention 
in adulthood, nor are there long-term studies assessing the risk in 
children and adolescents. Further evidence in young adult pop­ 
ulations at risk, such as those with PCOS, may show benefit in 
statin therapy over the long term. For now, however, first-line 
therapy in obese women with PCOS should focus on lifestyle and 
dietary change with additional antiandrogen or ovulatory ther­ 
apy as indicated. Although additional therapeutic choices such as 
statin therapy may prove to have substantial benefit, the evidence 
is still pending.
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Context: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular mor­ 
bidity, whereas statins are proven to reduce cardiovascular mortality and morbidity through lipid- 
lowering and perhaps through their pleiotropic effects. Statins can also reduce testosterone in vitro 
by inhibiting ovarian theca-interstitial cell proliferation and steroidogenesis and reducing inflam­ 
mation in vivo.
Objective: Our objective was to assess the effect of atorvastatin on inflammatory markers, insulin 
resistance, and biochemical hyperandrogenemia in patients with PCOS.
Design and Setting: We conducted a randomized, double-blind, placebo-controlled study at a 
tertiary care setting in United Kingdom.
Patients: Patients included 40 medication-naive patients with PCOS and biochemical 
hyperandrogenemia.
Methods: Patients were randomized to either atorvastatin 20 mg daily or placebo.
Main Outcome Measures: The primary endpoint of the study was a change in the inflammatory 
marker high-sensitivity C-reactive protein. The secondary endpoints were a change in insulin re­ 
sistance and total testosterone.
Results: After 12 wk atorvastatin, there was a significant reduction (mean ± SEM) i n total cholesterol 
(4.6 ± 0.2 vs. 3.4 ± 0.2 mmol/liter, P < 0.01), low-density lipoprotein cholesterol (2.9 ± 0.2 vs. 1.8 ± 
0.2 mmol/liter, P < 0.01), triglycerides (1.34 ± 0.08 vs. 1.08 ± 0.13 mmol/liter, P <0.01), high- 
sensitivity C-reactive protein (4.9 ± 1.4 vs. 3.4 ± 1.1 mg/liter, P= 0.04), free androgen index (13.4 ± 
0.6 vs. 8.7 ± 0.4, P < 0.01), testosterone (4.1 ± 0.2 vs. 2.9 ± 0.1 nmol/liter, P < 0.01) and insulin 
resistance as measured by homeostasis model assessment for insulin resistance (HOMA-IR) (3.3 ± 
0.4 vs. 2.7 ± 0.4). There was a significant increase in SHBG (31.1 ± 1.0 vs. 35.3 ± 1.2 nmol/liter, P< 
0.01). There was a positive correlation between the reduction in HOMA-IR in the atorvastatin group 
with the reduction in triglycerides and the reduction of free androgen index. There was a signif­ 
icant deterioration of HOMA-IR in the placebo group (3.0 ± 0.4 vs. 3.8 ± 0.5).
Conclusions: This study suggests that atorvastatin is effective in reducing inflammation, biochem­ 
ical hyperandrogenemia, and metabolic parameters in patients with PCOS after a 12-wk period. 
(J Clin Endocrinol Metab 94: 103-108, 2009)
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Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age with a 
reported prevalence of 5-7% (1-3). PCOS is associated with a 
broad range of adverse sequelae, including dyslipidemia, hyper­ 
tension, insulin resistance, hyperandrogenemia, and gestational 
and type 2 diabetes, which ultimately increase the risk of car­ 
diovascular morbidity (4-12). High-sensitivity C-reactive pro­ 
tein (hsCRP) is an indicator or cardiovascular mortality, and the 
elevated levels of this inflammatory marker hsCRP have been 
reported in PCOS patients compared with controls (13-15). 
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins) have been shown to reduce cardiovascular mor­ 
bidity and mortality in several studies (16-19). They also may have 
other, non-lipid-lowering effects, suggested by their benefits among 
hypertensive patients with normal lipids (20) as well as their anti- 
inflammatory effect in patients with rheumatoid arthritis (21). 
Other pleiotropic effects of statins include an improvement in CRP, 
endothelial dysfunction, increased nitric oxide bioavailability, an- 
tioxidant properties, inhibition of inflammatory responses, and sta­ 
bilization of atherosclerotic plaques (22).
In patients with PCOS, simvastatin with concomitant oral 
contraceptive pill (OCP) therapy has recently been shown to 
reduce testosterone, LH, and markers of systemic inflammation 
incrementally more than OCP treatment alone (23). In that 
study, OCP treatment showed an adverse effect on glucose me­ 
tabolism with an increase in fasting glucose and insulin, without 
a statin-attributable effect (23). Furthermore, the addition of 
statins to OCP treatment had a significant beneficial effect on 
testosterone, and although the OCP alone had no significant 
effect on CRP, the addition of a statin led to a significant decrease 
of CRP below the baseline level.
Hypothetically, the reduction of inflammation through statin 
therapy should have a beneficial effect in PCOS where the inflam­ 
matory marker hsCRP has been shown to be elevated. However, the 
effects of statins alone in patients with PCOS who are treatment 
naive are unknown, so we have therefore performed a double-blind, 
randomized, placebo-control study with atorvastatin to investigate 
this, powered so as to detect a change in hsCRP.
Patients and Methods
A randomized, double-blind, placebo-controlled study was undertaken 
"sing atorvastatin 20 mg daily. The diagnosis of PCOS was based on all 
three diagnostic criteria of the Rotterdam consensus being present for 
«h patient, namely clinical and biochemical evidence of hyperandro- 
Senemia [Ferriman-Gallwey score >8; free androgen index (FAI) >8], 
wigomenorrhea or amenorrhea, and polycystic ovaries on transvaginal 
ultrasound (24). Subjects had no concurrent illness, were not on any 
Prescription or over-the-counter medication that was likely to affect 
insulin sensitivity, lipids, or ovarian function including hormonal con- 
Haceptives for the preceding 6 months. None of the patients had statin 
therapy in the past. Subjects were not planning to conceive and were 
lsing barrier contraception. Subjects were advised not to change their 
lifestyle, including physical activity or dietary habits, during the study 
Nod. Nonclassical 21-hydroxylase deficiency, hyperprolactinemia, 
fishing's disease, and androgen-secreting tumors were excluded by ap­ 
propriate tests. Forty-four patients were screened before the study, and 
too patients were excluded due to use of oral contraceptives within the 
Previous 6 months and two patients due to use of metformin in the
previous 6 months. Forty subjects who fulfilled both inclusion and ex­ 
clusion criteria were randomly assigned to the atorvastatin or the placebo 
group based on a computer-generated randomization list. Each random­ 
ization number corresponded with one of the two possible interventions, 
and labeling was done by personnel not involved in the trial. Compliance 
with treatment was calculated by counting the returned medications. All 
patients gave informed consent. The study was approved by the Hull and 
East Riding Local Research Ethics committee. This study was registered 
in the International Standard Randomized Controlled Trial Number 
(ISRCTN) registry as ISRCTN24474824.
Clinical and fasting biochemical assessments were performed at base­ 
line and at the end of the 3-month period. The primary endpoint of the 
study was a change in hsCRP, and the secondary endpoints were a change 
in homeostasis model assessment for insulin resistance (HOMA-IR) and 
total testosterone.
Fasting venous blood was collected into serum gel and fluoride oxj 
alate tubes. Samples were separated by centrifugation at 2000 X g for 15 
min at 4 C, and the aliquots stored at -20 C. Serum testosterone was 
measured on an Architect analyzer (Abbott Laboratories, Maidenhead, 
UK) and SHBG by an immunometric assay with fluorescence detection 
on the DPC Immulite 2000 analyzer using the manufacturer's recom­ 
mended protocol. The FAI was calculated as the total testosterone X 
100/SHBG. Total cholesterol, triglycerides, and high-density lipoprotein 
cholesterol (HDL-C) levels were measured enzymatically using a Syn- 
chron LX20 analyzer (Beckman-Coulter, High Wycombe, UK). Low- 
density lipoprotein cholesterol (LDL-C) was calculated using the Friede- 
wald equation. Serum insulin was assayed using a competitive 
chemiluminescent immunoassay performed on the manufacturer's DPC 
Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). The analytical sen­ 
sitivity of the insulin assay was 2 ^lU/ml, the coefficient of variation was 
6%, and there was no stated cross-reactivity with proinsulin. Plasma 
glucose was measured using a Synchron LX 20 analyzer: (Beckman- 
Coulter), using the manufacturer's recommended protocol. The coeffi­ 
cient of variation for the assay was 1.2% at a mean glucose value of 5.3 
mmol/liter during the study period. The insulin resistance was calculated 
using the HOMA method [HOMA-IR = (insulin X glucose)/22.5]. Data 
are reported as mean ± SEM.
Statistical analysis
The sample size was based on the study on the known effect of ator­ 
vastatin on hsCRP inpatients with impaired fasting glucose (25), with the 
assumption that a similar effect would occur in those patients with 
PCOS. Powered specifically for CRP, the minimum difference worth 
detecting/observed difference was 32.7%, estimated within-group SD 
was 11.1; therefore, for 90% power and a significance level of 5%, a 
sample size of 16 per group was calculated. Adjusting for a possible 20% 
dropout rate meant a total of 40 patients needed to be recruited.
Comparisons between both the groups from baseline were carried out 
using the paired t test for biochemical data and clinical observations. The 
Wilcoxon signed rank test was applied to biochemical data that violated 
the assumptions of normality when tested using the Kolmogorov-Smir- 
nov test. The effect of treatment was evaluated by first calculating the 
percentage change from baseline for all variables studied and then the 
percentage change for each variable in each patient group, thus negating 
the differences in the baseline values of the two groups. Between-group 
comparison of percent changes was performed using independent-sam­ 
ples t test. For all analyses, a two-tailed P s 0.05 was considered to 
indicate statistical significance. Statistical analysis was performed using 
SPSS for Windows NT, version 14.0 (SPSS Inc., Chicago, IL).
Results
Thirty-seven patients completed the study. Two patients from 
the placebo group [patient 10, age 27, body mass index (BMI) 
32.9, and patient 14, age 26, BMI 33.4] and one patient from
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atorvastatin group (patient 37, age 26, BMI 32.9) dropped out 
of the study within 4 wk due to noncompliance. After their ex­ 
clusion, compliance was 99% in both groups. None of the sub­ 
jects developed significant side effects in the course of the study. 
None of them developed symptoms of muscle toxicity, and liver 
function tests and creatine kinase remained normal throughout 
the study.
The mean age group of patients was 27.7 ± 1.4 yr (atorva­ 
statin 26.6 ± 1.2 vs. placebo 28.8 ± 1.8; P = 0.44). The BMI 
were comparable in both atorvastatin and placebo group 
(33.20 ± 1.4 vs. 33.92 ± 1.4 kg/rrr, P = 0.62). There were no 
significant differences in baseline parameters between the two 
groups.
There was a significant absolute reduction in total choles­ 
terol, LDL-C, triglycerides, FAI, SHBG, and total testosterone in 
patients randomized to atorvastatin, whereas there were no 
changes in any of these parameters in the placebo group (Table 
1). The percent change in total cholesterol, triglycerides, LDL, 
FAI, SHBG, and total testosterone was greater in the atorvastatin 
group compared with placebo group. There was a significant 
reduction in serum insulin levels and HOMA-IR in patients tak­ 
ing atorvastatin, whereas there was a significant increase in both 
these parameters in patients randomized to placebo.
There was no change in cycle length before and after treat­ 
ment with atorvastatin (52 ± 12 vs. 50 ± 6 d) or placebo (55 ± 
8 vs. 52 ± 10 d).
There was a significant correlation between reduction in 
HOMA-IR and improvement in FAI (r2 = 0.56; P = 0.04) in the 
atorvastatin group. There was also a significant correlation be­ 
tween reduction of HOMA-IR with reduction in triglycerides 
(r2 = 0.68; P < 0.01). However, there was no linear correlation 
between reduction in total cholesterol with improvement of FAI 
(r2 = 0.015; P = 0.95), testosterone (r2 = 0.1; P = 0.69) or SHBG 
(r2 = 0.29; P = 0.22).
Discussion
In patients with PCOS, 12 wk treatment with atorvastatin 20 mg 
resulted in a significant reduction in inflammatory markers, in­ 
sulin resistance, and hyperandrogenemia in addition to the ex­ 
pected improvement in lipids. The reduction in hyperandrogen­ 
emia was also independent of the lipid improvement due to 
atorvastatin treatment.
The 26% reduction in total cholesterol, 36% reduction in 
LDL, and 21% reduction in triglycerides with atorvastatin is 
comparable with other trials (26,27), although in this study there 
were no detectable changes in HDL. PCOS is associated with an 
increase of cardiovascular risk factors, including dyslipidemia 
that typically is reflected in an elevated total cholesterol and LDL 
(28-31). This is in accord with a report using simvastatin 20 mg 
daily and an OCP containing 20 ju,g ethinyl estradiol and 150 jag 
desogestrel over 12 wk that reduced total cholesterol and LDL by 
7.5 and 20%, respectively (23). In contrast, the OCP alone in­ 
duced a modest increase in TCs of 5 % without any marked effect 
on LDL cholesterol. In that study, triglycerides remained virtu­ 
ally unchanged after statin and OCP treatment but increased
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significantly by 20% after OCP alone, again in accord with other 
studies (32, 33).
Of note is the finding that the magnitude of improvement in 
biochemical hyperandrogenemia with atorvastatin in this study 
(by up to 33%) is comparable to that of antiandrogen agents (34, 
35). The reduction in testosterone is also similar to that found 
when using the combined OCP (ethinyl estradiol/levonorgestrel 
combination), where falls of 27% have been described. How­ 
ever, OCPs are more effective in improving SHBG (by up to 
100%) when given for 3 months (32,36,37). Simvastatin 20 mg 
daily concomitant with an OCP gave a 38% decrease in total 
testosterone (23) compared with a 25% reduction found by us 
with atorvastatin 20 mg daily alone. This study was too short to 
investigate the improvement of clinical hyperandrogenemia.
Even modest weight loss of less than 10% of initial body 
weight has been shown to reduce testosterone in women with 
PCOS (38). However, it seems unlikely that this is the mechanism 
for the changes found here, because there was no weight change 
associated with atorvastatin treatment. Indeed, the reduction in 
testosterone in this study was more than that seen by targeting 
weight using orlistat (17% reduction) for 3 months (39).
Among other agents known to influence hyperandrogenemia 
in PCOS, the reduction of testosterone is better with atorvastatin 
comparable to improvement with insulin sensitizers like met- 
formin that gave a 14 % decrease in total testosterone in 3 months 
(39) and thiazolidinediones that gave a 6-15% reduction in se­ 
rum testosterone (40-42). No improvement in hirsutism with 
metformin may be seen (43).
There was a 25 % reduction in hsCRP with atorvastatin in this 
group of patients with PCOS. PCOS has already been associated 
with increased levels of indices of low-grade chronic inflamma­ 
tion such as hsCRP (13, 44) that appears to be a predictor of 
cardiovascular events in women (45, 46). Atorvastatin has also 
been shown to significantly reduce hsCRP with a trend to re­ 
ducing insulin resistance in patients with impaired fasting glu­ 
cose (25). In the study using simvastatin and OCP, OCP alone 
had no significant effect on CRP, whereas the addition of sim­ 
vastatin led to a significant decrease of CRP below the baseline 
level (23) .
A reduction in insulin resistance may be central to the im­ 
provements seen for hyperandrogenemia and hsCRP. There was 
a21% reduction in serum insulin levels and a consequent 20% 
improvement in HOMA-IR with atorvastatin. This improve­ 
ment in insulin resistance correlated with the improvement in 
FAI. In addition, the HOMA-IR changes were also positively 
correlated with the degree of reduction in triglyceride levels and 
is consistent with other studies that have demonstrated a similar 
link in patients with the metabolic syndrome and type 2 diabetes 
treated with atorvastatin (47,48). Hypothetically, the reduction 
in triglyceride availability leads to an increased use of glucose as 
the main intracellular substrate (48), thereby improving insulin 
sensitivity. Whatever the reason, this mechanism may explain 
other findings such as reduced development of diabetes among 
patients treated with pravastatin in the WOSCOPS trial (49,50).
Improvement in biochemical hyperandrogenemia appears to 
be independent of the reduction in total cholesterol, LDL, or 
triglycerides. There was no correlation between reduction of
lipid levels and improvement in biochemical hyperandrogenemia 
that supports the concept of a pleiotropic effect of statins. Statins 
inhibit ovarian theca-interstitial cell proliferation and steroido- 
genesis in vitro (51). The ovaries of women with PCOS are typ­ 
ically enlarged with prominent hyperplasia of ovarian theca- 
interstitial cells and excessive production of androgens by these 
cells (52-54). The effects of statins on steroidogenesis are most 
likely related to the inhibition of cholesterol synthesis by the 
mevalonate pathway and a consequent decrease in the availabil­ 
ity of the precursors of progesterone and testosterone (51).
We made no assessment of ovulatory function in this study, 
and because blood tests were done without respect to the bleed­ 
ing pattern, there may have been temporary hormonal fluctua­ 
tions that we have not identified. What can be said is that patients 
continued to have irregular periods, suggesting atorvastatin has 
not overtly affected menstrual function over the 3-month period. 
Irrespective of any changes in fertility brought about by atorva­ 
statin, we would emphasize that this drug is not recommended 
while contemplating pregnancy because of its potentially tera- 
togenic effects.
In conclusion, atorvastatin 20 mg daily improved biochem­ 
ical hyperandrogenemia, insulin resistance, and markers of in­ 
flammation in patients with PCOS when given over a 12-wk 
period. Statin treatment may therefore prove to be a useful ad­ 
junct for women with PCOS.
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Abstract
Aims To determine the biological variability of lipids in patients with Type 2 diabetes (T2DM) who are on statin 
treatment and then to assess any implications for current lipid targets.
Methods A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg 
or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. 
Following 3 months on the other statin, 10 further samples were taken over 5 weeks. The main outcome measures were 
biological variability of total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol and triglycerides.
Results The coefficient of variation (CV) of TC, LDL, HDL and triglycerides on simvastatin was 8.17,13.11, 7.95 and 
12.06%, respectively, whereas the CV on atorvastatin was 6.92, 10.30, 5.13 and 19.71%, respectively, with no statisti­ 
cally significant differences between statins. Treating to sustain a target TC< 5.0 mmol/1 or LDL < 3.0 mmol/1 means 
needing to maintain a mean TC of 4.3-4.4 mmol/1 or LDL of 2.4-2.5 mmol/1. Treating to consistently achieve an 
LDL < 2.0 mmol/1 means aiming for a mean of only 1.5-1.6 mmol/1.
Conclusion In patients with T2DM taking either simvastatin or atorvastatin, the mean TC and LDL concentrations needed 
to consistently remain below a target are much lower than the target value itself. This means that guideline target limits 
extrapolated from the mean values of patients participating in clinical studies may overestimate the lipid reductions required.
Diabet. Med. 25, 909-915 (2008)
Keywords Biological variation, Coefficient of variation, statins, Type 2 Diabetes, lipids
Abbreviations apoB, apolipoprotein B; CHD, coronary heart disease; CV, coefficient of variation; HDL, high-density 
lipoprotein; JBS2, Joint British Societies' guidelines; LDL, low-density lipoprotein; NICE, National Institute for Health and 
Clinical Excellence; NSF, National Service Framework; QOF, Quality and Outcomes Framework; TC, total cholesterol; 
T2DM, Type 2 diabetes
introduction
While there is very strong evidence that low-density lipoprotein 
(LDL) cholesterol lowering using statin treatment can reduce 
the incidence of coronary and other major vascular events [1 -4], 
in the UK there is current controversy and confusion about what 
lipid targets should be aimed for once a statin drug is initiated. 
Current guidance from the National Service Framework for 
Coronary Heart Disease and the National Institute for Health
Correspondence to: Dr. T. Sathyapalan, Michael White Centre for Diabetes, 
Brocklehurst Building, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK. 
E-mail: tsathyapal@rediffmail.com
and Clinical Excellence (NICE) recommends targets for serum 
total cholesterol (TC) < 5.0 mmol/1 and LDL < 3.0 mmol/1, 
and this has formed the basis of the Quality and Outcomes 
Framework (QOF) of the new General Medical Services 
(nGMS) [5,6]. However, more recent guidance from the Joint 
British Societies, published in December 2005 [7], recommends 
patients should aim for a lower target of TC < 4.0 mmol/1 and 
an LDL < 2.0 mmol/1. This disparity has led the UK's National 
Director for Heart Disease and Stroke to issue a statement in 
November 2006 declaring that the previous targets of 5.0 and 
3.0 mmol/1 should be kept, at least until revised NICE guidance 
is published [8].
Whether a patient consistently achieves any target depends 
on both the lipid-lowering ability of the statin and the variability
© 2008 The Authors.
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of lipid parameters while on the drug. Thus, a statin drug may 
be effective in lowering the mean cholesterol in a patient, but 
if the measurement is extremely variable, then they may not 
always be below their target when tested. Lipid measurements 
in healthy volunteers and in patients with Type 2 diabetes 
(T2DM) who are not on lipid-lowering treatment can indeed 
vary on a day-to-day basis [9-1 1]. However, no study to date 
has looked at lipid variability in patients already on statin 
treatment. Indeed, arguments can be made for statin treatment 
leading to either possible increases or reductions in cholesterol 
variation within an individual. Added to this is the fact that 
short half-life statins, such as simvastatin, may have an effect 
on lipid variability which is quite different to that of a long 
half-life statin, such as atorvastatin. This study has therefore 
aimed to establish how the biological variability of lipids in 
patients with T2DM who are on statin treatment could influ­ 
ence the ability for patients to maintain cholesterol values 
below target. In order to assess any difference between long 
and short half-life statins, we have conducted the investigation 
as a cross-over study with equivalent doses of simvastatin and 
atorvastatin.
Patients and methods
Thirty Caucasian patients with Type 2 diabetes for at least 
3 years and glycated haemoglobin (HbAlc ) of 6.0-9.0% were 
recruited into the study with informed consent. Nineteen patients 
were taking 10 mg atorvastatin before bed and 11 patients took 
simvastatin 40 mg before bed. All the patients were on stable 
doses of the medications for at least 3 months. None of the 
patients was on additional lipid-lowering therapy or over- 
the-counter medications. The insulin doses of patients who 
took insulin were not changed by > 10% throughout the study. 
The patients were advised to maintain their normal diet, alcohol 
intake, smoking and exercise habits during the study period. 
Patients with untreated hypothyroidism or nephrotic syndrome 
were excluded. The biological variation of TC, high-density 
lipoprotein (HDL), LDL and triglycerides was assessed by 
measuring 12-h fasting blood samples at 4-day intervals on 10 
consecutive occasions. Thereafter, the patients on simvastatin 
were changed to the equivalent dose of atorvastatin and vice 
versa [12]. After 3 months, the biological variation of lipid 
parameters were again assessed by measuring fasting blood 
samples at 4-day intervals on 10 consecutive occasions in these 
patients.
Fasting venous blood was collected into serum gel tubes 
(Becton Dickinson, Oxford, UK) at the same time each day 
(08.00-09.00 h) after the patient had been seated for at least 
5 min and a tourniquet was not applied for more than 1 min. 
Samples were separated by centrifugation at 2000 g for 15 min 
at 4°C and two aliquots of the serum were stored at - 20°C 
within 1 h of collection. All samples were analysed within 
12 months of collection and studies have found no stability 
issues when stored for this period of time at this temperature 
[13]. The serum samples were split before assay. Before analysis, 
all of the serum samples were thawed and thoroughly mixed. 
The duplicate samples (i.e. two per visit) were randomized and
then analysed for cholesterol, triglycerides and HDL cholesterol 
in a continuous batch on a Synchron LX 20 analyser (Beckman- 
Coulter, High Wycombe, UK) using a single batch of reagents 
according to our previous studies [14], Lipid assays used 
calibrators assigned from Centers for Disease Control (CDC) 
standards and LDL cholesterol was calculated using the Friede- 
wald formula [15]. All subjects gave their informed written 
consent before entering the study, which had been approved by 
the Hull and East Riding Local Research Ethics Committee.
Statistical analysis
Statistical analysis was performed using SPSS for Windows NT, 
version 15.0 (SPSS, Chicago, IL, USA) and Microsoft Excel. 
Biological variability data was analysed by calculating the 
analytical and within-subject variability according to the methods 
of Fraser and Harris [16]. Using this technique, analytical
variance (SD.) was calculated from the difference between? duplicate results for each specimen (SDA = £d /2N, where d is
the difference between duplicates and N is the number of paired 
results ) . The variance of the first set of duplicate results for each 
subject on the 10 assessment days was used to calculate the 
average biological intra-individual variance (SDj) by subtrac­ 
tion of the mean SDA from the observed dispersion (equal to 
SDj + SDA ). The standard deviation of intra-individual varia­ 
tions (SD,) was estimated as square roots of the respective 
variance component estimates. An individual's coefficient of 
variation (CV) for each lipid parameter was calculated as the 
SD[/mean value x 100% and then expressed as a mean value for 
each treatment (simvastatin and atorvastatin).
The CV was used to calculate which mean lipid values 
would be required to maintain total cholesterol < 5.0 mmol/1 
(4.9 mmol/1 or lower) or < 4.0 mmol/1 and LDL < 3.0 mmol/1 or 
< 2.0 mmol/1 on 95% or more of testing occasions using a one­ 
sided analysis (mean ± 1.645xCV) [16]. A similar method was 
used to calculate the value that a single lipid measurement 
would have to be in order to be 95% confident that (i) the mean 
for a patient was below target or (ii) subsequent measurements 
would consistently be below target.
Results
The baseline demographic data of patients are given in Table 1. 
The baseline lipid profiles were comparable in both groups. 
One patient from each group dropped out after completing one 
arm because of difficulty in adhering to study protocols. One 
patient who was on atorvastatin initially withdrew from the 
study because of development of myalgia without any rise in 
creatine kinase when changed over to simvastatin. Another 
patient on atorvastatin initially withdrew from the study as a 
result of development of lethargy while on simvastatin, which 
got better after changing back to atorvastatin. None of the patients 
developed elevated liver transaminases or creatine kinase during 
the study. There was no significant change in glycaemic control 
during the course of the study in any patients (median ± inter­ 
quartile range) (7.7 ± 0.98 vs. 7.7 ± 0.88%, P = 0.60).
Table 2 shows the mean lipid values and the biological 
variability in lipids expressed as standard deviation (so) and
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Table 1 Baseline characteristics
Simvastatin crossed over 
to atorvastatin group
Atorvastatin crossed over 
to simvastatin group
Total number of patients completing the study
Duration of diabetes median (25-75 inter-quartilc range) months
HbA,c % (mean ± SD)
Sex (male : female)
Age, years and median (range)
Body mass index (mean ± SD) kg/m2
Waist circumference (mean + so) cm
Baseline TC (mean ± SD) mmol/l
Baseline LDL cholesterol (mean ± SD) mmol/l
Baseline HDL cholesterol (mean ± so) mmol/l
Baseline triglyceridcs (median ± inter-quartilc range) mmol/l
10
84(108)
7.8 ±0.98
7:3
58 (48-76)
34.7 ±6.64
119.8 ±16.01
4.1+0.71
2.2 ± 0.4
1.08 ±0.23
1.9 ±0.6
16
108(108)
7.7 ±0.91
10:6
64(46-73)
34.5 ± 7.23
114.8 ±17.29
4.0 + 0.49
2.2 + 0.44
1.08 ±0.24
1.7 + 0.7
HbAk , glycatcd haemoglobin; HDL, high-density lipoprotcin; LDL, low-density lipoprotein; SD, standard deviation; TC, total cholesterol.
Table 2 The biological variation of lipid parameters in 26 patients on simvastatin 40 mg and atorvastatin 10 mg
Simvastatin Atorvastatin
Lipid Parameters
Total cholesterol
LDL cholesterol
HDL cholesterol
Triglycerides
Mean (mmol/l)
3.8
2.1
1.0
2.7
SD (mol/1)
0.3
0.3
0.1
0.3
CV(%)
8.2
13.1
7.7
12.1
Mean (mmol/l)
4.0
2.2
1.0
1.7
so (mmol/l)
0.3
0.2
0.1
0.3
CV(%)
6.9
10.3
6.2
19.7
P-value*
0.21
0.19
0.17
0.95
CV, coefficient of variation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation of lipid parameter. 
*SD simvastatin vs. SD atorvastatin.
CV in each treatment group. It shows no statistical difference 
in lipid variability (SD) when the same patients take either 
simvastatin or atorvastatin (Figure 1). Whether patients started 
on simvastatin or atorvastatin made no difference to the results. 
Table 3 shows the mean values of total cholesterol required 
to maintain values < 5.0 or < 4.0 mmol/l and to maintain LDL 
cholesterol < 3.0 mmol/l or < 2.0 mmol/l on up to 95% of 
occasions. Table 4 shows the concentrations of total cholesterol 
and LDL required from a single lipid measurement on statin 
treatment so that two different criteria are met. The first 
criterion is to be 95% confident that the mean lipid value for 
a patient is truly below target; for example, that their mean 
total cholesterol is 4.9 mmol/l or lower when the target is 
5.0 mmol/l. The second is to be 95% confident that 95% of 
subsequent lipid measurements are below the specified target. 
In this regard, Table 3 gives values which show 50% confidence 
that 95% of subsequent measurements are below target.
Discussion
To our knowledge, this study is the first to show that there is 
clinically significant biological variability in the lipid profiles 
of patients with Type 2 diabetes who are on statin treatment
and that this does not significantly differ between the short 
and long half-life statins simvastatin and atorvastatin. Taken 
together, the coefficient of variation of total cholesterol 
suggests that values can vary by approximately ± 15% (2 SD 
from the mean value) in the same individual on treatment, 
while that of LDL cholesterol can vary by ± 24% before any 
laboratory analytical variability is also taken into consideration.
Studies which examine the normal biological variation in 
lipids and lipoproteins have generally been conducted on 
healthy subjects [9-11], but the biological component should 
be studied for each disease or treatment state as this may 
influence the extent of intra-individual variation. A meta-analysis 
of previously published studies has found that the mean bio­ 
logical variability (CV) found in healthy individuals is < 6.1, 
< 9.5, S 7.4 and < 22.6% for TC, LDL, HDL and triglycerides, 
respectively [17], whereas these figures in patients with T2DM 
who are not on statins were 5.1,8.3,4.4 and 17%, respectively. 
In this study, the CV of TC on atorvastatin and simvastatin 
was comparable at 6.9 and 8.2%, respectively, while that for 
LDL is somewhat higher at 10.3 and 13.1%, respectively.
The variability in lipids on statin treatment found here have 
several clinical implications, the first of which relates to the 
ongoing debate regarding setting lipid targets in patients with
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FIGURE 1 Means (range) of low-density lipoprotein (LDL) cholesterol on simvastatin 40 mg and atorvastatin 10 mg daily.
Table 3 Mean values of total cholesterol and LDL cholesterol to achieve different targets on 95% of sampling occasions
Mean TC to be achieved to produce a consistent TC < 5.0 mmol/l
Mean TC to be achieved to produce a consistent TC < 4.0 mmol/l
Mean LDL-C to be achieved to produce a consistent LDL-C < 3.0 mmol/l
Mean LDL-C to be achieved to produce a consistent LDL-C < 2.0 mmol/l
On simvastatin
40 mg (mmol/l)
4.32
3.43
2.39
1.56
On atorvastatin
10 mg
4.40
3.50
2.48
1.62
(mmol/l)
LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
or without T2DM. The National Service Framework (NSF) 
for Coronary Heart Disease (CHD) in the year 2000 laid down 
standards of care for the prevention and treatment of CHD 
[18]. It set a target for TC lowering of < 5.0 mmol/l and 
LDL < 3.0 mmol/l, or by 20-25% for TC and 30% for LDL, 
whichever results in the lowest absolute level [18]. In contrast, 
in December 2005 the Joint British Societies' (JBS2) guidelines 
set similar audit targets, but recommended an optimal total 
cholesterol target level < 4.0 mrnol/1 and an LDL < 2.0 mmol/l
[7]. Since the publication of JBS2, a statement from Professor 
Roger Boyle, National Director for Heart Disease and Stroke 
[8], points out that current UK national policy for lipid man­ 
agement and current targets for cholesterol levels remain those 
recommended in the NSF for CHD and not those recommended 
by the JBS2. This has been followed by a response from the 
Association of British Clinical Diabetologists (ABCD), which 
criticized this statement, arguing that in the Collaborative 
Atorvastatin Diabetes Study (CARDS) [19] the 30% of patients
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Table 4 Single lipid measurement results which give 95% confidence of the true mean value being below target or of each subsequent measurement 
being below target
Simvastatin
LDL-C, low-density lipoprotcin cholesterol; TC, total cholesterol.
Atorvastatin
TC < 5.0 mmol/1
TC < 4.0 mmol/1
LDL-C < 3.0 mmol/1
LDL-C < 2.0 mmol/1
True mean
below target
<4.24
<3.37
<2.28
< 1.49
Subsequent
measurements
below target
<3.74
<2.97
<1.87
<1.23
True mean
below target
<4.34
<3.46
<2.41
<1.58
Subsequent
measurements
below target
<3.90
<3.10
<2.06
<1.35
who had TC and LDL cholesterol levels < 5.0 and 3.0 mmol/1, 
respectively, still benefited from statins [20]. Diabetes UK has 
also criticized this decision, as current NICE guidance does not 
take account of new evidence in patients with T2DM [21],
The evidence for the new JBS2 targets themselves arose from 
the findings of the Heart Protection Study, the ASCOT-LLA, 
PROVE-IT, TNT, REVERSAL and GREACE studies [22-27]. 
In these studies, the mean LDL cholesterol in the active or 
intensively treated groups was 2.3, 2.3, 1.6, 2.0, 2.1 and 
2.5 mmol/1, respectively. However, the target for LDL cholesterol 
did not become a mean of 2.0 mmol/1, but less than 2.0 mmoM. 
From our study, as shown in Table 3, we can determine that, 
in order to consistently maintain an LDL of 1.9 mmol/1 or lower, 
the mean LDL for someone taking atorvastatin or simvastatin 
has to be around 1.5-1.6 mmol/1 or lower. This means the 
average LDL needs to be lower than that found in the clinical 
studies from which the target itself is based. This, in turn, is 
likely to have a knock-on effect regarding the potency, dosage 
and cost of statins (as well as possibly other agents) required. 
In addition, if the aim is to achieve a TC < 5.0 mmol/1 (as 
suggested by the QOF for UK general practitioners) or an 
LDL < 3.0 mmol/1 on a consistent basis, then the mean values 
for a patient needs to be 4.3-4.4 and 2.4-2.5 mmol/1, respec­ 
tively. This means that existing NICE lipid targets may not be 
as far removed from current evidence than the values of 5.0 
and 3.0 mmol/1 suggest, especially given the fact that adding 
laboratory analytical variation to the biological variation 
determined here will only reduce these mean values further.
This study has thus highlighted the difference between aiming 
to consistently have a patient below a cholesterol target at each 
visit (as demanded by financial incentives schemes such as the 
QOF) compared with aiming for just their mean value to be 
below the same target. By definition, the latter means that a 
patient whose mean is the same as the target value will have 
half their individual measurements above it, whereas with the 
former any result above target is unacceptable. One effect of 
this difference is shown in Table 4, where a single total cholesterol 
reading on treatment must be under 3.7-3.9 mmol/1 before it 
can be assumed that subsequent measurements will remain
below 5.0 mmol/1, whereas this value can be around 0.5 mmol/1 
higher if only a mean below 5.0 mmol/1 is desired. Repeated 
measurements help in this regard but, for example, the mean 
of three measurements still has to be below 4.0-4.1 mmol/1 to 
be sure that 95% of ensuing results are < 5.0 mmol/1.
There are potential limitations to this study. LDL was calcu­ 
lated using the Friedewald formula rather than using direct 
measurement or analysis after ultracentrifugation. This means 
the variability in cholesterol, triglycerides and HDL could each 
be contributing to the overall variation in LDL found here. 
There is also a possibility that the Friedewald formula may 
have limitations when applied to a population with diabetes 
[28]. Nevertheless, this is the means by which most laboratories 
currently report LDL and none of the patients in the study had 
triglycerides > 4.5 mmol/1, which would prohibit use of the 
calculation. There is also some evidence that calculating LDL 
in this way may not in fact lead to any spurious increase in 
variability, at least compared with direct measurement [29].
Given these difficulties in using estimated LDL in Type 2 
diabetic patients, it is perhaps an opportunity to reassess the 
utility of non-HDL and apolipoprotein B (apoB) measurement 
which seem to be equally useful in detecting high-risk pheno- 
types in hypertriglyceridaemic Type 2 diabetic patients, with 
apoB possibly being superior in normotriglyceridaemic sub­ 
jects [30]. The fact that apoB can be accurately measured in non- 
fasting individuals would only strengthen its appeal.
It is reassuring that none of the patients in the study developed 
serious adverse effects on statins. The two patients who with­ 
drew because of non-severe adverse effects is probably in keep­ 
ing with the 5-10% of patients who develop problems on 
statin treatment outside trial situations [31].
Our data are also reassuring for patients where a switch from 
10 mg of atorvastatin to the less costly generic simvastatin 
40 mg is being considered. Not only were the mean values of 
TC and LDL achieved by individuals on simvastatin not inferior 
to that of atorvastatin (which is in accordance with other studies 
[ 12]), but there were no significant differences in lipid variability. 
This means that the relatively short half-life of simvastatin 
(2-3 h) compared with atorvastatin (up to 24 h) [32] does not
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seem to influence its ability to keep a patient below their lipid 
target, at least when taken at night-time [33].
In summary, this study has found that, in patients with 
T2DM taking either simvastatin or atorvastatin, the mean TC 
and LDL concentrations needed to keep below target levels are 
much lower than the target value itself. When evidence for 
lipid targets are derived from the mean values obtained in 
patients participating in the different treatment groups of 
clinical studies, the mean value often becomes the upper target 
limit for patients [1-3,12,25,34]. In doing so, we have shown 
that this may lead to lipid targets in patients with diabetes 
which are significantly lower than the current evidence suggests 
and thereby more difficult to achieve.
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